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ABSTRACT 
Schizophrenia is a devastating disorder thought to evolve from a combination 
of environmental and genetic factors. Evidence suggests that the glutamatergic N-
methyl-D-aspartate receptor (NMDAR) may play a central role in the development 
of the disorder. The NMDAR, including the NR2B subunit of this receptor, is critical 
for normal brain development and has been implicated in the pathophysiology of 
schizophrenia, particularly the cognitive symptoms. It is hypothesised that 
developmental disruption to the NMDAR can cause a cascade of events resulting in 
altered developmental trajectories of other systems known to be involved in 
schizophrenia, such as the neuregulin (NRG), gamma-aminobutyric acid (GABA), 
and cannabinoid systems. The overall aim of this PhD thesis was to assess the 
potential role of the NR2B subunit in the pathophysiology and development of 
schizophrenia, with a particular focus on the examination of brain regions that 
mediate cognitive functions.  
Part A of the thesis used two postmortem human brain cohorts to determine 
whether NR2B alterations play a role in the pathophysiology of schizophrenia. 
NR2B protein and binding density (using the NR2B specific radioligand 
[3H]Ifenprodil) were first examined in the hippocampus (specifically the dentate 
gyrus sub-region) of a cohort of 20 schizophrenia subjects and 20 matched controls 
(Chapter 2). There was a 43% reduction in NR2B protein levels, specifically in the 
left hemisphere, in schizophrenia subjects, but this was accompanied by no change in 
[3H]Ifenprodil binding to NR2B, suggesting the reduction in protein may be specific 
to certain cellular compartments. These findings provide the first evidence of NR2 
protein abnormalities in the hippocampus in schizophrenia, highlighting the 
hippocampal lateralisation in this disorder. Considering the importance of 
 
 
 
xv
hippocampal NR2B to cognitive function, it may be that these observed alterations in 
NR2B are related to cognitive dysfunction in schizophrenia subjects. Building on 
these findings, chapter three examined NR2B protein and binding density in another 
brain region highly implicated in cognitive symptoms, the dorsolateral prefrontal 
cortex (DLPFC). Using a larger cohort (n=37/group), there was no evidence of 
hemisphere specific alterations in schizophrenia, however a 37% decrease in NR2B 
protein density (but not binding) was observed in the female schizophrenia subjects 
(n=13) compared to the male schizophrenia subjects (n=24) suggesting a gender 
difference in NR2B protein in schizophrenia subjects. 
Experimental part B of the thesis (Chapters 3-5) utilised a novel rodent model 
to assess whether developmental disruption to the NR2B subunit of the NMDAR 
could alter the developmental trajectory of key systems implicated in schizophrenia. 
In this model, mice were treated with the highly specific NR2B antagonist, Ro 63-
1908 (30 mg/kg s.c.) from postnatal days (PN) 7-14. Brains from both male and 
female mice were then collected at PN14 (8 hours after treatment), PN35 
(adolescence) or PN70 (adulthood). Immunoblot and receptor autoradiography were 
used to examine NMDA, NR2A, NR2B, NRG1, ErbB4, GABAA and CB1 receptors, 
with a particular focus on the prefrontal cortex and hippocampus brain regions. It 
was shown that perinatal NR2B antagonism caused a 70% reduction in NR2B 
binding at PN14 in the prefrontal cortex and hippocampus (p<0.001), validating the 
NR2B blockade. It was also shown that this treatment caused a 23% increase in 
NR2B protein in the prefrontal cortex at PN35 (p=0.020) and a 13% decrease in 
NRG1 protein in the hippocampus at PN35 (p=0.012), effects that were independent 
of gender. Perinatal NR2B antagonism did not however alter the other 
receptors/proteins examined.  
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In chapters three, four and five, the normal developmental trajectory of the 
NMDA, NRG1/ErbB4, GABAAR and CB1R systems was also examined. Gender 
specific developmental trajectories were observed with differences most evident at 
the adolescent time point. Female mice showed a 166% increase in NR2A binding 
compared to males in the prefrontal cortex and hippocampus (144-166%; p<0.001). 
This result was positively correlated to that of GABAAR binding in which there was 
a similar increase in binding in the female mice at adolescence (81-181%; p<0.01). 
In contrast, males showed greater expression of the CB1R compared to females at 
adolescence (25-38%; p<0.02). 
Collectively, this thesis has provided novel insights into the changes that 
occur in the NR2B subunit in schizophrenia, revealing for the first time that 
expression of NR2B is altered in the DLPFC and hippocampus of schizophrenia 
subjects, in a gender and hemisphere specific manner. These alterations may be 
related to cognitive symptoms experienced by patients, however further studies are 
required to determine this. This thesis also showed that perinatal NR2B antagonism 
causes some alterations to schizophrenia relevant systems including NR2B and 
NRG1 at adolescence, which could potentially make this animal model more 
vulnerable to further impacts at adolescence. It should be noted however, that this 
model did not cause widespread changes in systems (at least in terms of protein 
expression) relevant to the pathophysiology of schizophrenia. Finally, this thesis has 
identified that the developmental profiles of schizophrenia relevant systems, differs 
between the two genders (at least in a mouse model), highlighting the importance of 
considering this in the design of future studies.  
Chapter 1 
 
 
1
1 THE ROLE OF THE NMDA RECEPTOR IN SCHIZOPHRENIA 
Schizophrenia is a debilitating mental disorder characterised by a range of 
positive, negative and cognitive symptoms, which include delusions, hallucinations, 
anhedonia, social isolation and learning and memory impairments (Koenig, 2006). 
These symptoms commonly emerge during adolescence to young adulthood. 
Pathophysiological studies have revealed alterations in the brain structure of patients 
with schizophrenia, such as ventricular enlargement, reductions in cortical grey 
matter, and altered cytoarchitechture (Keshavan and Hogarty, 2000, Mueser and 
McGurk, 2004, Jarskog et al., 2005). These atypical physical traits do not deteriorate 
as the patient ages and are a sign of defective formation as opposed to damage and 
degeneration (Weinberger, 1995). Together with data showing an increased risk of 
developing schizophrenia following perinatal complications (Mueser and McGurk, 
2004), these findings have lead researchers to consider schizophrenia as a 
neurodevelopmental disorder with origins in early life, even though the symptoms 
are not apparent until later in life.    
Epidemiological evidence suggests that there is an earlier onset in males 
compared to females in many populations (Hafner et al., 1993, Shimizu, 1988, 
Szymanski et al., 1995). Gender differences have also been observed in the symptom 
profiles of schizophrenia patients (Goldstein and Link, 1988, Gur et al., 1996), for 
example in clinical cognitive studies, male schizophrenia patients show greater 
cognitive deficits than females (Aylward et al., 1984), with females displaying a 
reduced level of negative symptoms (Gur et al., 1996). Brain imaging studies have 
since been conducted to try to elucidate these gender differences, with studies 
showing differences in cortical size, for example in the inferior parietal lobule, 
between male and female patients (Frederikse et al., 2000). These gender differences 
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in schizophrenia may extend to brain neurochemistry with some studies reporting 
gender specific alterations (Schroder et al., 1997). Furthermore, Frederikse and 
colleagues revealed a gender difference in the lateralisation of the brain, with healthy 
male subjects displaying a greater asymmetry (greater volume on left than right side) 
than females (Frederikse et al., 1999). This asymmetry is reversed (more prominent 
on right than left side) in male schizophrenia patients, whereas female schizophrenia 
patients show no difference to healthy subjects (Frederikse et al., 2000). Findings of 
reduced cortical volumes or lateralisation effects specific to one gender could have 
an effect on proteins at a cellular level and therefore it is important to examine both 
gender and hemispheric effects in the brain in relation to schizophrenia studies.  
Various family, twin and adoption studies have provided strong support for 
genetic involvement in the pathogenesis of schizophrenia (Pulver, 2000, Maynard et 
al., 2001), however the inheritance appears to be in a complex polygenetic and non-
Mendelian manner (Risch and Baron, 1984). Genetic linkage analyses have 
identified several loci that are associated with the disorder and there are a number of 
candidate genes that are implicated in schizophrenia, including Glutamate (NMDA) 
receptor epsilon-2 (GRIN2B) and neuregulin 1 (NRG1) (Brzustowicz et al., 2000, 
Martucci et al., 2006, Miyatake et al., 2002). This suggests that no single genetic 
mechanism can be responsible for the aetiology of schizophrenia and although there 
is a genetic component to schizophrenia, it is likely that schizophrenia develops from 
an interaction of genetic and environmental factors. Some of the environmental 
factors that have been found to increase the risk for developing schizophrenia include 
insults during early brain development, such as drug abuse during pregnancy, 
maternal stress or malnutrition, obstetric complications and neonatal anaesthetic 
agents (Ikonomidou et al., 2001, Abel et al., 2008, Shen et al., 2008), which all affect 
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the brain development of the foetus, as well as other insults during the periadolescent 
brain developmental period, such as cannabis use (Henquet et al., 2005). The N-
methyl-D-aspartate receptor (NMDAR), a protein which is vitally important in brain 
development, appears to be a convergence point for many genetic and environmental 
factors implicated in schizophrenia (Snyder and Gao, 2013) and is the focus of one of 
the leading hypotheses of schizophrenia aetiology, the glutamate hypothesis. 
1.1 The Glutamate Hypothesis: Excitatory Neurotransmission in 
Schizophrenia 
It is widely acknowledged that an imbalance of neurotransmission is involved 
in the pathogenesis of schizophrenia, particularly the imbalance of excitatory 
(glutamatergic) and inhibitory (GABAergic) neurotransmission. A considerable 
amount of research has focused on the ionotropic NMDAR in the pathogenesis of 
schizophrenia since the discovery several decades ago that antagonists of this 
receptor, such as phencyclidine (PCP) and ketamine, mimic symptoms of the 
disorder in humans and exacerbate symptoms in schizophrenia patients (Olney et al., 
1999).  The NMDAR is critically involved in many central nervous system (CNS) 
functions, especially during early brain development. It is vital for neuronal 
proliferation, differentiation, migration and establishment in the developing brain 
(Komuro and Rakic, 1993, Contestabile, 2000). Altered or diminished function of the 
NMDAR during this time could therefore interfere with essential neuronal processes 
resulting in various long-term effects. As schizophrenia is considered to have origins 
in early neurodevelopment, with alterations to such processes as neuronal migration, 
the developmental NMDAR hypofunction hypothesis is certainly feasible. In the 
mature brain, the NMDAR plays a key role in synaptic plasticity processes such as 
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long-term potentiation, which underlie functions such as learning and memory, and 
therefore may be involved in the cognitive symptoms experienced by schizophrenia 
patients.  
Various studies have been conducted using animal models in an effort to 
uncover the effects of developmental NMDAR hypofunction and its relationship to 
schizophrenia-like symptoms. NR1 hypomorphic mice which display 5-10% levels 
of functional NMDARs show deficits in prepulse inhibition, reduced social 
interaction, hyperactivity, cognitive deficits, which model the positive, negative and 
cognitive aspects of schizophrenia (Mohn et al., 1999). These behaviours were 
influenced by antipsychotic drug treatment, providing this model with face and 
predictive validity (Mohn et al, 1999). However it has been suggested that the global 
effects produced by this model are too general to model a specific disorder, 
suggesting that more targeted insults to the NMDAR, for example, at a specific 
developmental period, may result in a more relevant model (Barkus et al., 2012). 
Pharmacological models provide the opportunity to target specific molecules 
at specific points in time. The administration of NMDAR antagonists such as 
dizoclipine (MK-801), PCP, nitrous oxide and ketamine, to rodents during the first 
two weeks of life [when NMDAR expression and brain developmental 
synaptogenesis are at their peak (du Bois and Huang, 2007)] produces, long-term 
behavioural effects such as enhanced locomotion (Facchinetti et al., 1993, Harris et 
al., 2003, du Bois et al., 2008), impairments in cognitive function as examined by 
spatial working memory, cognitive set-shifting and other learning tests (Andersen 
and Pouzet, 2004, Stefani and Moghaddam, 2005) and deficits in prepulse inhibition 
(Harris et al., 2003). These behavioural changes mimic certain aspects of 
schizophrenia and provide support for the involvement of the glutamatergic system 
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in schizophrenia pathophysiology. These behavioural changes are accompanied by 
neurotransmitter alterations (Wang et al., 2001, Sircar and Soliman, 2003, Wang et 
al., 2008, du Bois et al., 2009), which have to some extent paralleled that observed in 
the human schizophrenia brain. For example perinatal NMDAR antagonism has been 
shown to increase gamma-amino-butyric-acid A receptors (GABAARs) in various 
brain regions of female rats (du Bois et al., 2009). As well as this, a loss of 
GABAergic interneurons has been observed following perinatal NMDAR blockade 
(Nakatani-Pawlak et al., 2009), which is representative of the GABAergic 
dysfunction seen in schizophrenia pathology (Benes et al., 1996b, Dean et al., 1999, 
Deng and Huang, 2006, Newell et al., 2007b). Furthermore, these 
neurodevelopmental models promote an enhanced apoptotic response in several 
regions of the developing rodent brain (Ikonomidou et al., 1999, Ikonomidou et al., 
2000, Wang et al., 2001, Harris et al., 2003, Jevtovic-Todorovic et al., 2003). It has 
been proposed that an alteration in apoptotic activity occurring early in development 
may contribute to human schizophrenia pathology (Jarskog, 2006), with excessive 
neuronal depletion contributing to the array of cognitive and behavioural effects 
observed later in life (Jevtovic-Todorovic et al., 2003).  
1.2 NMDAR: Structure, Function and Developmental Distribution  
NMDARs are composed of a heterometric assembly of subunits where at 
least one obligatory NR1 subunit combines with distinct arrangements of NR2 and/or 
NR3 subunits. To add to the complexity of these receptors, there are eight different 
splice variants of the gene encoding for the NR1 subunit and six other genes that 
encode for different forms of the NR2 (NR2A, NR2B, NR2C, NR2D) and NR3 
(NR3A, NR3B) subunits, producing a multitude of different NMDARs (Paoletti and 
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Neyton, 2007). This formation of NMDARs gives rise to a diverse range of 
functional and pharmacological properties (Sheng et al., 1994, Flint et al., 1997, 
Kristiansen et al., 2007).  
The extracellular N-terminal domain of the NR2 subunits contains the 
binding site for glutamate, the primary activator of the NMDAR, while the NR1 
subunit (and NR3 subunits) binds glycine, a co-activator. Inside the cell, the C-
terminal region of the NR2 subunits is anchored to PDZ (Post-synaptic density 95, 
Drosophila disc large tumor suppressor, Zonula occludens-1)-containing scaffold 
proteins in the postsynaptic density (PSD) including PSD-95, synapse associated 
protein (SAP)102, PSD-93 and SAP97, with PSD-95 being the most studied (Kornau 
et al., 1995, Muller et al., 1996, Niethammer et al., 1996, Bassand et al., 1999, Sans 
et al., 2000, Chen et al., 2006, Sato et al., 2008, Cousins et al., 2009). These 
scaffolding proteins form part of the membrane associated guanylate kinases 
(MAGUKs), which due to their close positioning to the postsynaptic membrane and 
their signalling capacity, are also involved in critical processes during synaptogenesis 
and synapse maturation including localisation, trafficking and organisation of many 
membranous and cellular proteins (Sheng and Hoogenraad, 2007, Elias et al., 2008, 
Howard et al., 2010).  
The NR2 subunits of the NMDAR are spatially and developmentally 
regulated, providing an important level of receptor regulation (Herin and Aizenman, 
2004, Mueller et al., 2004). Whereas NR2C subunits are primarily restricted to the 
cerebellum and NR2D subunits to the thalamus and brainstem, NR2A and NR2B are 
the predominant subunits in the cortex, striatum and hippocampus (Watanabe et al., 
1992, Portera-Cailliau et al., 1996, Wenzel et al., 1997). Widespread NR2B 
expression during development becomes confined to forebrain areas in adulthood, 
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whereas the NR2A subunit is increasingly expressed in all brain regions throughout 
development (Watanabe et al., 1992, Portera-Cailliau et al., 1996, Wenzel et al., 
1997). These forebrain areas in particular are closely associated with schizophrenia 
pathology as the neural circuits contained within and between these regions play a 
central role in eliciting the positive, negative and cognitive symptoms that are 
experienced by patients with the disorder (Heimer, 2000). Therefore this regional 
expression of NR2 subunits may play an important role in schizophrenia symptoms.  
In terms of the developmental regulation, animal studies have revealed that 
the NR2B and NR2D subunits emerge early in development with NR2B and NR2D 
mRNA present prenatally in the rodent brain, as early as embryonic day 14, while the 
NR2A and NR2C mRNAs are not detectable until at or after birth (Watanabe et al., 
1992, Monyer et al., 1994, Sheng et al., 1994). Similarly NR2B protein is already 
widely and strongly expressed by birth with very little expression of NR2A and 
NR2C protein at postnatal day (PN) zero (Portera-Cailliau et al., 1996, Wenzel et al., 
1997, Sans et al., 2000, Liu et al., 2004). The expression pattern of the PSD and SAP 
proteins mirrors that of the NR2 subunits with the SAP97 and SAP102 proteins 
present early in development and involved in synaptogenesis while PSD-93 and 
PSD-95 emerge later during synapse maturation (Sans et al., 2000, Elias et al., 2008, 
Howard et al., 2010). There has been evidence to suggest that certain NR2 subunits 
preferentially associate with one or another of the postsynaptic density proteins; one 
study has shown that NR2A has a slight but not complete preference for PSD-95 and 
NR2B a preference for SAP102 (Sans et al., 2000). On the other hand it has been 
found that the number of binding domains for PSD-95 on the NR2B subunit is 
greater than on the NR2A subunit and thus NR2B may be more closely associated to 
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PSD-95 (Cousins et al., 2009), or the NR2 subunits may interact comparably with the 
postsynaptic density proteins (Al-Hallaq et al., 2007).  
Throughout postnatal development, expression of NR2A mRNA and protein 
increases to adult levels in all areas at around the third postnatal week in the rodent 
brain (Monyer et al., 1994, Sheng et al., 1994, Zhong et al., 1995, Wenzel et al., 
1997, Guilarte and McGlothan, 1998, Ritter et al., 2002). Peak NR2B expression in 
the rodent occurs during the first week in most brain regions (Monyer et al., 1994, 
Wenzel et al., 1997, Ritter et al., 2002). However there appears to be conflicting 
results of NR2B expression from this point until adulthood with some studies 
showing cortical NR2B expression remains constant from early development to 
adulthood (Sheng et al., 1994, Zhong et al., 1995, Portera-Cailliau et al., 1996) while 
others have found a decrease in NR2B levels to adulthood (Monyer et al., 1994, 
Wenzel et al., 1997). The expression of NR2C mRNA and protein in the rodent brain 
is fairly weak until the third postnatal week when there is a dramatic increase in the 
cerebellum and thalamus (Monyer et al., 1994, Zhong et al., 1995, Wenzel et al., 
1997). This increase in NR2C levels correlates with a decrease in NR2B levels in the 
cerebellum at this time (Monyer et al., 1994). Compared to the other subunits NR2D 
expression peaks earlier in development, around PN7, but is restricted to regions 
such as the midbrain and thalamus (Monyer et al., 1994). 
A similar pattern of NR2 mRNA and protein expression has been observed in 
a study of the human foetal brain, where NR2B is the predominant subunit expressed 
in all of the cortical layers as early as gestational week 8 with transient increases at 
week 11, 13 and 19 (Ritter et al., 2001). There is a decline in NR2B mRNA in the 
human hippocampus from its peak expression during the neonatal stage of life to 
adulthood, whereas NR2A mRNA expression appears to remain consistent 
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throughout the life stages (Law et al., 2003). Interestingly, NR2B mRNA levels 
remain significantly higher than NR2A in the dentate gyrus of the hippocampus 
during development and at adulthood (Law et al., 2003).  
NR2A and NR2B containing NMDARs often have functionally different 
roles via their activation of opposing cellular pathways. For example, activation of 
synaptic NR2A containing receptors activates cell survival pathways e.g. CREB, 
whereas activation of extrasynaptic NR2B containing NMDARs deactivates these 
same pathways, leading to neuronal death (Hardingham et al 2002). Similarly, Hu et 
al (2008) reported that NR2A containing NMDARs in the hippocampus regulate 
neurogenesis positively, while NR2B containing NMDARs regulate it negatively 
(Hu et al., 2008). Further, it has been reported that blockade of NR2B subunits with 
ifenprodil, in rat hippocampal slices, results in an enhanced depolarisation response 
of NMDARs, mediated via NR2A subunits. This suggests that an inhibitory 
relationship exists between NR2A and NR2B subunits, whereby NR2B containing 
NMDARs normally maintain inhibitory control over NR2A containing NMDARs 
(Mallon et al., 2005). In vivo, Mao et al (2006) found that blocking NR2B containing 
NMDARs with ifenprodil during the mouse neurodevelopmental critical period 
reduced synaptic plasticity in the adult mouse auditory cortex, suggesting that it is 
the NR2B subunit that is critical to synaptic plasticity/modulation. This data 
highlights that the balance between NR2A and NR2B containing NMDARs is key in 
determining neuronal function, synaptic plasticity and normal brain development. 
Therefore abnormalities in the balance between NR2A and NR2B during 
development and maturation may play a role in the pathophysiology of 
schizophrenia. Evidence suggests that the NR2B subunit in the hippocampus is 
particularly important for NMDAR channel function (Akashi et al., 2009), long-term 
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potentiation (LTP) and associated cognitive functions such as spatial learning 
(Clayton et al., 2002). Accordingly, specifically targeting the NR2B subunit has been 
suggested as a novel mechanism to treat cognitive dysfunction in schizophrenia 
patients (Mony et al., 2009, Menniti et al., 2013). 
There has been little investigation on whether this developmental regulation 
of NR2 subunits differs between the two genders. However, there are gender 
differences in brain maturation (De Bellis et al., 2001) and there is evidence to 
suggest that males and females are at different susceptibility to stress-induced 
cognitive disruptions mediated by the prefrontal cortex (Markham et al., 2013). 
Therefore it is likely that the developmental profile of underlying systems such as the 
NMDA system are differentially regulated between the two genders, especially at 
adolescence. The hormone oestrogen has also been shown to depress NMDAR 
function and reduce phosphorylation of the NR2B subunit in the prefrontal cortex 
(Liu et al., 2012), while in the hippocampus it enhances LTP via a functional 
increase in NR2B-containing NMDARs (Vedder et al., 2013). The higher density of 
NMDARs at the synapse however are possibly due to the recruitment of NR2B-
containing receptors from extrasynaptic locations (Vedder et al., 2013) rather than 
increased expression of NR2B protein, as oestrogen does not appear to affect 
NMDAR, NR2A or NR2B protein levels (Snyder et al., 2011).). These findings 
reveal potential differences in NMDAR-associated biochemistry in the male versus 
female brain due to differing hormone levels. 
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1.3 NMDAR Subunits and Schizophrenia 
1.3.1 Evidence from Genetic Studies 
While genetic vulnerability is clearly associated with schizophrenia, 
schizophrenia has a heterogeneous aetiology involving multiple genes. Several of the 
genes associated with schizophrenia include sites on the NMDAR itself, including 
the receptor subunits NR1, NR2A and NR2B coded for by the GRIN1 (Galehdari et 
al., 2009), GRIN2A (Tang et al., 2006) and GRIN2B (Qin et al., 2005) genes, or 
genes that regulate NMDAR function (Snyder and Gao, 2013). The GRIN2B gene 
appears particularly associated with schizophrenia with the frequency of a genetic 
variation in the promoter region found to be higher in schizophrenia patients and this 
has been shown to considerably affect the transcription of the gene (Miyatake et al., 
2002). This genetic polymorphism was also found to be selective to schizophrenia in 
a similar study that examined overall haplotype frequency in schizophrenia, bipolar 
disorder and control subjects (Martucci et al., 2006). In a recent study investigating 
the association of GRIN1 and GRIN2A-D with schizophrenia, a genetic variation in 
the 3’ region of GRIN2B, but not the other GRINs, was found to be significantly 
associated with schizophrenia (Demontis et al., 2011).  
1.3.2 Evidence from Environmental Factors 
Environmental factors, such as early life stress, have shown aetiological 
relevance to schizophrenia in animal models, as early life stress has been found to 
reduce hippocampal NR2B levels and alter the synaptic NR2A/NR2B balance 
leading to potential learning and memory deficits in later life (Zhao et al., 2013). A 
similar study, adding weight to the above results, found that prenatal stress reduces 
NR1 and NR2A protein in the hippocampus and reduces NR1 protein in the 
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prefrontal cortex and striatum in male and female rats (NR2B protein was not 
examined) (Sun et al., 2013). Another study has shown a decrease in NMDAR 
binding and NR2A mRNA expression in the hippocampus of rats exposed to 
repeated postnatal hypoxia (a factor of obstetric complications) and an increase in 
NR1 mRNA that remained in the adult rat brain (Schmitt et al., 2007).  
1.3.3 Evidence from Postmortem Human Brain Studies 
Studies in postmortem human brain support the hypothesis of NMDAR 
dysfunction in schizophrenia. For example altered NMDAR binding density has been 
reported in several cortical brain regions in schizophrenia (Kornhuber et al., 1989, 
Zavitsanou et al., 2002, Newell et al., 2005, Pilowsky et al., 2005) although not all 
studies and/or brain regions have shown changes (Weissman et al., 1991, Scarr et al., 
2005). Many studies have examined the status of the specific NMDAR subunits in 
schizophrenia, due to their different functional properties, with results showing 
alterations in the level of NR1 and NR2 mRNA and protein, as well as the proteins in 
the PSD, in schizophrenia subjects in comparison to control subjects (see Table 1.1). 
Most recently, protein and mRNA expression of the obligatory NR1 subunit was 
reported to be decreased in the dorsolateral prefrontal cortex in schizophrenia 
subjects, using one of the largest cohorts to date (n=37/group) (Weickert et al, 2012). 
Interestingly, genetic variation in the GRIN2B gene was associated with the reduced 
expression and was also predictive of cognitive dysfunction. While this study 
reported no change in NR2B mRNA, they did not explore NR2B protein levels; it is 
known that mRNA levels do not always denote corresponding changes in protein 
levels (Greenbaum et al, 2003), so assessing NR2B protein levels in this region in 
schizophrenia subjects may be important. They did however report that NR2B 
mRNA expression was 39% higher in the left versus right DLPFC and 33% greater 
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in males relative to females, independent of diagnosis (Weickert et al., 2013), but this 
highlights the importance of considering gender and hemisphere in studies of this 
nature. 
NR1 mRNA has been reported to be decreased in the hippocampus and 
thalamus and increased in the occipital and anterior cingulate cortices in 
schizophrenia (Gao et al., 2000, Ibrahim et al., 2000, Dracheva et al., 2001, 
Kristiansen et al., 2006). However these results vary in terms of the specificity of the 
probe used to detect the mRNA with some studies using pan probes while others are 
specific to certain splice variants of NR1. There are alterations reported in NR2 
subunit mRNA and protein in the prefrontal cortex, including an increase in NR2D 
mRNA, and a reduction in NR2A and NR2C mRNA as well as NR2B protein 
(Akbarian et al., 1996, Beneyto and Meador-Woodruff, 2008, Kristiansen et al., 
2010b). NR2B subunit mRNA has been found to be increased in the hippocampus 
(Gao et al., 2000) while NR2B subunit protein has been found to be selectively 
upregulated in the superior temporal cortex (Grimwood et al., 1999). Furthermore 
alterations in associated transporter and regulatory proteins of the NMDAR subunits 
has been reported in schizophrenia, particularly associated with the NR2B subunit 
(Kristiansen et al., 2010a).  These findings show significant changes however there 
are also studies showing no changes in the same brain regions (see Table 1.1). 
Clinton and colleagues have found that the use of an elderly versus a younger cohort 
of samples can influence direction of change in the subunits, particularly in the 
thalamus. The PSD and SAP proteins appear to be particularly vulnerable to age with 
opposite changes in both the prefrontal cortex and thalamus depending on whether 
the cohort is elderly or younger (Clinton et al., 2003, Clinton and Meador-Woodruff, 
2004, Clinton et al., 2006). Furthermore differences in the specificity of the brain 
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region and cellular compartments, as well as examination of hemisphere and gender 
effects are also likely contributing factors to the various results found. For example, 
while Kristiansen (2010b) found no change in NR2B protein levels in the DLPFC in 
total cell homogenates, when examined in endoplasmic reticulum enriched fractions 
they revealed a significant reduction in schizophrenia subjects. Therefore due to the 
inconsistent findings, which could be attributed to differences in tissue cohorts and 
methodologies, these results must be interpreted with some caution. 
1.3.4 Evidence from Rodent Studies 
While human postmortem data supports that NMDARs and their subunits are 
altered in schizophrenia, at least in some cohorts, animal studies have and will 
continue to assist in unravelling the functional and developmental significance of 
those alterations in schizophrenia patients. There are a number of animal studies that 
have examined the role of a non-specific NMDAR blockade on behaviour and 
neurochemical alterations in the rodent (see du Bois and Huang, 2007), however 
there is currently limited animal data available with regard to the importance of the 
specific subunits. Blockade of the NR2A subunit with NVP-AAM077 (PEAQX) has 
been reported to reduce locomotor activity (5-10 mg/kg) and not alter prepulse 
inhibition (PPI) (5-20 mg/kg) (Chaperon et al., 2003). On the other hand, the NR2B 
antagonist Ro 25-6981, produced hyperlocomotor activity (20 mg/kg), disrupted PPI 
(5-20 mg/kg), an increase in anxiety-like behaviour (10mg/kg) and an impairment in 
learning and memory (5-10 mg/kg) in adult rats, which may be recognised as 
schizophrenia-like behaviours in the rodent (Chaperon et al., 2003, Duffy et al., 
2007, Mathur et al., 2009). However, a lack of locomotor changes in rodents treated 
with 10 mg/kg Ro 25-6981 has also been reported (Kosowski and Liljequist, 2004). 
Adult rats treated with a more potent and selective NR2B antagonist, Ro 63-1908, 
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displayed increased locomotor activity (10-30 mg/kg) and impaired response 
inhibition (1-10 mg/kg) but no disruption to PPI (1-10 mg/kg) (Higgins et al., 2003).
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Table 1.1. Changes in NMDAR subunits in human postmortem brain tissue in schizophrenia. 
NMDAR subunit Brain region  Cohort 
NR1         Prefrontal cortex  
                 mRNA Increase in DLPFC by 100%a n=13C/26SZ 
                   Decrease in DLPFC by 22%b  Lamina specific reductions in DLPFCc 
n=37C/37SZ 
n=15C/15SZ  
 No change in BA10d n=15C/15SZ 
                 protein No change in DLPFCe or ER fraction of DLPFCf n=8C/13SZ;  n=8C/13SZ 
 Hippocampus  
                 mRNA Decrease in dentate gyrus by 15%g n=35C/31SZ  
 No change in any subdivision of hippocampush,i,j n=8C/8SZ; n=15C/15SZ; n=8C/13SZ 
 Decrease in NR1-4 of hippocampus (subdivisions combined) in LH by 33%j Decrease in NR1-2 of hippocampus (subdivisions combined) in RH by 41%j  
n=13C/16SZ 
n=13C/16SZ 
                 protein Decrease in male SZ subjects by 55% in LHj n=7C/8SZ 
 No change in dentate gyrusk n=15C/15SZ 
 Other regions  
                 mRNA Decrease in DM and CM thalamus by 55%l n=8C/12SZ 
 No change in any subdivision of thalamusm,n n=16C/14SZ; 15C/15SZ 
 Increase in occipital cortex by 230%a n=13C/26SZ 
 Increase in NR1 (pan) by 15% and NR1-1 (isoform) by 22% in STGo  n=6C/6SZ 
 No change in parietotemporal cortex (BA39)d  No change in middle frontal and visualo, entorhinal and perirhinal cortexi 
n=15C/15SZ  
n=6C/6SZ; n=15C/15SZ 
 No change in cerebellumd n=15C/15SZ  
                 protein No change in ventral or DM thalamusp n=8C/15SZ 
 Increase in ACC by 35%e  n=8C/13SZ  
 Increase in NR1 by 30% of STGs n=14C/14SZ 
 No change in STGk, orbitofrontal cortexq or ER fraction of ACCf n=15C/15SZ; n=15C/15SZ; n=8C/13SZ 
NR2A Prefrontal cortex  
                mRNA Lamina specific reductions in DLPFCc  n=15C/15SZ 
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 No change in DLPFCa or BA10d n=13C/26SZ; n=15C/15SZ 
               protein No change in DLPFCc,e n=15C/15SZ; n=8C/13SZ 
 Hippocampus  
               mRNA No change in any subdivision of hippocampusg,h,i n=35C/31SZ; n=8C/8SZ; n=15C/15SZ 
               protein No change in any subdivision of hippocampusi n=15C/15SZ 
 Other regions  
               mRNA No change in any subdivision of thalamusl,m,n n=8C/12SZ; n=16C/14SZ; 15C/15SZ 
 Increase in occipital cortex by 230%a n=13C/26SZ 
 No change in parietotemporald, entorhinal and perirhinal cortexi n=15C/15SZ;  n=15C/15SZ 
 No change in cerebellumd,r n=15C/15SZ; n=9C/10SZ 
               protein No change in any subdivision of the thalamusl,p n=8C/12SZ; n=8C/15SZ 
                No change in ACCe,s n=8C/13SZ; n=14C/14SZ 
NR2B Prefrontal cortex  
               mRNA No change in DLPFC or BA10a,c,d 
n=13C/26SZ; n=15C/15SZ; 
n=15C/15SZ 
               protein Decrease in ER fraction of DLPFC by 55%f n=8C/13SZ 
 No change in DLPFCc,e n=15C/15SZ; n=8C/13SZ 
 Hippocampus  
               mRNA Increase in CA2 by 40%g n=35C/31SZ 
 No change in any subdivision of the hippocampush,i n=8C/8SZ; n=15C/15SZ 
               protein No change in any subdivision of the hippocampusi n=15C/15SZ 
 Other regions  
               mRNA Decrease in CM thalamus by 60%l n=8C/12SZ 
 Increase in combined subdivisions of thalamus by 30%n n=15C/15SZ 
 No change in any/other subdivision of thalamusl,m n=8C/12SZ; n=16C/14SZ 
 
No change in occipital and parietotemporala,d, entorhinal and perirhinal 
cortexi 
n=13C/26SZ; n=15C/15SZ; 
n=15C/15SZ 
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 No change in cerebellumd,r n=15C/15SZ; n=9C/10SZ 
               protein Decrease in anterior, DM and CM thalamus by 20-29%l n=8C/12SZ 
 Increase in DM thalamus by 375% but no change in ventral thalamusp n=8C/15SZ 
 No change in LD, reticular or ventral thalamusl n=8C/12SZ 
 Increase in STG by 100%s n=14C/14SZ 
 No change in ACCe, entorhinal and perirhinal cortexi n=8C/13SZ; n=15C/15SZ 
NR2C Prefrontal cortex  
               mRNA Decrease in BA10 by 22-41%d  n=15C/15SZ 
 Lamina specific reductions in DLPFCc n=15C/15SZ 
               protein No change in DLPFCe n=8C/13SZ 
 Hippocampus  
               mRNA No change in any subdivision of hippocampush,i n=8C/8SZ; n=15C/15SZ 
 Other regions  
              mRNA Decrease in anterior, DM, LD and CM thalamus by 54-73%l n=8C/12SZ 
               No change in any subdivision of thalamus m,n n=16C/14SZ; 15C/15SZ 
 No change in parietotemporald, entorhinal and perirhinal cortexi n=15C/15SZ; n=15C/15SZ 
 No change in cerebellumd,r n=15C/15SZ; n=9C/10SZ 
              protein No change in ACCe n=8C/13SZ 
NR2D Prefrontal cortex  
             mRNA No change DLPFC or BA10c,d n=15C/15SZ; n=15C/15SZ 
             protein  No change in DLPFCe n=8C/13SZ 
 Hippocampus  
             mRNA No change in any subdivision of hippocampush,i n=8C/8SZ; n=15C/15SZ 
 Other regions  
             mRNA No change in any subdivision of thalamusl,m,n n=8C/12SZ; n=16C/14SZ; 15C/15SZ 
 No change in parietotemporald, entorhinal and perirhinal cortexi n=15C/15SZ; n=15C/15SZ 
 Increase in vermis and RH of cerebellum by 100-110%r n=9C/10SZ 
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             protein No change in ACCe n=8C/13SZ 
Abbreviations: aDracheva et al., 2001, bWeichert et al., 2012, cBeneyto and Meador-Woodruff, 2008, dAkbarian et al., 1996, eKristiansen et 
al., 2006, fKristiansen et al., 2010a, gGao et al., 2000, hMcCullumsmith et al., 2007, iBeneyto et al., 2007, jVrajova et al., 2010, kToro and 
Deakin, 2005, lIbrahim et al., 2000, mDracheva et al., 2008, nClinton and Meador-Woodruff, 2004, oLe Corre et al., 2000, pClinton et al., 
2006, qNudmamud-Thanoi and Reynolds, 2004, rScmitt et al., 2010, sGrimwood et al., 1999. ACC=anterior cingulate cortex, 
BA=Brodmann’s area, C=control, CA2=cornu ammonis 2 of hippocampus, CM=central medial thalamus, DLPFC=dorsolateral prefrontal 
cortex, DM=dorsomedial thalamus, ER=endoplasmic reticulum, LD=lateral dorsal thalamus, LH=left hemisphere, NMDAR=N-methy-D-
aspartate receptor, NR1/2A/2B/2C/2D=NMDAR subunits, RH=right hemisphere, STG=superior temporal cortex, SZ=schizophrenia. 
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 Although these studies show behavioural abnormalities that mirror 
schizophrenia symptoms following NR2B but not NR2A antagonist treatments in 
adult animals, these abnormalities are not as extensive as those observed with non-
selective NMDAR antagonists. Due to the expression pattern of the NR2 subunits in 
early development and the relevance of the developmental neurobiology of 
schizophrenia, NR2 antagonist treatment may need to be further examined in a 
perinatal model in order to verify its relevance to the aetiology of schizophrenia. 
Gene knockout studies have shown that targeting the NR2 subunits specifically 
causes different outcomes. For example, NR2A knockout mice exhibit reduced 
anxiety and depression-like behaviour (Boyce-Rustay and Holmes, 2006) and normal 
PPI (Spooren et al, 2004) but do also show evidence of cognitive deficits with 
reduced LTP and spatial memory impairments (Bannerman et al., 2008). Mice with a 
complete knockout of NR2B die shortly after birth due to an impaired suckling 
response and cannot undergo behavioural analysis without hand feeding (Kutsuwada 
et al., 1996), highlighting the importance of this subunit to development. A recent 
study has shown that there are spatial and non-spatial memory deficits following a 
gene-targeted forebrain-specific deletion of NR2B in adult mice, whereas 
hippocampal-restricted deletion of NR2B induces a selective working memory 
deficit (von Engelhardt et al., 2008). 
Anastasio and colleagues (2009) have investigated the behavioural and 
cellular effects of perinatal NR2A and NR2B antagonism. They reported enhanced 
apoptosis following perinatal (PN7, 9 and 11) NR2A antagonist treatment (10 and 20 
mg/kg NVP-AAM077) in addition to a locomotor sensitisation effect to a PCP 
challenge, while perinatal NR2B antagonist treatment (1 or 5 mg/kg ifenprodil) did 
not produce elevated apoptosis or a locomotor sensitisation to PCP (Anastasio et al., 
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2009). The NR2B antagonist (ifenprodil) used, is not as potent or specific to the 
NR2B subunit as Ro 63-1908 (Zhou et al., 1999) in which doses of up to 30 mg/kg 
have been used in adult rodents. Therefore, this dose of ifenprodil may not be high 
enough to see any behavioural effects and hence there remains the possibility that 
NR2B antagonist-induced apoptosis does occur. Furthermore NVP-AAM077 is not 
completely specific to NR2A, it also has NR2B binding properties (Frizelle et al, 
2006). While it is possible that the apoptotic effect may be related to the NR2A-
containing NMDAR’s, this may leave an imbalance of NR2 subunits (possibly via a 
responsive upregulation of NR2A subunits and hence a relative decrease in NR2B), 
which may cause behavioural and neurochemical abnormalities reminiscent of 
schizophrenia. To our knowledge no-one has investigated the effect of a perinatal 
NR2B blockade on neurotransmitter receptors or proteins in the brain. 
Changes in NMDAR subunit expression have been observed following 
NMDAR antagonist treatment. Acute treatment with PCP on PN7, increased the 
expression of membrane NR2B protein and decreased the level of NR2B protein 
eight hours after administration in the endoplasmic reticulum in the frontal cortex of 
the rat brain (Anastasio and Johnson, 2008). This was suggested to be due to an 
increase in the trafficking of the NR2B subunit to the membrane. This short-term 
upregulation of NR2B was accompanied by an increase in the level of PSD-95 but 
not the NR2A subunit (Anastasio and Johnson, 2008). On the other hand sub-chronic 
treatment with PCP resulted in an elevated membrane and endoplasmic reticulum 
level of NR2A but not NR2B or PSD-95 which has been attributed to an increase in 
synthesis of NR2A protein (Anastasio and Johnson, 2008). Eight hours following 
NMDAR blockade an increase in the insertion of new NR2A subunit containing 
NMDARs has also been found in hippocampal cell cultures, however no change in 
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the NR2B subunit (von Engelhardt et al., 2009). Similarly Wilson et al (1998) found 
that NR2A mRNA was significantly increased in the striatum, cortex and 
hippocampus four hours following MK-801 treatment to rats on PN7 (Wilson et al., 
1998). It has been hypothesised that this imbalance of the NMDAR subunits, 
particularly the disproportionate NR2A/NR2B ratio, after treatment with NMDAR 
antagonists causes an acceleration of the normal NMDAR development processes 
(Wilson et al., 1998). This disproportionate development of the NMDAR subunits 
and the consequent alteration in NMDAR function could trigger a cascade of 
modifications to other signalling pathways and hence, render the brain more 
susceptible to schizophrenia onset later in life. Long-term analysis of NMDAR 
subunits in adult rats following perinatal PCP treatment has shown that the NR2A 
and NR2B subunit protein are increased in the prefrontal cortex but not the 
hippocampus (Owczarek et al., 2011). A similar study from our group found 
increases to NR2A in the hippocampus and NR2B in the prefrontal cortex at five 
weeks of age after perinatal PCP treatment but decreases to NR2A and NR2B in the 
hippocampus, but not prefrontal cortex, at adulthood highlighting the region-specific 
natures of these models (du Bois et al., 2012). 
1.4 The NRG1 Signalling Pathway and Schizophrenia: 
As previously mentioned, genetic linkage studies in several populations have 
provided evidence of NRG1 as a susceptibility gene for schizophrenia (Stefansson et 
al., 2002, Williams et al., 2003, Bakker et al., 2004, Fukui et al., 2006, Munafo et al., 
2006, Walss-Bass et al., 2006). NRG1 belongs to a family of genes encoding for 
growth/differentiation factors that exert their effects on various organs, including the 
brain, by activating the ErbB tyrosine kinase receptors (Garcia et al., 2000). The 
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NRG1 gene transcripts can be classed as six types and comprise over 31 different 
isoforms of NRG1 due to the presence of multiple promoter regions and alternative 
splicing of the gene sequence (Falls, 2003, Harrison and Law, 2006, Mei and Xiong, 
2008).   
NRG1 is synthesised in a membrane-bound form, often referred to as pro-
NRG1, a precursor to the mature NRG1 signalling protein that is generated from the 
proteolytic cleavage at the extracellular transmembrane (TM) region. The release of 
the soluble extracellular portion (inclusive of the epidermal growth factor (EGF) 
domain) of NRG1 occurs in most isoforms, with the exception of type III which 
remains in contact with the cell as both the N-terminal and C-terminal of the protein 
are located intracellularly (For review see Mei and Xiong, 2008). The cleavage is 
catalysed by the proteases tumor necrosis factor-α converting enzyme (TACE), β-site 
of amyloid precursor protein cleaving enzyme (BACE) and meltrin β, and leads to 
the diffusion of mature NRG1 into the extracellular space for functional purposes 
(Hu et al., 2006, Yokozeki et al., 2007, Mei and Xiong, 2008). 
The pattern of expression of NRG1 mRNA and protein in the rodent central 
nervous system during gestational development varies between the different 
isoforms. Type I mRNA is predominant during early embryogenesis whereas type II 
and III mRNA are not detected until midgestation but display a broader expression 
pattern in the brain (Meyer et al., 1997). Similarly NRG1 type I protein is expressed 
early in embryonic development with a strong distribution already present in the 
cortical plate, piriform cortex, septum, putamen and basal telencephalon by 
embryonic day 17 (Pinkas-Kramarski et al., 1994). This differential expression 
indicates that each isoform may have a distinct functional role during development 
(Meyer et al., 1997). At adulthood, the regional distribution of NRG1 transcripts and 
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protein is widespread throughout the rodent brain, mirroring that seen in the adult 
human brain (Law et al., 2004), however the expression remains in a distinct nuclei 
and cortical layer specific manner (Meyer and Birchmeier, 1994, Pinkas-Kramarski 
et al., 1994). To our knowledge the normal developmental expression of NRG1 
protein has not been studied from postnatal to adult levels but is essential to our 
understanding of the NRG1 signalling system, its location, function and interactions 
with other proteins. 
ErbB4 is the predominant receptor for NRG1 in neurons (Bjarnadottir et al., 
2007) with emerging evidence showing a preferential location on parvalbumin-
containing GABAergic interneurons (Fazzari et al., 2010).  Alternative splicing of 
ErbB4 transcripts is known to generate at least four isoforms made up of different 
combinations of juxtamembrane (JMa and JMb) and intracellular regions (CYT1 and 
CYT2), which consequently are coupled to distinct signalling pathways inside the 
cell (For review see Mei and Xiong, 2008). The activation of ErbB receptors by 
NRG1 results in the formation of homodimers or heterodimers of the various 
receptor subtypes (ErbB1-4) and the phosphorylation of the intracellular kinase 
domain. These phosphorylated tyrosine residues are protein binding sites for 
downstream signalling molecules and enzymes that can have varying effects on the 
regulation of transcriptional and translational factors in the cell (Mei and Xiong, 
2008). 
 Researchers have found altered levels of NRG1 subtypes in postmortem 
brain tissue of schizophrenia patients. An upregulation of NRG1 type I mRNA has 
been observed in the dorsolateral prefrontal cortex and hippocampus of 
schizophrenia subjects compared to control (Hashimoto et al., 2004, Law et al., 
2006), however results are inconsistent for the protein levels and depend on the 
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fragment or isoform of NRG1 examined (Chong et al., 2008, Boer et al., 2009, 
Barakat et al., 2010, Stuart et al., 2011, Marballi et al., 2012). Furthermore, an 
association between a single nucleotide polymorphism (SNP) in the at-risk haplotype 
of NRG1 and altered NRG1 transcript expression in the hippocampus has been 
reported (Law et al., 2006).  
An association between the ErbB4 gene and schizophrenia has also been 
reported. The identification of single SNP’s in the non-coding, intronic region of the 
candidate gene and the increased disease risk for individuals who carry these SNP’s 
has lead researchers to investigate the possible functional consequences of these 
genetic variations (Norton et al., 2006, Silberberg et al., 2006, Law et al., 2007). 
Indeed it has been shown that certain splice-variants of ErbB4 mRNAs are altered in 
the brain of schizophrenia subjects (Law et al., 2007). CYT-1 and JM-a isoforms of 
ErbB4 are increased in the prefrontal cortex but not the hippocampus compared to 
controls and interestingly a positive correlation has been found between the 
abnormal expression of these isoforms and the various risk SNPs for schizophrenia 
(Silberberg et al., 2006, Law et al., 2007). A similar increase in ErbB4 protein in the 
prefrontal cortex but not the hippocampus has also been observed in schizophrenia 
subjects (Chong et al., 2008, Stuart et al., 2011). 
Several genetic knockout animal studies have also highlighted the potential 
role of NRG1 in brain and behavioural abnormalities that are related to 
schizophrenia. Results have revealed that TM-domain Nrg1 heterozygous mutant 
mice display hyperlocomotion, increased aggressive and exploratory behaviours, 
social interaction deficits and have impaired PPI compared to wild type mice when 
tested at adulthood (Stefansson et al., 2002, Karl et al., 2007, O'Tuathaigh et al., 
2007, O'Tuathaigh et al., 2008). Chen and colleagues (2008) recently reported that 
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adult mutant mice heterozygous for type III Nrg1 also show disrupted PPI as well as 
impairments in working memory tasks, but no change in locomotor activities (Chen 
et al., 2008). These behavioural alterations are similar to those observed with 
NMDAR hypofunction in rodents and are also representative of schizophrenia 
symptomology. While these animal models support the possibility that genetic 
mutations in NRG1 could contribute to schizophrenia symptomology, as stated by Li 
and colleagues (2007), mutations in NRG1 genes are only likely to account for a 
small fraction of schizophrenia cases. In other cases, primary dysfunction in other 
genes/signalling pathways (eg glutamate/NMDAR) may lead to disrupted 
development of the NRG1 system and subsequently schizophrenia symptomology.  
1.5 NMDAR and NRG1 Interactions: 
The NR2 subunits of the NMDAR and the ErbB4 receptor share a common 
anchoring region on the PDZ2 domain of PSD-95 and other molecules in the PSD 
and through this commonality it is thought that interactions occur (Garcia et al., 
2000) (Figure 1.1).  
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Figure 1.1. Interactions and locations of NMDAR, NRG1, ErbB4, GABAAR and CB1R molecules on glutamatergic and GABAergic neurons.  
There have been various reports of NMDAR modulation by NRG1 
signalling. Firstly, it has been shown that Nrg1 EGF-domain heterozygous mutant 
mice display a reduction in MK-801 binding in the prefrontal cortex, suggestive of 
reduced NMDAR expression (Stefansson et al., 2002). Other studies have found that 
NRG1 stimulation in the prefrontal cortex enhances the association of ErbB4 with 
both PSD-95 and the NR1 subunit in schizophrenia patients and causes a reduction in 
NR2A phosphorylation and NMDAR activation and an increase in NMDAR 
internalisation (Gu et al., 2005, Hahn et al., 2006). Highlighting a regional difference 
in signalling pathways, the disruption of NRG1-mediated ErbB4 stimulation in the 
hippocampus, also results in the loss of NMDARs (Li et al., 2007). Application of 
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NRG1 to cultured hippocampal neurons does not affect the mRNA expression levels 
of the NR2 subunits (Okada and Corfas, 2004) however, it has been found that 
NRG1 signalling in the hippocampus enhances phosphorylation of the NR2B 
subunit, concurrent with ErbB4 phosphorylation and the activation of Fyn and Pyk2 
(proline-rich tyrosine kinase 2), two non-receptor tyrosine kinases thought to be 
involved in the downstream amplification of NRG1 signalling (Bjarnadottir et al., 
2007). NR2B was also found to be hypophosphorylated in the hippocampus of TM-
domain NRG1+/- mutant mice, as well as in ErbB4+/- mutant mice, which can lead to 
reduced channel opening and functioning of the NMDAR, but the 
hypophosphorylation was reversed with clozapine treatment (Moghaddam, 2003, 
Bjarnadottir et al., 2007). Interestingly, clozapine has also been shown to increase 
NR2B-containing NMDAR currents in the nucleus accumbens (Wittmann et al., 
2005). From these findings it has been speculated that attenuated NRG1 signalling in 
the hippocampus may cause abnormal modulation of NMDAR function through the 
altered regulation of NR2B phosphorylation and hence, contribute to the 
pathophysiology of schizophrenia (Bjarnadottir et al., 2007). Adding further 
complications to the regional specificity of NRG1 signalling, NR2C mRNA 
expression has been found to be decreased in the cerebellar molecular layer of the 
right hemisphere and vermis in a population of schizophrenia patients with a NRG1 
polymorphism (Schmitt et al., 2010). Supporting this finding, the NRG1-β isoform 
has been shown to upregulate the expression of NR2C mRNA in cultured cerebellar 
slices (Ozaki et al., 1997). Together these findings reveal the differential effects that 
NRG1 signalling has on the NMDAR subunits in the different brain regions, 
however there is still work to be done in order to further understand this complex 
signalling system. 
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While it has been shown that the NRG1-ErbB4 signalling pathway can affect 
glutamatergic function, the reverse may also be true and the activity of NRG1 could 
be influenced by the NMDAR. The link between the NR2 subunits and the PSD 
provides support for a disruption to the NRG1/ErbB4 system following an NMDAR 
insult, as ErbB4 is also physically linked to PSD proteins (Figure 1.1). Results have 
shown that PSD-95 and ErbB4 are capable of forming a ternary complex in neurons, 
which considerably increases tyrosine phosphorylation of the ErbB4 receptor and 
enhances NRG1-induced ErbB4 signalling (Huang et al., 2000). It is therefore likely 
that this regulation of the NRG1/ErbB4 pathway by PSD-95 could be affected by 
disruptions to the NMDAR, or more specifically the NR2 subunits, and play a major 
role in schizophrenia pathophysiology. Recent data from our laboratory has shown 
that perinatal PCP treatment produces alterations in NRG1 and ErbB4 protein 
expression throughout development in the prefrontal cortex but not the hippocampus 
(du Bois et al., 2012). In addition, an article by Feng and colleagues (2010) found 
that chronic treatment with the specific NMDAR antagonist MK-801 in adult rats 
produced an increase in NRG1 and ErbB4 protein expression in the prefrontal cortex 
and hippocampus (Feng et al., 2010). Therefore regulation of NRG1/ErbB4 
signalling via the NMDAR is possible, however the exact mechanism of how this 
occurs remains unknown and whether there is region or subunit specificity also 
remains elusive. Furthermore, a blockade of the NMDAR has the ability to produce 
functional deficits in GABAergic interneurons in certain cortical areas and the 
hippocampus (Li et al., 2002, Braun et al., 2007, Homayoun and Moghaddam, 2007) 
which similarly has been noted in schizophrenia pathology (Wassef et al., 2003). 
More specifically it has been shown that the loss of parvalbumin and GAD67 in 
cortical interneurons following NMDA antagonism can be attributed to the NR2A 
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subunit (Kinney et al., 2006). As mentioned previously these interneurons are the 
preferential location of ErbB4 receptors and so it is highly probable that alterations 
to NMDAR functioning will affect ErbB4.  
1.6 Inhibitory Neurotransmission and Schizophrenia 
The GABAergic and cannabinoid systems are key regulators of inhibition 
within the brain. Both systems play an important role in regulating glutamatergic 
transmission (Figure 1.1). GABA signals through the ionpotropic GABAAR as well 
as the metabotropic GABAAR. The endogenous cannabinoids (anadamide, 2-
arachidonylglycerol) signal via the g-protein coupled CB1 and CB2 receptors. 
Cannabinoid CB1 receptors (CB1R) are more abundant in the CNS than CB2, with the 
latter playing a leading role in immune related functions. CB1Rs are highly abundant 
on glutamatergic and GABAergic neurons in the CNS where it plays a role in the 
inhibition of glutamate and GABA release. In humans and rodents, CB1Rs are 
involved in the regulation of a variety of behaviours including, but not limited to, 
motor activity, pain sensitivity, learning, memory and cognition (Rodriguez de 
Fonseca et al., 1998; Strangman et al., 1998; Varvel et al., 2009). CB1Rs are 
functionally active in early gestation (Berrendero et al., 1998; Berrendero et al., 
1999; Mato et al., 2003) and throughout development there is a general increase in 
CB1R levels in the human, monkey and rat brain, although expression remains region 
specific (Belue et al., 1995; Berrendero et al., 1999; Eggan et al., 2010a; Mato et al., 
2003). The GABAAR also displays a distinct developmental and regional expression 
in the rat brain (Xia and Haddad, 1992), particularly in terms of the individual 
subunits, with expression emerging in embryonic development, highlighting the 
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major role of the GABAergic system in neuronal migration, differentiation and 
survival (for review see Galanopoulou, 2008). 
Both the GABAergic and cannabinoid systems have been implicated in 
neurodevelopmental disorders of psychosis, such as schizophrenia. A deficit of 
GABAergic signalling has been implicated in schizophrenia as reductions in 
GABAergic interneurons and increased levels of GABAARs have been observed in 
postmortem human schizophrenia brain tissue compared to controls (Benes et al., 
1992; Benes et al., 1996a; Benes et al., 1996b; Dean et al., 1999; Deng and Huang, 
2006; Newell et al., 2007b). Increased levels of CB1R binding in the prefrontal and 
cingulate cortices have also been found in schizophrenia brain tissue (Dalton et al., 
2011; Giuffrida et al., 2004; Newell et al., 2006; Zavitsanou et al., 2004), however a 
decrease in CB1Rs has been found in two areas of the prefrontal cortex (Egan et al., 
2008; Egan et al., 2010b). Furthermore it has been shown that susceptible individuals 
who use cannabis (which activates the CB1R), especially at the developmental stage 
of adolescence, display a range of schizophrenia-like symptoms and have an 
increased risk for the development of schizophrenia (Caspari, 1999; Linszen et al., 
1994; van der Stelt and Di Marzo, 2003). Considering not every individual who uses 
cannabis develops schizophrenia symptoms it is thought that there may be an 
underlying predisposition that renders that brain more vulnerable to the effects of 
cannabis (Boucher et al., 2007b). 
Young adult rats treated subchronically with PCP show schizophrenia-like 
cognitive deficits, which are worsened when subjected to ∆9-tetrahydrocannabinol 
(THC; the active ingredient in cannabis) (Viagno et al, 2009). These rats also display 
a reduction in functional CB1Rs in the prefrontal cortex, hippocampus and substantia 
nigra, which may contribute to the greater sensitivity (Vigano et al, 2009). Similarly, 
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a genetic knockout animal study has highlighted the potential role of a disruption in 
the NRG1 signalling system in inducing a vulnerability to the effects of cannabis 
(Boucher et al., 2007b). As previously mentioned, TM-domain Nrg1 heterozygous 
mutant mice already display schizophrenia-like behaviours (Stefansson et al., 2002, 
Karl et al., 2007, O'Tuathaigh et al., 2007, O'Tuathaigh et al., 2008). Interestingly, 
when treated with THC these mice show a greater sensitivity to the behavioural 
effects of this main psychoactive ingredient of cannabis (Boucher et al., 2007a). 
These mice also show a borderline significant alteration in CB1Rs, which may 
contribute in part, to this increased susceptibility (Newell et al, 2013).   
1.7 The Hippocampus and Prefrontal Cortex in Schizophrenia 
The hippocampus and prefrontal cortex are important brain regions that 
display structural abnormalities and functional disruptions in the schizophrenia brain 
(Breier et al., 1992). The hippocampus plays an important role in learning and 
memory. Several lines of research have shown that there are various structural and 
functional abnormalities in the hippocampus of the schizophrenia brain, including a 
reduction in hippocampal volume, altered synaptic connections and changes in 
neurotransmitter receptors (for review see Harrison 2004), as well as impairments in 
declarative and recognition memory that are associated with reduced hippocampal 
activation (for review see Preston et al., 2005). Furthermore animal models involving 
a neonatal hippocampal lesion have shown schizophrenia relevant behaviours and 
neurochemical changes at the periadolescent period such as deficits in social 
interactions, deficits in learning and memory, increased locomotor activity and 
disruptions to dopaminergic and glutamatergic signalling (for review see Tseng et 
al., 2009). This animal model has also shown gender differences in terms of age of 
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onset and symptom severity that closely model that seen in the human disease (Tseng 
et al., 2009). Therefore study into the levels of proteins implicated in the disorder in 
the hippocampus and associated connections appears critical to understanding the 
disorder and providing better treatment options. 
The prefrontal cortex plays a crucial role in cognitive planning and working 
memory and has been heavily implicated in schizophrenia (for review see Glahn et 
al., 2005). Many neuroimaging studies have found a decrease in activation of the 
prefrontal cortex and a reduction in blood flow to the dorsolateral prefrontal cortex 
specifically in schizophrenia patients when performing tasks related to working 
memory, a cognitive function performed by the prefrontal cortex (Glahn et al., 2005; 
Grace, 2000, Weinberger et al., 1986). While the frontal cortex as a whole appears to 
show no differences in cortical volume between schizophrenia and control subjects 
or gender or hemispheric differences (Highley et al., 2001), structural anomalies 
have been found in the prefrontal cortex, including reduced grey matter volume in 
the inferior prefrontal cortex of schizophrenia patients (Buchanan et al., 1998, Harms 
et al., 2010). Animal studies with a genetic knockout targeted to the NR1 subunit of 
the NMDAR in the excitatory neurons of the medial prefrontal cortex have shown 
impairments of certain aspects of schizophrenia-like behaviours such as PPI and 
short-term memory (Rompala et al., 2013). Although there were no impairments in 
other schizophrenia related behaviours this suggests that the prefrontal cortex or 
glutamatergic connections to and/or from the prefrontal cortex play a role in a subset 
of cognitive symptoms integral to schizophrenia (Rompala et al., 2013). Therefore 
with the hippocampus and prefrontal cortex consistently reported to be involved in 
schizophrenia we chose to focus on these brain regions in this study. 
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1.8 Summary 
Schizophrenia is a complex, neurodevelopmental disorder that is thought to 
involve NMDAR dysfunction in the hippocampus and prefrontal cortex. The NR2B 
subunit of the NMDAR is the most abundantly expressed in early development and 
is the only NR2 subunit to show protein changes in the postmortem schizophrenia 
brain to date. The NR2 subunits and NRG1 are functionally connected, with 
alterations to NRG1 stimulation of ErbB4 affecting NMDAR channel properties and 
subunit specific phosphorylation. More research is required to determine whether 
this interaction is reciprocal, developmentally regulated, brain region specific and 
particularly whether it is altered in disorders such as schizophrenia. Furthermore, 
cannabis use, particularly among adolescents, is also implicated as being a risk factor 
for developing schizophrenia symptoms however it is unknown why some 
individuals are more vulnerable than others. An early developmental disruption, such 
as a blockade of the NR2B subunit and consequent imbalance of NR2 subunits, may 
render the brain more susceptible to the effects of cannabis via altering the 
endogenous cannabinoid system. Alterations to NR2B functioning during this time 
may consequently affect NRG1 signalling which has already been shown to increase 
sensitivity to the effects of cannabis. Ultimately the determination of the relationship 
between NR2B and NRG1 during development and the role these systems may play 
in modulating other aspects of brain chemistry will further our understanding of 
schizophrenia pathophysiology. 
1.9 Aims and Hypotheses 
The overall aim of this PhD thesis was to assess the role of the NR2B subunit 
in the pathophysiology and development of schizophrenia. To assess this, the thesis 
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was divided into two parts. Part A utilised postmortem human brain tissue to 
examine whether there are alterations in NR2B protein in schizophrenia. Part B 
utilised an animal model to examine whether disruptions to NR2B during early brain 
development could produce changes in brain systems that are involved in 
schizophrenia.  
 
Aims - Part A: 
1. To examine protein and binding levels of the NR2B subunit in the hippocampus of 
schizophrenia subjects compared to controls, and determine any gender or 
hemisphere specific alterations. To investigate the relationship between NR2B and 
NRG1 in the hippocampus of the schizophrenia brain. 
 
2. To examine protein and binding levels of the NR2B subunit in the dorsolateral 
prefrontal cortex of schizophrenia subjects compared to controls, and determine any 
gender or hemisphere specific alterations.  
 
Aims – Part B: 
1. To determine the normal developmental profile of NMDAR, NR2A, NR2B, 
NRG1, ErbB4, GABAAR and CB1Rs in the mouse brain. 
 
2. To determine the effect of a perinatal disruption to brain development (NR2B 
antagonist treatment) on the developmental profile of the NMDAR, NRG1, 
GABAergic and cannabinoid signalling systems. 
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3. To investigate the effect of gender on the developmental profiles of the NMDAR, 
NRG1, GABAergic and cannabinoid signalling systems. 
 
Hypotheses  
Disruptions to the NMDAR are widely believed to contribute to the cognitive 
deficits associated with schizophrenia. It was hypothesised that this thesis will show 
evidence of altered expression of the NR2B subunit of the NMDAR in cognitive 
related brain regions (prefrontal cortex and hippocampus) in schizophrenia. As there 
is evidence to suggest that a) schizophrenia shows gender-specific phenotypes and b) 
glutamatergic alterations in the schizophrenia brain may be lateralised, it was 
hypothesised that changes in NR2B in these regions in schizophrenia will be gender 
and hemisphere specific.  
Evidence from both genetic and environment studies suggest that the NR2B 
subunit of the NMDAR may not only be involved in the pathophysiology and 
symptomology of schizophrenia, but may also be causal to the development of 
schizophrenia. It is hypothesised that impacts that target this receptor subunit at a 
critical point in development will lead to long-term changes, not only in the 
NMDAR, but also in other related systems (such as neuregulin, GABA, cannabinoid) 
that are implicated in the pathophysiology of schizophrenia.  
1.10 Methodologies: 
The techniques of Western blot and In situ Radioligand Binding 
Autoradiography were used throughout this thesis to measure protein and binding 
densities, respectively, of the proteins of interest. Western blot utilises specific 
antibodies to determine the levels of particular proteins in homogenised tissue 
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samples. This technique can be applied to crude tissue homogenates (which include 
membrane, cytosol, nucleus, organelles etc) or fractionated samples to measure 
levels in specific cell compartments. Throughout this study, Western blot was 
performed on crude homogenates to allow the measure of total protein expression in 
the brain region of interest. 
In situ radioligand binding autoradiography uses radiolabelled ligands that bind 
to specific sites on protein receptors or receptor subunits in tissue slices and is widely 
used to characterise receptors and their anatomical distribution. In addition, these 
binding sites are often the sites for binding by endogenous and exogenous ligands, 
which compete for that site with the radiolabelled ligand. As a result, radioligand 
binding is often used in pharmacological studies to measure receptor occupancy 
following administration of various pharmacological compounds to assess drug 
targets and general ability of pharmacological compounds to bind to sites of interest. 
Western blot and radioligand binding are often used in parallel to measure 
protein levels in tissue samples (Dean et al., 2002). It should not be expected 
however that these two methods always yield the same result. Often the antibodies 
and radioligands will bind to different sites on the protein and due to the 
homogenised versus sliced tissue approach, they have different access to cellular 
compartments to label the relevant proteins. For example, due to the major cell lysis 
that occurs following tissue homogenisation it is likely that Western blot in crude 
homogenates will label the majority of available proteins. In contrast, in situ 
radioligand binding on tissue slices may not have access to label all sites within the 
cell. Previous studies have shown differences between findings obtained from 
radiologand binding and crude Western blot, for example reported changes in 
binding to the Mu opioid receptor in schizophrenia that were not observed when the 
Chapter 1 
 
 
38
protein levels were measured via Western blot. The authors interpreted this as 
representing a change in availability of receptor binding sites, independent of 
changes in total protein levels (Scarr et al., 2012). 
1.11 Significance: 
Schizophrenia is a severely debilitating mental disorder that affects 
approximately 1% of the Australian population. Currently, the treatments available 
for the disorder are unable to provide relief of all symptoms, as the underlying 
neuronal mechanisms of schizophrenia pathophysiology are not known. Furthermore, 
there are various side effects associated with these treatments and both the treatment 
and support costs place a major burden on many Australian families. Unravelling the 
neurochemical disturbances that contribute to the cause of schizophrenia and their 
interactions with other neurotransmitter systems would benefit not only those 
suffering from the disorder, but their families and friends and those that surround 
them. 
 This study was the first to examine the gender and hemisphere specific 
alterations of NR2B in the prefrontal cortex and hippocampus in the postmortem 
schizophrenia brain, which hopefully will encourage others to investigate these 
variables in the future in pursuit of a more specific pathophysiological discovery of 
schizophrenia or a gender specific treatment.  This study was also the first to 
examine the neurochemical effects of perinatal NR2B antagonist treatment in a 
mouse model and provides further understanding of the relationship between the 
NMDAR and NRG1 signalling pathways, both of which have been implicated in 
schizophrenia, as well as the role they may play in increasing sensitivity to the 
psychosis-inducing effects of cannabis. 
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2 HEMISPHERE SPECIFIC ALTERATIONS IN NR2B PROTEIN IN THE 
HUMAN HIPPOCAMPUS 
2.1 Introduction 
The hippocampus plays an important role in learning and memory, cognitive 
functions that are widely believed to be disrupted in schizophrenia (Boyer et al., 
2007). Several lines of research have shown that there are various structural and 
functional abnormalities in the hippocampus of the schizophrenia brain, including a 
reduction in hippocampal volume, altered synaptic connections (evidenced through 
reductions in synaptosomal proteins such as synaptophysin, SNAP-25 and synapsin) 
and changes in neurotransmitter receptors (for review see Harrison, 2004). 
Furthermore, with schizophrenia being a disorder of neurodevelopment, animal 
models involving a neonatal hippocampal lesion have shown promising results in 
terms of schizophrenia relevant behaviours and neurochemical changes at the 
periadolescent to adult period (Tseng et al., 2009). Collectively, studies point to the 
hippocampus as central to the pathophysiology of schizophrenia. 
Dysregulation of glutamatergic neurotransmission is a widely accepted 
occurrence in the schizophrenia brain (Konradi and Heckers, 2003). The NMDAR is 
an ionotropic glutamate receptor that appears to play a central role in schizophrenia 
pathophysiology. The NMDAR is assembled in various subunit combinations, with 
two obligatory NR1 subunits and two other NR2 A, B, C, D or rarely NR3 A, B 
subunits (Paoletti, 2011). Various studies have found alterations in NMDAR binding 
and NR1 subunit mRNA and protein in the hippocampus of schizophrenia subjects 
(for review see Geddes et al, 2011). Some replicated findings include a decrease in 
NR1 mRNA in the dentate gyrus of schizophrenia patients (Gao et al., 2000, Law 
and Deakin, 2001), a decrease or no change in NMDAR binding density (Gao et al., 
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2000, Pilowsky et al., 2005, Beneyto et al., 2007) and most interestingly a more 
pronounced decrease in NMDAR binding and NR1 mRNA and protein 
measurements in the left hippocampal hemisphere of schizophrenia subjects 
compared to the right hemisphere (Law and Deakin, 2001, Pilowsky et al., 2005, 
Vrajova et al., 2010). These studies suggest a lateralised dysregulation of NR1 
mRNA and protein in the hippocampus of schizophrenia subjects. With regards to 
the NR2 subunits, one study has reported an increase in NR2B subunit mRNA in the 
CA2 region of the hippocampus in schizophrenia, with two further studies reporting 
no change, and no changes being reported for the NR2A mRNA, or the less 
expressed 2C and 2D subunits (Gao et al., 2000, Beneyto et al., 2007, 
McCullumsmith et al., 2007). One study did measure NR2B binding density in the 
hippocampus, and while they found no change in schizophrenia subjects (Beneyto et 
al., 2007), it is important to highlight that they did not consider hemisphere effects, 
which appear to be important to schizophrenia pathology in the hippocampus 
(Harrison et al, 2003). 
The NR2 subunit composition defines the functional properties of the 
NMDAR (Hardingham et al., 2002, Hu et al., 2008), therefore to understand the 
NMDAR dysregulation in schizophrenia it is critical to investigate alterations to the 
NR2 subunits. NR2A and NR2B subunits are the principle NR2 subunits in the 
hippocampus (Law et al., 2003); evidence suggests that the NR2B subunit in the 
hippocampus is particularly important for NMDAR channel function (Akashi et al., 
2009), LTP and associated cognitive functions such as spatial learning (Clayton et 
al., 2002). Accordingly, specifically targeting the NR2B subunit has been suggested 
as a novel mechanism to treat cognitive dysfunction in schizophrenia patients (Mony 
et al., 2009, Menniti et al., 2013). Of the studies that have examined NR2A and 
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NR2B proteins in various brain regions in schizophrenia, NR2B is predominantly 
implicated with four studies showing altered NR2B protein (Grimwood et al., 1999, 
Ibrahim et al., 2000, Clinton et al., 2006, Kristiansen et al., 2010a) and none 
reporting altered NR2A (see Geddes et al, 2011), however there are also a number of 
studies that have found no change in NR2B protein levels (Grimwood et al., 1999, 
Ibrahim et al., 2000, Clinton et al., 2006, Kristiansen et al., 2006, Beneyto et al., 
2007, Beneyto and Meador-Woodruff 2008). Furthermore, a number of studies have 
suggested an association or reciprocal signalling between the NMDAR and NRG1 
protein, NRG1 being one of the leading candidate genes for schizophrenia, 
(Stefansson et al., 2002, Gu et al., 2005, Hahn et al., 2006, Walss-Bass et al., 2006, 
Li et al., 2007, Feng et al., 2010, Geddes et al., 2011, du Bois et al., 2012), with 
NR2B and NRG1 particularly associated in the hippocampus (Bjarnadottir et al., 
2007). The NR2 subunits share a structural link with NRG1 via its receptor, ErbB4, 
with both anchoring to the PSD95 family of scaffolding proteins, providing a basis 
for this association. NRG1 mRNA is reported to be altered in the hippocampus of the 
schizophrenia brain (Law et al., 2006) and the 50 kDa fragment of NRG1 protein is 
reduced in the hippocampus of the schizophrenia brain (Marballi et al., 2012). Our 
group has shown that NRG1 protein is decreased, specifically in the left hippocampal 
hemisphere of schizophrenia subjects compared to controls (Stuart et al., 2011), 
further supporting a hemisphere specific deficit in the hippocampus.  
The aim of this study was to determine whether there were alterations in 
NR2B subunit protein and [3H]Ifenprodil binding density in the hippocampus of 
schizophrenia subjects compared to control subjects and to determine whether any 
effects are hemisphere or gender specific.  In addition, we aimed to determine 
whether there was a relationship between the observed NR2B protein and binding 
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measurements and NRG1 and ErbB4 protein measured in the same tissue cohort 
(Stuart et al., 2011).  
2.2 Materials and Methods 
2.2.1 Brain Tissue 
Postmortem human brain tissue was acquired from the New South Wales 
Tissue Resource Centre (NSW TRC) at the University of Sydney. The cohort 
consisted of schizophrenia samples, with the diagnosis of schizophrenia confirmed 
according to the Diagnostic and Statistical Manual of Mental Disorders Fourth 
Edition (DSM-IV), and healthy controls, with no known history of psychiatric 
illness. For the protein analysis, 20 schizophrenia subjects versus 20 control subjects, 
and for the binding analysis, 20 schizophrenia subjects and 21 control subjects were 
included from the same cohort (Table 2.1). There were no significant differences in 
age, brain pH, postmortem interval (PMI) or brain weight between the schizophrenia 
and control subjects included in the protein (Age: t38 = -0.036, p = 0.971; Brain pH: 
t26.801 = 0.069, p = 0.945; PMI: t38 = -0.307, p = 0.761; Brain Weight: t38 = 1.085, p = 
0.285) or binding (Age: t39 = 0.132, p = 0.895; Brain pH: t28.384 = -0.381, p = 0.706; 
PMI: t39 = 0.388, p = 0.700; Brain Weight: t39 = 0.792, p = 0.433) studies. All 
clinical assessments, selection of cases and brain region dissections were performed 
by the NSW TRC. The study was approved by the University of Wollongong Human 
Research Ethics Committee (HE99/222). 
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Table 2.1. Subject demographic and clinical characteristics. 
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2.2.2 Western Blot 
Tissue from the dentate gyrus of the hippocampus was weighed and manually 
homogenised in nine volumes of buffer containing 0.1 M Tris-HCl, 10 µl/ml 
protease inhibitor cocktail (Sigma), 0.625 µl/ml apoprotinin and 0.5 µl/ml glycerol. 
The amount of protein in each sample was determined using the Bradford Reagent 
Assay (BioRad, Hercules, CA, USA) following manufacturer’s instructions. Samples 
were diluted to 4 µg/µl and stored at -80°C until use. The following procedure was 
performed in triplicate. Samples were diluted in Laemmli’s sample buffer (Bio-Rad) 
and loaded into precast 4-12% bis-tris gels (Bio-Rad) with 10 µg of total protein per 
well, along with a molecular weight ladder (Precision Plus Protein™ Standards; Bio-
Rad) and run in XT-MOPS buffer (Bio-Rad) at 200 V for 55 minutes. The protein 
was transferred to polyvinylidene fluoride (PVDF) membrane (Bio-Rad) at 100 V for 
1 hour using Tris-glycine buffer (Bio-Rad) containing 20% methanol and blocked in 
phosphate-buffered saline containing Tween-20 (PBS-T) containing 5% skim milk 
for 1 hour at room temperature. Blots were then incubated overnight (4⁰C) with an 
anti-NR2B antibody (#MAB5778, 1/625; Millipore, Billerica, MA, USA) diluted in 
PBS-T containing 1% skim milk. A mouse anti-actin antibody was used as an 
internal standard (#MAB1501, 1/100 000; Millipore). Following primary antibody 
exposure, blots were washed for 3 x 5 minutes in PBS-T and incubated for 1 hour 
(room temperature) with a horseradish peroxidase (HRP)-conjugated secondary 
antibody (anti-rabbit: #AP307P, anti-mouse: #AP308P, 1/3 000; Millipore). Blots 
were washed for 3 x 5 minutes in PBS-T and the proteins of interest detected on 
Kodak BioMax MR Film (Sigma-Aldrich, Castle Hill, NSW, Australia) using the 
ECL Plus Western Blotting Detection Reagents kit (GE Healthcare, Piscataway, NJ, 
USA). The films were developed using the AGFA CP1000 film developer (AGFA 
Chapter 2 
 
 
46
Healthcare, Rydalmere, NSW, Australia) and analysed using Quantity One software 
version 4.6.7 (BioRad) connected to a GS-800 Calibrated Densitometer (BioRad). 
Quantification was performed blind to diagnosis. The optical density of each band 
was normalised to the respective β-actin band and averaged over the three runs.  
Western blot results for NR2B were correlated with NRG1 and ErbB4 protein levels 
from a previous study conducted in the laboratory (Stuart et al., 2011). 
2.2.3 In situ Radioligand Binding Autoradiography 
Hippocampus tissue sections for radioligand binding were cut on a cryostat at 
-18°C, at a thickness of 14 µm, mounted onto SuperFrost Plus slides (Menzel, 
Brunswick, Germany) and stored at -80°C until use. [3H]Ifenprodil binding was 
performed based on the methods previously used by Ibrahim et al., (2000) and 
Basham et al., (1999). Three slides from each subject were incubated in 0.05 M 
TrisHCl buffer (pH 7.4) with 20 nM [3H]Ifenprodil (NR2B antagonist: specific 
activity 40 Ci/mmol; PerkinElmer, Boston, MA, USA). Due to previous findings that 
[3H]ifenprodil has some affinity for sigma receptors, piperazine acceptor sites, and 
non-GluN2B polyamine sites (Basham et al., 1999, Hashimoto et al., 1993, 
Hashimoto et al., 1994), the following pharmacological inhibitors were included in 
the incubation assay:  3 µM R(+)-3-(3-hydroxyphenyl)-N-propylpiperidine 
hydrochloride (+3PPP; to block non-specific binding to the sigma receptor), 30 µM 
GBR-12909 (to block piperazine sites) and 1 mM trifluoperazine (to block low 
affinity polyamine sensitive sites on adrenergic, dopaminergic and cholinergic 
receptors) for 3 hours at 4oC to determine total binding. Adjacent sections were 
incubated in the same buffer, with the addition of 20 µM Ifenprodil (Sigma-Aldrich) 
to determine non-specific binding. All sections were then washed in 0.05 M Tris-HCl 
(pH 7.4) for 3 x 5 minutes at 4oC, rinsed in distilled water and air-dried overnight.  
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All slides were placed in cassettes and exposed to tritium-sensitive Kodak 
BioMax MR Film (Sigma-Aldrich) for 10 weeks. The films were developed using 
the AGFA CP1000 film developer (AGFA) and analysed using Quantity One 
software version 4.6.7 (BioRad) connected to a GS-800 Calibrated Densitometer 
(BioRad). Quantification was performed blind to diagnosis by obtaining the optical 
density (background corrected) in the dentate gyrus and averaging it from the three 
slides. 
2.2.4 Statistics 
 The statistical package used for data analysis was SPSS version 17 (IBM, 
Armonk, NY, USA). The data were checked for triplicate (standard deviation>30% 
mean) and population outliers (two standard deviations above or below the mean), as 
is widely used in this field (Weickert et al., 2013) and a Kolmogrov-Smirnov test 
was used to confirm the normality of the data. An independent samples t-test was 
used to determine differences between the schizophrenia and control subjects. 
Pearson’s correlations were then used to determine correlations between NR2B 
protein or binding density and diagnostic variables such as age, PMI and pH with all 
the data and antipsychotic medication, age of illness onset, and duration of illness in 
the schizophrenia group. An ANCOVA was then performed if there were any 
significant correlations with the demographic variables. Two-Way ANCOVAs, 
adjusted for demographic variables, were performed to examine the effect of 
hemisphere and gender on the diagnosis and if a significant effect was found, a one-
way ANOVA with Tukeys post-hoc analysis was conducted. Pearson’s correlations 
were then performed between NR2B binding and protein measurements and between 
NR2B protein and NRG1 and ErbB4 protein measurements from the same cohort 
(Stuart et al., 2011).  
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2.3 Results 
2.3.1 Left hippocampal deficits in NR2B subunit protein in schizophrenia subjects. 
We observed one band for NR2B protein at the expected molecular weight of 
approximately 175 kDa (see Figure 2.1a) as previously reported (Laurie et al., 1997). 
Two outliers were removed due to technical error, one from each diagnostic group. 
The schizophrenia and control groups remained matched for age (t36 = -0.402, p = 
0.690), PMI (t36 = -0.551, p = 0.585), brain pH (t25.626 = -0.076, p = 0.939) and brain 
weight (t36 = 1.129, p = 0.266). 
An Independent t-test showed that there was no difference between the NR2B 
protein density in the dentate gyrus of schizophrenia and control subjects (t36 = 
1.452, p = 0.155). NR2B protein density correlated significantly with brain pH (r = -
0.386, p = 0.017) and there was a trend for a correlation with the PMI (r = -0.318, p 
= 0.051) in the whole cohort (see Table 2.2). Similar correlation results were 
observed in the control subjects only (pH: r = -0.662, p = 0.002; PMI: r = -0.483, p = 
0.036) but were not observed in the schizophrenia subjects only (pH: r = 0.162, p = 
0.506; PMI: r = -0.116, p = 0.636). An ANCOVA correcting for brain pH and PMI 
confirmed that there was no difference in NR2B protein density between 
schizophrenia and control subjects (F1,34 = 2.004, p = 0.166). There was no 
correlation between protein density in the schizophrenia subjects and duration of 
illness, age of onset or medication history (Table 2.2). 
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Table 2.2. Pearson’s correlations for continuous variables with NR2B binding and 
protein. 
Variable  All subjects Control Schizophrenia 
  NR2B 
binding 
NR2B 
protein 
NR2B 
binding 
NR2B 
protein 
NR2B 
binding 
NR2B 
protein 
Age r -0.309 0.160 -0.408 0.207 -0.212 0.152  p 0.049* 0.338 0.067^ 0.395 0.369 0.534 PMI r 0.054 -0.318 0.061 -0.483 0.030 -0.116  p 0.738 0.051^ 0.794 0.036* 0.901 0.636 Brain pH r 0.068 -0.386 0.226 -0.662 -0.255 0.162  p 0.671 0.017* 0.324 0.002* 0.278 0.506 BW r -0.029 -0.067 0.152 -0.028 -0.218 -0.023 
 p 0.885 0.688 0.512 0.908 0.356 0.926 
Age Onset r     -0.007 0.313 
 p     0.977 0.193 
DOI r     -0.192 -0.056 
 p     0.430 0.819 
APD use r 
p 
    -0.368 
0.111 
-0.156 
0.525 
Abbreviations: AP = antipsychotic drug, BW = body weight, DOI = duration of illness, 
pH = brain acidity, PMI = post mortem interval. *: p<0.05; ^: 0.05<p<0.07. 
 
A two-way ANCOVA with the main effects of DIAGNOSIS and 
HEMISPHERE revealed a significant effect of hemisphere (F1,31=5.222, p=0.011) 
but no significant effect of diagnosis (F1,31=3.225, p=0.082) and no significant 
interaction (F1,31=0.673, p=0.418). A one-way ANOVA with Tukey’s post-hoc 
analysis revealed a significant difference between groups (F3,34=2.882, p=0.050) and 
a trend for a 43% decrease in the left hemisphere of the schizophrenia group 
compared to the left hemisphere of the control group (p=0.066) (see Figure 2.1b) 
(see Table 1 in Appendix for comparison of demographic variables by hemisphere). 
There was no effect of gender on NR2B protein density in the hippocampus (see 
Table 2 in Appendix for comparison of demographic variables by gender). 
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Figure 2.1. A: Representative Western blot bands of NR2B and actin protein. B: 
Hippocampal NR2B protein density in the left and right hemisphere of the 
schizophrenia and control brain. There was a 43% decrease in the left hemisphere of 
the schizophrenia subjects compared to the left hemisphere of the control subjects.  
^: p = 0.066 compared to Control Left. Horizontal and vertical bars represent 
mean±SEM for each group. Abbreviations: Sz = schizophrenia. 
 
 
2.3.2 No change in NR2B binding density in schizophrenia subjects compared to 
control.  
An Independent t-test showed that there was no difference between 
[3H]Ifenprodil binding in the schizophrenia and control subjects (t39 = 0.808, p = 
0.424).  
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Figure 2.2. Representative total and non-specific [3H]Ifenprodil binding in the 
hippocampus of this human tissue cohort. 
 
 [3H]Ifenprodil binding density correlated with age at death of the subjects in 
the whole cohort (r = -0.309, p = 0.049); there was a trend for a correlation in the 
control subjects only (r = -0.408, p = 0.067) but no correlation between the 
schizophrenia subjects and age at death (r = -0.212, p = 0.369) (Table 2.2). An 
ANCOVA to correct for age at death confirmed no difference in [3H]Ifenprodil 
binding density between schizophrenia and control subjects (F1,38 = 0.780, p = 
0.383). There was no correlation between [3H]Ifenprodil binding density in the 
schizophrenia subjects and length of illness, age of onset or medication history 
(Table 2.2). There were no effects of [3H]Ifenprodil binding on gender or hemisphere 
(Figure 2.3) (see Table 1 and 2 in Appendix for comparison of demographic 
variables in gender and hemisphere subgroups). 
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Figure 2.3. Hippocampal [3H]Ifenprodil binding density in the left and right 
hemisphere of the schizophrenia and control brain. Horizontal and vertical bars 
represent mean±SEM for each group. Abbreviations: Sz = schizophrenia. 
 
2.3.3 Positive relationship between NR2B and NRG1 protein.  
There was no correlation between NR2B binding and protein measurements 
(Table 2.3). The NR2B protein measurements and NRG1 (130-140 kDa) protein 
levels (from a previous study in our laboratory using the same cohort (Stuart et al., 
2011)) were found to have a significant positive correlation (r=0.343, p=0.043) 
(Table 2.3). Interestingly, this positive correlation was significant in the left 
hemisphere (r=0.462, p=0.047) but not right hemisphere (r=0.211, p=0.433) of the 
hippocampus (Table 2.3). There was no correlation between NR2B and ErbB4 (180 
kDa) protein levels (from a previous study using the same cohort (Stuart et al., 
2011)) (Table 2.3). 
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Table 2.3. Pearson’s correlations between NR2B binding and protein, and NR2B, NRG1 
and ErbB4 protein levels.   
  NR2B binding 
vs 
NR2B protein 
NR2B protein 
vs 
NRG1 protein 
NR2B protein 
vs 
ErbB4 protein 
NRG1 protein 
vs 
ErbB4 protein 
All subjects  r -0.050 0.343 0.210 0.157 
 p 0.776 0.043* 0.213 0.354 
Control r 0.003 0.296 0.141 0.141 
 p 0.990 0.218 0.564 0.554 
Schizophrenia r -0.187 0.281 0.167 0.070 
 p 0.457 0.293 0.509 0.789 
Left hemi r 0.134 0.462 0.269 0.117 
 p 0.596 0.047* 0.251 0.624 
Right hemi r -0.344 0.211 0.133 0.210 
 p 0.192 0.433 0.667 0.418 
Abbreviations: hemi = brain hemisphere, vs = versus. *: p<0.05. 
 
2.4 Discussion 
2.4.1 Left hippocampal deficits in NR2B subunit protein in schizophrenia  
In the present study we identified a 43% reduction in NR2B protein levels in 
the hippocampal dentate gyrus in schizophrenia. Interestingly, this reduction was 
present in the left hemisphere and not the right hemisphere, highlighting the 
hippocampal lateralisation in the pathology of schizophrenia. Further, we identified 
for the first time, a positive correlation between NR2B protein and NRG1 protein, 
which was also specific to the left hippocampal hemisphere. In addition, we have 
confirmed previous results, this time in a larger cohort (n=15 cf. n=20), indicating no 
change in [3H]-Ifenprodil binding to NR2B subunits in the hippocampus of 
schizophrenia subjects in comparison to control subjects (Beneyto et al., 2007) and 
extended these findings to report no hemisphere specific alteration in NR2B binding 
density.  
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It is well documented that the hippocampus is altered in schizophrenia and 
there is evidence to suggest that the left hemisphere shows more pronounced deficits 
in NMDAR expression than the right hemisphere. Studies investigating the effect of 
hemisphere have found a more pronounced decrease in NR1 mRNA and protein in 
the left hemisphere of schizophrenia subjects (Law and Deakin, 2001, Vrajova et al., 
2010) as well as a reduction in [123I]-CNS-1261 binding to the NMDAR channel in 
the left hippocampus of medication free schizophrenia subjects (Pilowsky et al., 
2005). Ours is the first study in the hippocampus to report such a lateralisation effect 
with any of the NR2 subunits, however, to our knowledge, the protein density of the 
other NR2 subunits has not yet been investigated in the hippocampus. It has 
previously been discussed (Beneyto and Meador-Woodruff, 2008) that deletion of 
the NR1 subunit in the CA1 region of the hippocampus results in reduced expression 
of the NR2B subunit in the dendrites of pyramidal neurons in mice (Fukaya et al., 
2003), suggesting our current findings could be associated with the reductions in 
NR1 previously reported in the left hippocampus in schizophrenia.  
While the present study found a reduction in NR2B protein levels, this was 
accompanied by no change in NR2B binding density. [3H]Ifenprodil binds to the 
polyamine site on NR2B subunits. While ifenprodil does also have some affinity for 
sigma, piperazine, adrenergic receptors and other polyamine sites (Basham et al., 
1999, Hashimoto et al., 1993, Hashimoto et al., 1994), pharmacological inhibitors 
were used to block these sites in the binding assay. Therefore, it is unlikely that the 
discrepancy between binding and protein is a result of [3H]Ifenprodil binding to sites 
other than NR2B. It is possible however that that these two techniques label different 
populations of NR2B subunits. Under the conditions used in the present study (i.e. 
the use of tissue sections rather than cell lysed homogenates), [3H]ifenprodil would 
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bind primarily to cell surface receptors. This suggests that the reduction observed in 
NR2B protein in the present study, might represent a reduction in intracellular levels. 
The implications of such localised reductions remain unclear (McCullumsmith et al., 
2014). Similar to our study, in cortical brain areas it has been shown that despite no 
change in NR2B binding (Beneyto and Meador-Woodruff, 2008), there was a 
reduction in NR2B protein in schizophrenia compared to control subjects, which was 
specific to the endoplasmic reticulum fraction of the cells (Kristiansen et al., 2010b). 
While we did not examine NR2B mRNA in the present study, two previous studies 
reported no change in NR2B mRNA levels in the dentate gyrus in schizophrenia 
(Beneyto et al., 2007, McCullumsmith et al., 2007), therefore it is unlikely the 
findings in the present study represent changes in NR2B production. It is possible 
however that our findings reflect disturbances to NR2B trafficking, degradation, or 
other aspects of NR2B regulation. Further studies, specifically examining isolated 
cellular compartments and proteins that regulate trafficking/degradation of NR2B, as 
well as assessments of NR2B phosphorylation and activation would be important to 
further understand the NR2B alterations in the hippocampus in schizophrenia.  
 It is possible that our results and others reporting left hippocampal deficits in 
NMDAR density could be due to asymmetries in hippocampal volume reduction in 
schizophrenia subjects, their first degree relatives or high risk individuals as 
described in studies utilising MRI technology to analyse various brain parameters 
(Breier et al., 1992, Shenton et al., 1992, Hirayasu et al., 1998, Narr et al., 2002, 
Seidman et al., 2002, Prestia et al., 2011). Although, not all of these studies have 
shown consistent results (Nelson et al., 1998, Wright et al., 2000) and it has been 
shown that even though hippocampal volume is reduced in schizophrenia the 
neuronal density has been found unchanged in the dentate gyrus (Zaidel et al., 1997, 
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Walker et al., 2002), the specific hippocampal region examined in the present study. 
Therefore these NMDAR deficits observed in the left hippocampus in the present 
study and others may represent actual alterations in protein amount, as opposed to 
reductions in protein due to associated reductions in neuronal density.   
NR2B-containing NMDARs play a critical role in cognitive functions, 
especially in the hippocampus (For review see Nakazawa et al., 2004). Selective 
reduction of NR2B-containing NMDARs in the hippocampus has been reported to 
produce cognitive deficits in rodents (Brigman et al., 2010; Clayton et al., 2002) as 
well as disrupting underlying molecular processes such as LTP (Clayton et al., 
2002). Specifically, the left hippocampus has previously been associated with verbal 
and visual memory performance in schizophrenia subjects (DeLisi et al., 1991; 
Seidman et al., 2002). Therefore, a reduction in NMDARs or altered composition of 
the NMDAR subunits in hippocampal subregions, such as that found in the present 
study, may be a contributing factor to the cognitive deficits observed in these 
patients. Therapies aiming to enhance NR2B function or activity have been shown to 
improve cognitive function in animal models of ageing-induced cognitive 
impairment (Brim et al., 2013). Similarly, over-expression of NR2B in transgenic 
mice results in increased cognitive ability (Tang et al., 1999). Along these lines, 
positive allosteric modulation, selective for NR2B-containing NMDARs has been 
proposed as a novel therapeutic strategy for the treatment of schizophrenia and 
cognitive dysfunction more generally (Menniti et al., 2013; Mony et al., 2009). Our 
findings therefore of reduced NR2B protein in the hippocampus, where it plays a 
critical role in cognitive function, and is possibly related to cognitive dysfunction in 
schizophrenia patients, supports the idea that NR2B positive allosteric modulators 
could potentially be therapeutic for cognitive dysfunctions in schizophrenia. 
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2.4.2 Effects of confounding variables on NR2B binding and protein in the 
hippocampus 
As with all postmortem human brain studies of this nature, we cannot rule out 
an influence of ante-mortem medication on our data. However, we observed no 
correlation between antipsychotic dose (measured as chlorpromazine equivalents) 
and NR2B binding or protein levels. Furthermore, there is evidence from animal 
studies that antipsychotic drug treatment does not alter NR2B mRNA or protein 
levels in the brain (Fumagalli et al., 2008; O’Connor et al., 2006; Schmitt et al., 
2003), suggesting that our findings are unlikely to be due to the effects of pre-
mortem antipsychotic drug treatment. While the confounding variables, brain pH and 
PMI, correlated significantly with NR2B protein levels, these variables were factored 
into ANCOVA analyses, in which the finding of a decrease in the left hippocampal 
hemisphere of schizophrenia subjects remained. 
2.4.3 Relationship between NR2B and the NRG1 signalling system in the 
hippocampus in schizophrenia 
This study found a significant positive correlation between NR2B and NRG1 
protein, particularly in the left hemisphere of the hippocampus. This is the first study 
to correlate NR2B and NRG1 protein levels in a human brain tissue cohort. Both 
NR2B and NRG1 protein were decreased in the left hippocampal hemisphere in 
schizophrenia subjects and since the correlation was found in the left but not the right 
hemisphere, this suggests that the positive relationship between these two proteins 
may be related to schizophrenia pathology. Unfortunately the cohort was not 
powered to enable diagnosis/hemisphere specific correlations and therefore we 
cannot confirm this suggestion. It is possible that an abnormal relationship between 
NR2B and NRG1 protein in the left hemisphere of the hippocampus contributes to 
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the pathology of schizophrenia. A functional correlation between NRG1 and NR2B 
has been previously reported in the hippocampus of a human cell line, with NRG1 
stimulation increasing the tyrosine phosphorylation of the NR2B subunit 
(Bjarnadottir et al., 2007). The phosphorylation of NR2B in the hippocampus of 
schizophrenia subjects has not yet been studied, but it is possible that the relationship 
between NRG1 and NR2B protein expression in the left hippocampal hemisphere of 
schizophrenia subjects may contribute to associated functional alterations/deficits in 
this region.  
ErbB4 protein did not correlate with NR2B protein and has also shown no 
correlation with NRG1 in the hippocampus (Stuart et al., 2011). The NRG1 
signalling system, via an interaction with ErbB proteins, is both physically and 
functionally associated with the NR2 subunits of the NMDAR and this connection 
appears to occur via proteins in the postsynaptic density (Geddes et al., 2011). 
However ErbB4 has been found to be exclusively located on GABAergic 
interneurons in the hippocampus (Vullhorst et al., 2009) and with NMDAR location 
not confined to a certain cell type, this could explain the lack of correlation with 
NR2B. Furthermore ErbB4 mRNA has been found predominantly in the CA1 region 
of the hippocampus (Okada and Corfas, 2004) and it has been suggested that ErbB2 
is the predominant ErbB protein in the dentate gyrus of the hippocampus (Thompson 
et al., 2007) which adds further weight to the lack of correlation seen with NR2B and 
ErbB4 protein. 
2.4.4 Conclusion 
In conclusion, the present study for the first time, revealed that NR2B protein 
levels are decreased in the left hippocampal (dentate gyrus) hemisphere of 
schizophrenia subjects compared to control subjects and that there is a left 
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hemisphere specific positive relationship between the NR2B and NRG1 proteins. 
This reduction may be associated with cognitive symptoms arising in schizophrenia 
subjects, although caution is warranted in interpreting this result as it did not reach 
significance (p-=0.066). While further studies are warranted to confirm this finding 
and determine if this reduction is common to other NR2 subunits or hippocampal 
subregions, our findings provide support for the development of NR2B selective 
positive modulators as a novel therapy for schizophrenia, especially the cognitive 
dysfunctions.  
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3 GENDER SPECIFIC ALTERATIONS IN NR2B PROTEIN IN THE 
HUMAN PREFRONTAL CORTEX 
3.1 Introduction 
Glutamatergic dysregulation in the cortex and hippocampus plays an intrinsic 
role in schizophrenia pathology (Falkenberg et al., 2014, Konradi and Heckers, 
2003). We previously showed that the NR2B subunit of the NMDAR is reduced in 
the hippocampus in schizophrenia, specifically in the left hemisphere, which we 
suggest may contribute to the cognitive deficits in schizophrenia. The prefrontal 
cortex plays a crucial role in cognitive planning and working memory as well as 
personality, judgement and thought differentiation and has been heavily implicated 
in schizophrenia (Glahn et al., 2005). Many neuroimaging studies have found 
abnormalities in prefrontal cortical function in schizophrenia patients when 
performing tasks related to working memory, especially in the right hemisphere 
(Callicott et al., 2000, Perlstein et al., 2001, Barch et al., 2003, Lee et al., 2008).  
Structural anomalies have also been found, including reduced grey matter volume in 
the inferior prefrontal cortex of schizophrenia patients (Buchanan et al., 1998, Harms 
et al., 2010). 
In the prefrontal cortex, it has been found that NMDAR binding levels 
remain largely unchanged (Kornhuber et al., 1989, Weissman et al., 1991, Scarr et 
al., 2005), however alterations to specific subunit mRNA has been observed in 
schizophrenia subjects compared to controls (Akbarian et al., 1996, Dracheva et al., 
2001, Beneyto and Meador-Woodruff, 2008). This suggests that there may be 
alterations to specific NMDAR subunit protein in the prefrontal cortex of 
schizophrenia subjects. NR2B is the only NR2 subunit to show protein alterations in 
any brain region of the schizophrenia brain to date (Grimwood et al., 1999, Ibrahim 
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et al., 2000, Clinton et al., 2006), including a reduction in NR2B protein in the 
endoplasmic reticulum cellular fraction in the prefrontal cortex (Kristiansen et al., 
2010b), however none of these studies have examined the effect of hemisphere or 
gender. Considering the hemisphere dependent alteration in NR2B protein we found 
in the hippocampus of schizophrenia subjects compared to control (see Chapter 2) 
and the deficits in prefrontal cortical function seen in the right hemisphere (as 
mentioned above), it is important to examine protein changes in the brain in relation 
to hemisphere. Furthermore, there are gender differences in the onset, symptom 
profile and pathology of schizophrenia (Frederikse et al., 2000, Gur et al., 1996) and 
we may be missing valuable information on gender specific neurochemical changes 
in the brain by not examining gender effects in postmortem brain tissue cohorts.  
Therefore the aim of this study was to determine whether there is an 
alteration in density of NR2B subunit protein and binding in the DLPFC of 
schizophrenia subjects compared to controls in a brain tissue cohort with enough 
power to examine the effects of hemisphere and gender. 
3.2 Materials and Methods 
3.2.1 Brain Tissue 
Postmortem human brain tissue was acquired from the NSW TRC at the 
University of Sydney. The cohort consisted of 37 schizophrenia samples, with the 
diagnosis of schizophrenia confirmed according to the DSM-IV, and 37 healthy 
controls, with no known history of psychiatric illness. Samples were matched for 
age, brain pH, PMI and RNA integrity (Table 3.1). All clinical assessments, selection 
of cases, matched controls, assessment of tissue quality, identification of the DLPFC 
(Figure 3.2) and preparation of the tissue were performed by the NSW TRC and/or 
Schizophrenia Research Laboratory (SRL) (see Weickert et al., 2010). Clinical and 
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demographic characteristics of the subjects were obtained including gender, brain 
hemisphere, antipsychotic drug history, subclass of schizophrenia and duration of 
illness (see Table 3.1) The study was approved by the Human Research Ethics 
Committees of the University of Wollongong (HE99/222) and University of New 
South Wales (HREC 07261). 
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Table 3.1. Subject demographic and clinical characteristics. 
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3.2.2 Western Blot 
Homogenised tissue from the DLPFC was obtained at a concentration of 2 
µg/µL from the SRL. The following procedure was performed in triplicate. Samples 
were diluted in Laemmli’s sample buffer (Bio-Rad, Hercules, CA, USA) and loaded 
into precast 4-12% bis-tris gels (Bio-Rad) with 10 µg of total protein per well, along 
with a molecular weight ladder (Precision Plus Protein™ Standards; Bio-Rad) and 
run in XT-MOPS buffer (Bio-Rad) at 200 V for 55 minutes. The protein was 
transferred to PVDF membrane (Bio-Rad) at 100 V for 1 hour using Tris-glycine 
buffer (Bio-Rad) containing 20% methanol and blocked in PBS-T containing 5% 
skim milk for 1 hour at room temperature. Blots were then incubated overnight (4oC) 
with an anti-NR2B antibody (#MAB5778, 1/500; Millipore) diluted in PBS-T 
containing 1% skim milk. A mouse anti-actin antibody was used as an internal 
standard (#MAB1501, 1/100000; Millipore). Following primary antibody exposure, 
blots were washed for 3 x 5 minutes in PBS-T and incubated for 1 hour (room 
temperature) with a HRP-conjugated secondary antibody (anti-rabbit: #AP307P, 
anti-mouse: #AP308P, 1/3000; Millipore). Blots were washed for 3 x 5 minutes in 
PBS-T and the proteins of interest detected on Kodak BioMax MR Film (Sigma-
Aldrich, Castle Hill, NSW, Australia) using the ECL Plus Western Blotting 
Detection Reagents kit (GE Healthcare, Piscataway, NJ, USA). The films were 
developed using the AGFA CP1000 film developer (AGFA Healthcare, Rydalmere, 
NSW, Australia) and analysed using Quantity One software version 4.6.7 (BioRad) 
connected to a GS-800 Calibrated Densitometer (BioRad). Quantification was 
performed blind to diagnosis. The optical density of each band was normalised to the 
respective β-actin band and averaged over the three runs.  
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3.2.3 In situ Radioligand Binding Autoradiography 
DLPFC tissue for radioligand binding was coronally sectioned on a cryostat 
at -18°C, at a thickness of 14 µm, mounted onto gelatinised slides and stored at -
80°C until use. [3H]Ifenprodil binding was performed based on the methods 
previously used by Ibrahim et al., (2000) and Basham et al., (1999). Three slides 
from each subject were incubated in 0.05 M TrisHCl buffer (pH 7.4) with 5 nM 
[3H]Ifenprodil (NR2B antagonist: specific activity 40 Ci/mmol; PerkinElmer, 
Boston, MA, USA), 3 µM R(+)-3-(3-hydroxyphenyl)-N-propylpiperidine 
hydrochloride (+3PPP; to block non-specific binding to the sigma receptor), 30 µM 
GBR-12909 (to block piperazine sites) and 1 mM trifluoperazine  (to block low 
affinity polyamine sensitive sites on adrenergic, dopaminergic and cholinergic 
receptors) for 3 hours at 4°C to determine total binding. Adjacent sections were 
incubated in the same buffer, with the addition of 10 µM Ifenprodil (Sigma-Aldrich) 
to determine non-specific binding. All sections were then washed in 0.05 M Tris-HCl 
(pH 7.4) for 3 x 5 minutes at 4°C, rinsed in distilled water and air-dried overnight.  
Autoradiographic images were taken using a Beta-Imager camera (BioSpace, 
Paris, France). Quantification was performed blind to diagnosis using the B vision+ 
program (BioSpace), with the aid of histological standards obtained from Weickert et 
al (2010). The relative density from three slides per case was averaged to give the 
final analysis value. 
3.2.4 Statistics 
The statistical package used for data analysis was SPSS version 17 (IBM). 
The data was checked for triplicate (standard deviation>30% mean) and population 
outliers (two standard deviations above or below the mean) and a Kolmogrov-
Smirnov test was used to confirm the normality of the data. An Independent samples 
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t-test was used to determine differences between the schizophrenia and control 
subjects. Pearson’s correlations were then used to determine relationships to 
diagnostic variables such as age, PMI, brain pH and RNA integrity with all the data 
and antipsychotic medication and duration of illness in the schizophrenia group. An 
ANCOVA was then performed if there were any significant correlations with the 
diagnostic variables.  Two way ANCOVAs, adjusted for demographic variables, 
were performed to test the effect of hemisphere and gender on the diagnosis and if a 
significant difference was found, a one way ANOVA with Tukey’s post-hoc analysis 
was conducted. Pearson’s correlations were then performed between NR2B binding 
and protein measurements. 
3.3 Results 
3.3.1 Gender difference in NR2B protein in schizophrenia subjects. 
One band was observed and quantified at approximately 175 kDa as 
previously reported (Laurie et al., 1997). An Independent t-test showed that there 
was no difference in NR2B protein density between schizophrenia and control 
subjects (t72 = 0.671, p = 0.504). NR2B protein density correlated significantly with 
PMI (r = -0.332, p = 0.004) and there was a trend for a correlation with age at death 
of the subjects (r = 0.212, p = 0.069) when assessed in the whole cohort (See Table 
3.2). A similar correlation of NR2B protein density and PMI was observed in the 
control subjects (r = -0.408, p = 0.012) but not in the schizophrenia subjects (r = -
0.277, p = 0.096). An ANCOVA correcting for these variables showed no difference 
in NR2B protein density between schizophrenia and control subjects (F1,71 = 0.073, p 
= 0.787). There was no correlation between NR2B protein density in the 
schizophrenia subjects and duration of illness, age of onset or medication history 
(Table 3.2). A two way ANCOVA with the main effects of DIAGNOSIS and 
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GENDER showed a significant diagnosis x gender interaction (F1,69=4.073, p=0.047) 
but no significant main effect of diagnosis (p=0.377) or gender (p=0.099). Post hoc 
analyses revealed a 37% decrease in the female schizophrenia subjects compared to 
the male schizophrenia subjects (p=0.040) (see Figure 3.1) with a one way ANOVA 
showing that the male/female control/schizophrenia groups were still matched for 
age (F3,70=1.711, p=0.173), PMI (F3,70=0.563, p=0.641), pH (F3,70=0.766, p=0.517), 
RNA integrity (F3,70=1.014, p=0.392) and freezer storage time (F3,70=1.954, 
p=0.129). Brain weight was different between the groups (F3,70=11.240, p=0.000) 
with the schizophrenia female group having a significantly smaller brain weight than 
the control male (p=0.000) and the schizophrenia male (p=0.000) (see Table 4 in 
Appendix for comparison of demographic variables).  
There was no difference in NR2B levels between the female schizophrenia 
and female control subjects (p=0.244) however a power analysis, as performed by 
Scarr and colleagues 2012, (http://www.biomath.info/power/ttest.htm) (Scarr et al., 
2012) revealed that our cohort was underpowered and needed 17 per/group in order 
to detect a difference between the female control and female schizophrenia groups. 
There was no effect of hemisphere on NR2B protein density (see Table 3 in 
Appendix for comparison of demographic variables). 
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Figure 3.1. A: Representative Western blot bands of NR2B and actin protein. B: 
NR2B protein density in the dorsolateral prefrontal cortex of the male and female, 
schizophrenia and control brain. There was a 37% decrease in the female 
schizophrenia subjects compared to the male schizophrenia subjects.  *: p = 0.040 
compared to Female Sz. Horizontal and vertical bars represent mean±SEM for each 
group. Abbreviations: Sz = schizophrenia. 
 
3.3.2 No change in NR2B binding density in schizophrenia subjects compared to 
control. 
An Independent t-test showed that there was no difference between 
[3H]Ifenprodil binding in the schizophrenia and control subjects (t72 = -0.263, p = 
0.793). 
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Figure 3.2. Representative total and non-specific [3H]Ifenprodil binding in the 
dorsolateral prefrontal cortex of this human tissue cohort. Box highlights area of the 
dorsolateral prefrontal cortex as identified by the SRL. 
 
 [3H]Ifenprodil binding density correlated with freezer storage time (r = 
0.359, p = 0.002) and there was a trend for a correlation with age at death of the 
subjects (r = -0.222, p = 0.057) in the whole cohort. There was a correlation with 
freezer storage time in the control subjects only (r = 0.324, p = 0.051) and the 
schizophrenia subjects only (r = 0.405, p = 0.013) (Table 3.2). An ANCOVA to 
correct for freezer storage time and age at death showed no difference in 
[3H]Ifenprodil binding sites between schizophrenia and control subjects (F1,70 = 
0.009, p = 0.927). There was no correlation between [3H]Ifenprodil binding density 
in the schizophrenia subjects and length of illness, age of onset or medication history 
(see Table 3.2). There were no effects of hemisphere or gender on [3H]Ifenprodil 
binding in the prefrontal cortex (see Table 3 and 4 in Appendix for comparison of 
demographic variables). 
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Figure 3.3. [3H]Ifenprodil binding density in the dorsolateral prefrontal cortex of the 
male and female, schizophrenia and control brain. Horizontal and vertical bars 
represent mean±SEM for each group. Abbreviations: Sz = schizophrenia. 
 
Table 3.2. Pearson’s correlations for continuous variables with NR2B binding and 
protein. 
Variable  All subjects Control Schizophrenia 
  NR2B 
binding 
NR2B 
protein 
NR2B 
binding 
NR2B 
protein 
NR2B 
binding 
NR2B 
protein 
Age r -0.222 0.212 -0.221 0.248 -0.226 0.194  p 0.057^ 0.069^ 0.188 0.139 0.179 0.250 PMI r -0.058 -0.332 0.120 -0.408 -0.240 -0.277  p 0.622 0.004* 0.481 0.012* 0.153 0.096 Brain pH r 0.066 -0.082 0.091 -0.113 0.044 -0.074 
 p 0.574     0.486 0.592 0.506 0.795 0.665 
BW r -0.112 0.080 -0.005 -0.114 -0.209 0.169 
 p    0.341 0.497 0.978 0.500 0.214 0.317 
RIN r 0.147 -0.045 0.251 0.131 0.029 -0.173 
 p 0.212 0.706 0.134 0.440 0.863 0.305 
FST r 0.359 0.014 0.324 -0.072 0.405 0.105  p 0.002* 0.906 0.051^ 0.673 0.013* 0.537 Age Onset r     -0.062 0.147 
 p     0.716 0.385 
DOI r     -0.204 0.134 
 p     0.226 0.429 
APD use r 
p 
    -0.082 
0.627 
-0.036 
0.833 
Abbreviations: AP = antipsychotic drug, BW = body weight, DOI = duration of illness, 
FST = freezer storage time, pH = brain acidity, PMI = post mortem interval, RIN = RNA 
integrity. *: p<0.05; ^: 0.05<p<0.07. 
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3.3.3 Correlations 
 Overall there was no significant correlation between NR2B binding density 
and NR2B protein density (r = -0.161, p = 0.171).  This was similar for the control 
subjects only (r = -0.262, p = 0.117), however in the schizophrenia subjects there 
was a significant negative correlation (r = -0.346, p = 0.036) between NR2B binding 
and protein density.  
3.4 Discussion 
This study has shown a significant reduction in NR2B protein but not binding 
density in the DLPFC of female schizophrenia subjects compared to male 
schizophrenia subjects. There were however no significant differences in NR2B 
protein or binding density between schizophrenia and control subjects in this tissue 
cohort.  
3.4.1 Gender difference in NR2B protein in the prefrontal cortex in schizophrenia  
This study is the first to observe a gender difference in NR2 subunit protein 
in the schizophrenia brain. Despite the uneven grouping/decreased sample number 
when analysing gender effects and the lack of effect of oestrogen on NMDAR, 
NR2A or NR2B protein levels (Snyder et al., 2011), this suggests that the influence 
of gender in the schizophrenia brain may be important. While oestrogen levels and 
oestrous cycle status were not controlled for in this study, previous reports suggest 
that oestrogen does not affect NMDAR, NR2A or NR2B protein levels (Snyder et 
al., 2011), albeit it may effect NR2B phosphorylation and synaptic localisation (Liu 
et al., 2012; Vedder et al., 2013) The present study did find a decrease in brain 
weight in the schizophrenia female group compared to the control male and 
schizophrenia male groups, which may contribute to the difference in NR2B levels, 
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although no correlation between NR2B levels and brain weight were observed and 
there was no difference in NR2B levels between the schizophrenia female and 
control male groups, so this is unlikely. Known gender differences in schizophrenia 
that may contribute to the observed change in NR2B in female schizophrenia 
subjects include a later age of onset in females (although it should be noted that age 
of onset did not correlate with NR2B binding or protein in this study), higher 
prevalence of affective symptoms in females and differences in cognitive 
impairments, although results suggest worse cognitive deficits in males (for review 
see Ochoa et al., 2012). It is therefore surprising to find a reduction in NR2B protein 
levels in female schizophrenia subjects compared to males given the importance of 
the NR2B subunit in cognitive functions in the prefrontal cortex (Zhao et al., 2005, 
Wang et al., 2008). Female schizophrenia subjects in the present study also had a 
longer duration of illness than the male schizophrenia group (p=0.006) (see Table 4 
in the Appendix). However, there was no correlation of NR2B with duration of 
illness, so this is unlikely to account for the gender specific findings observed. 
Similar to our findings in the hippocampus, this reduction in NR2B protein levels 
was accompanied by no change in NR2B binding density suggesting a change in 
intracellular protein levels but not cell surface receptors. 
Previous studies on the same postmortem brain cohort have reported a 33% 
increase in NR2B mRNA in males relative to females, however this was independent 
of diagnosis (Weickert et al., 2013), and a gender x diagnosis interaction was found 
with regards to metabotropic glutamate receptor 5 (mGluR5) binding density 
(Matosin et al, 2013). This provides support to our finding in another aspect of the 
glutamatergic system, suggesting that changes in the glutamatergic system in 
schizophrenia are likely to be gender specific. The use of NMDAR antagonists, such 
Chapter 3 
 
 
73
as PCP, to induce a schizophrenia-like state are known to have gender specific 
effects, with females generally being more susceptible to its effects (Kokras and 
Dalla 2014). Gender differences in brain chemistry in healthy subjects, including the 
dopaminergic, serotonergic and GABAergic systems, have been reported showing 
differences in neurotransmitter and receptor levels, mainly an increase in the female 
brain (for review see Cosgrove et al., 2007). Although our study found no difference 
in NR2B expression between male and female control subjects, future studies 
exploring neurochemical changes in the schizophrenia brain should examine gender 
effects with the aim of linking any changes to schizophrenia symptomology or 
clinical characteristics.  
Gender is often overlooked in postmortem studies despite the gender specific 
differences observed in the onset and symptom profile of schizophrenia (Ochoa et 
al., 2012) and it may be important to consider gender specific treatments. Animal 
models are widely used to study the aetiology and treatments of psychiatric disorders 
such as schizophrenia, however, most commonly only males are used in these 
models (Kokras and Dalla 2014). Our findings show clear gender differences with 
regards to the NR2B subunit in the prefrontal cortex in schizophrenia and therefore a 
gender analysis should be included in future studies of both postmortem and animal 
models of schizophrenia. 
This study found no hemisphere effects of NR2B protein levels in the 
prefrontal cortex of schizophrenia subjects compared to controls despite the observed 
deficits in the right hemisphere in neuroimaging studies (Callicott et al., 2000, 
Perlstein et al., 2001, Barch et al., 2003, Lee et al., 2008). This is in contrast to our 
finding of a decrease in NR2B protein specifically in the left hippocampal 
hemisphere in schizophrenia subjects. This suggests that hemisphere effects of 
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NR2B protein may be brain region specific. In a previous study of the DLPFC using 
this same postmortem cohort, NR2B mRNA expression was reported to be 39% 
higher in the left versus the right prefrontal cortex however this effect was 
independent of diagnosis (Weickert et al, 2013). 
A previous study examining NMDAR subunit protein levels in the prefrontal 
cortex of the schizophrenia brain found no effect of diagnosis (Kristiansen et al., 
2006) however they did not examine gender differences probably due to low sample 
size. No effect of diagnosis has also been observed in a previous study examining 
[3H]Ifenprodil binding in the prefrontal cortex of the schizophrenia brain (Beneyto 
and Meador-Woodruff, 2008). Furthermore, no difference in NR2B mRNA in the 
prefrontal cortex has been reported in the schizophrenia compared to the control 
brain (Arkbarian et al., 1996, Beneyto and Meador-Woodruff, 2008, Dracheva et al., 
2001).  
There is one study which shows that NR2B protein is decreased in the 
endoplasmic reticulum cellular fraction in the prefrontal cortex of schizophrenia 
compared to control subjects (Kristiansen et al., 2010b) suggesting an alteration in 
intracellular production or trafficking of the NR2B subunit protein. We cannot rule 
out changes in the endoplasmic reticulum in our cohort as we did not separate the 
protein into different cellular compartments.  
3.4.2 Effects of confounding variables 
Due to the fact that there was no correlation between the NR2B binding or 
protein in the schizophrenia subjects and antipsychotic drug use, it appears that 
medication history does not affect NR2B levels. This is further supported by animal 
studies showing no change in NR2B levels in the brain following antipsychotic drug 
treatment (Schmitt et al., 2003, O'Connor et al., 2006, Fumagalli et al., 2008).  
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3.4.3 Conclusion 
In conclusion, this study reports a significant reduction in NR2B protein 
expression in the DLPFC of female compared to male schizophrenia subjects. This 
finding highlights the gender specific nature of the biology of schizophrenia. Sex 
differences are often overlooked in the biological examination of schizophrenia, 
despite the clear gender differences that are observed in the clinic including later age 
of disease onset, higher incidence of affective symptoms. The present findings 
suggest, where possible, both male and female subjects should be included in future 
schizophrenia studies. Furthermore, given this study was underpowered to detect 
differences between female schizophrenia subjects and controls (due to the nature of 
the cohort), future studies in a larger cohort are necessary to confirm these findings. 
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EXPERIMENTAL PART B: THE EFFECT OF A 
PERINATAL NR2B BLOCKADE ON THE 
DEVELOPMENTAL PROFILE OF RELATED 
NEUROTRANSMITTER SYSTEMS. AN 
ANIMAL MODEL
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4 THE EFFECT OF PERINATAL NR2B ANTAGONISM ON THE NMDA 
RECEPTOR AND ITS PRIMARY SUBUNITS 2A AND 2B: A MOUSE 
MODEL 
4.1 Introduction  
As detailed in Chapter 1, the perinatal NMDAR hypofunction hypothesis of 
schizophrenia is widely studied in animal models. Models of developmental 
NMDAR hypofunction (eg NR1 hypomorphic mice, perinatal NMDAR antagonist 
administration) demonstrate an array of behavioural and neurochemical effects in 
adult animals that mimic schizophrenia-like symptoms and neurochemical alterations 
that are observed in the schizophrenia brain (Facchinetti et al., 1993, Wang et al., 
2001, Harris et al., 2003, Sircar and Soliman, 2003, Andersen and Pouzet, 2004, 
Stefani and Moghaddam, 2005, du Bois et al., 2008, Wang et al., 2008, du Bois et al., 
2009). NMDARs are composed of different combinations of NR1, NR2 (A, B, C, D) 
and/or NR3 (A, B) subunits, with the NR2 subunits displaying distinct 
developmental and regional patterns of expression (For review see Geddes et al., 
2011). The NMDAR is vital for early brain development and the NR2B subunit 
shows a stronger and earlier expression in the brain during the perinatal period than 
the other NR2 subunits (Watanabe et al., 1992, Monyer et al., 1994, Wenzel et al., 
1997, Ritter et al., 2001). Furthermore the distribution of NR2B subunits is quite 
broad during early development and becomes more restricted to schizophrenia 
relevant forebrain structures, such as the prefrontal cortex and hippocampus, later in 
development (Wenzel et al., 1997, Heimer, 2000). Therefore an alteration to NR2B 
levels during this early, critical point in development could cause a disruption to the 
normal brain growth pattern and change the developmental profile of associated 
proteins. Indeed it has been suggested that an imbalance of NR2 subunits, 
particularly NR2A and NR2B, during early brain development could cause an 
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alteration of the normal NMDAR developmental processes, including synaptogenesis 
and synapse maturation (Gambrill and Barria, 2011). This is based on the ability of 
the C-terminus of the NR2B subunit to recruit signalling and scaffolding proteins 
necessary for synapse formation (Wilson et al., 1998, Akashi et al., 2009, Gambrill 
and Barria, 2011). 
NR2B blockade (using Ro 25-6981) in adult rodents causes hyperlocomotor 
activity, disrupted PPI, increases in anxiety-like behaviour and impairments in 
learning and memory, which are recognised as schizophrenia-like behaviours in the 
rodent (Chaperon et al., 2003, Duffy et al., 2007, Mathur et al., 2009).  However, a 
lack of locomotor changes in rodents treated with Ro 25-6981 has also been reported 
(Kosowski and Liljequist, 2004). Adult rats treated with the more selective NR2B 
antagonist, Ro 63-1908, displayed increased locomotor activity and impaired 
response inhibition (but no disruption to PPI) (Higgins et al., 2003). These 
behavioural alterations are similar, although not to the same extent, to those seen 
with total antagonism of the NMDAR (Higgins et al., 2003) and are not observed 
with NR2A blockade (Chaperon et al., 2003). 
Perinatal NR2B blockade (using ifenprodil) in a single study has shown that 
rats are not susceptible to hyperlocomotion following a PCP challenge at 
adolescence, while rats treated with the NR2A antagonist PEAQX display 
hyperlocommotive behaviour following the PCP challenge (Anastasio et al., 2009). 
This study suggests that it may be perinatal NR2A blockade that mirrors the 
behaviours seen with PCP administration, however the NR2B antagonist (ifenprodil) 
used, is not as potent or specific to the NR2B subunit as Ro 63-1908 (Zhou et al., 
1999) in which doses of up to 30 mg/kg have been used in adult rodents. Therefore 
further investigation is needed into the effects of perinatal NR2 antagonism, 
Chapter 4 
 
 
79
particularly as the NR2B subunit is critical for early synaptogenesis (Gambrill and 
Barria, 2011) and any impact that hinders synaptic formation and connection could 
have adverse consequences throughout brain development. 
While perinatal PCP treatment produces alterations in NMDAR proteins in 
the short (Anastasio and Johnson, 2008) and longer terms (du Bois et al., 2012), the 
effect of a perinatal NR2 blockade on related proteins has not been investigated. 
Considering the role that NR2B plays in early synaptic connections, a perinatal 
blockade of NR2B could have substantial effects, not only on other proteins at this 
perinatal period but also on protein levels later in development, particularly at the 
adolescent period when synaptic pruning is abundant. Furthermore, it is possible 
there is a gender difference in the normal developmental profile of NMDAR 
associated proteins or a difference in protein response to the perinatal NR2B 
antagonist treatment between genders, considering our findings of a gender 
difference in NR2B protein in the prefrontal cortex of schizophrenia patients. 
Therefore the aims of this study were to 1. Examine the effect of perinatal NR2B 
antagonist treatment on the NMDAR and its primary subunits, NR2A and NR2B at 
juvenile, adolescent and adult time points, 2.  Study the normal developmental 
profile of the NMDAR, NR2A and NR2B subunits, and 3. Examine the 
developmental and treatment effects in male and female mice. 
4.2 Materials and Methods 
4.2.1 Animals and Drug Treatment Procedure 
Thirty-eight female and nineteen male adult C57BL/6 mice were obtained 
from the Animal Resources Centre (Perth, Australia). They were housed at the 
University of Wollongong Animal House in a temperature controlled environment 
(20oC ± 2) under 12:12 hour light-dark cycle (lights off at 1900h). The mice were 
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provided with food and water ad libitum. The mice were acclimatised to these 
housing conditions for one week before mating. Upon successful mating, female 
mice were housed individually for the 21 days of gestation. The day of birth of the 
pups is considered PN0. On the morning of PN7 the cage of pups was assigned to 
either a treatment or control group. The treatment group was injected subcutaneously 
with 30 mg/kg of the NR2B antagonist Ro 63-1908 (Tocris, Bristol, UK) at a volume 
of 5 ul/g daily for eight days from PN7 to PN14. This dose is based on a previous 
experiment showing psycho-mimetic behavioural changes similar to MK-801 in 
adult rodents (Higgins et al., 2003). The duration of treatment was chosen based on 
the critical period for NMDAR antagonist-induced apoptosis in the rodent brain 
(Ikonomidou et al., 1999). The control group were similarly injected with the same 
volume of saline, containing 0.9% NaCl. One third of the litters were euthanased 
eight hours after the last treatment day on PN14 (n = 6 per gender per group). The 
remaining litters were weaned on PN28 with the mice housed 2/cage of the same 
gender and then cages were randomly allocated to either an adolescent or adult 
group, and euthanased on PN35 (adolescence) or PN70 (adult) (5-6 per gender per 
group). All procedures involving animals were approved by the University of 
Wollongong Animal Ethics Committee (AE08/12) under the Australian Code of 
Practice for the Care and Use of Animals for Scientific Purposes (7th Edition, 2004) 
guidelines. All efforts were made to minimise numbers of animals used.    
4.2.2 Autoradiography Procedures and Quantification 
Immediately following euthanasia mouse brains from 6 mice/group were 
removed and frozen whole in liquid nitrogen and stored at -80°C until sectioning. 
Brains were sectioned coronally (14 µm thick) with a Shandon Cryotome E (Thermo 
Fischer Scientific, Waltham, MA, USA) under -18°C conditions and then mounted 
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on Polysine™ microscope slides (Menzel-Glaser, Braunschweig, Germany). 
Sections were collected at levels corresponding to Bregma 2.34 and -1.94 mm 
(Paxinos and Franklin, 2001), which includes the structures of the prefrontal cortex 
and hippocampus and kept in -20°C conditions. 
4.2.3 NMDAR Binding 
[3H]MK-801 binding was performed based on the methods used previously 
(Newell et al., 2007a). Sections were incubated in 30 mM HEPES buffer (pH 7.5) 
containing 100 µM glycine, 100 µM glutamate and 1 mM EDTA, with the addition 
of 20 nM [3H]MK-801 (NMDA receptor antagonist: specific activity 27.5 Ci/mmol; 
PerkinElmer, Waltham, MA, USA) for 2½ hours at room temperature to determine 
total binding. Adjacent sections were incubated with 20 nm [3H]MK-801 in the 
presence of 20 µM MK-801 (Sigma-Aldrich, Castle Hill, NSW, Australia) to 
determine non-specific binding. All sections were then washed in 30 mM HEPES 
buffer (pH 7.5) containing 1 mM EDTA for 2 x 20 minutes at 4°C. Finally the 
sections were rinsed in distilled water and air-dried overnight.  
4.2.4 NR2A Binding 
 [3H]CGP39653 binding was performed based on the methods previously used 
by Scarr et al (2005). All sections were preincubated in 0.05 M TrisHCl buffer (pH 
7.6) with the addition of 0.0025 M CaCl2 for 45 minutes at room temperature. 
Sections were then incubated in the same buffer containing 20 nM [3H]CGP39653 
(NR2A antagonist: specific activity 47.25 Ci/mmol; PerkinElmer) for 45 minutes at 
room temperature to determine total binding, with adjacent sections incubated in the 
presence of 100 µM PEAQX (NR2A antagonist; Sigma-Aldrich) to determine non-
specific binding. All sections were then washed in 0.05 M TrisHCl buffer (pH 7.6) 
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with 0.0025 M CaCl2 for 2 x 30 seconds at 4°C, rinsed in distilled water and air-dried 
overnight. 
4.2.5 NR2B Binding  
[3H]Ifenprodil binding was performed based on the methods used previously 
(Basham et al., 1999). All sections were incubated in 0.05 M Tris HCl buffer (pH 
7.4) with the addition of 20 nM [3H]Ifenprodil (NR2B antagonist: specific activity 40 
Ci/mmol; PerkinElmer), 3 µM R(+)-3-(3-hydroxyphenyl)-N-propylpiperidine 
hydrochloride (+3PPP) (to block non-specific binding to the sigma receptor), 30 µM 
GBR-12909 (to block piperazine sites) and 1 mM trifluoperazine  (to block low 
affinity polyamine sensitive sites on adrenergic, dopaminergic and cholinergic 
receptors) for 3 hours at 4°C to determine total binding, with adjacent sections 
incubated in the presence of 20 µM Ifenprodil (Sigma-Aldrich) to determine non-
specific binding. All sections were then washed in 0.05 M Tris-HCl (pH 7.4) for 3 x 
5 minutes at 4°C, rinsed in distilled water and air-dried overnight.  
4.2.6 Quantification  
All slides were placed in cassettes and exposed to tritium-sensitive Kodak 
BioMax MR Film (Sigma-Aldrich) for 6-12 weeks. The films were developed using 
the AGFA CP1000 film developer (Agfa-Gevaert N.V.) and analysed using Quantity 
One software version 4.6.7 (BioRad) connected to a GS-800 Calibrated Densitometer 
(BioRad). Quantification was performed blind to grouping by measuring the average 
optical density in each brain region in three adjacent sections and then averaging 
across six mice per group. 
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4.2.7 Western Blot 
Brains from 5 mice/group were removed immediately upon euthanasia and 
dissected into prefrontal cortex and hippocampus regions, frozen in liquid nitrogen 
and stored at -80oC until use. The prefrontal cortex and hippocampus tissue was 
weighed and manually homogenised in 9 volumes of buffer containing 0.1 M Tris-
HCl, 10 µl/ml protease inhibitor cocktail (Sigma), 0.625 µl/ml apoprotinin and 0.5 
µl/ml glycerol. Samples were quantified using the DC protein assay (BioRad, 
Hercules, CA, USA) following manufacturer’s instructions. The standard curve was 
determined using 2 mg/mL BSA serial dilution as a control. Samples were then 
diluted in Laemmli’s sample buffer (Bio-Rad) and loaded in triplicate into precast 4-
12% bis-tris gels (Bio-Rad) with 3 µg of total protein per well, along with a 
molecular weight ladder (Precision Plus Protein™ Standards, Bio-Rad) and run with 
XT-MOPS buffer (Bio-Rad) at 200 V for 55 minutes. The protein was transferred to 
PVDF membrane (Bio-Rad) at 100 V for 1 hour using Tris-glycine buffer (Bio-Rad) 
containing 20% methanol and blocked in PBS-T and 5% skim milk for 1 hour at 
room temperature. Blots were then incubated overnight (4°C) with one of the 
following antibodies diluted in PBS-T containing 1% skim milk: anti-NR2B 
(#ab28373, 1/1250; Abcam, Cambridge, UK) or anti-NR2A (#ab65799, 1/250; 
Abcam). A mouse anti-actin antibody was used as an internal standard (#MAB1501, 
1/50000; Millipore, Billerica, MA, USA). Following primary antibody exposure, 
blots were washed for 3 x 5 minutes in PBS-T and incubated for 1 hour (room 
temperature) with a HRP-conjugated secondary antibody (anti-rabbit: #AP307P, 
anti-mouse: #AP308P, 1/3000; Millipore). Blots were washed for 3 x 5 minutes in 
PBS-T and the proteins of interest detected using the ECL Plus Western Blotting 
Detection Reagents kit (GE Healthcare, Piscataway, NJ, USA). Images were 
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captured using the Gel Logic 2200 PRO (Carestream Health Inc, New Haven, CT, 
USA) with exposure times of 5-10 minutes and quantified blind to grouping with the 
Carestream molecular imaging software, version 5.0 (Carestream Health Inc) and the 
average density of each band normalised to actin. 
4.2.8 Statistics 
The statistical package used for data analysis was SPSS version 17 (IBM). 
The data was checked for triplicate (SD>30% mean) and population outliers (two 
standard deviations above or below the mean) and a Kolmogrov-Smirnov test was 
used to determine the normality of the data. A three-way ANOVA with AGE, 
TREATMENT and GENDER as the main factors was performed for each brain 
region. With a significant effect or interaction effect, either a one-way ANOVA with 
tukey’s or dunnett’s T3 post hoc depending on levene’s test of homogeneity of 
variances (for AGE) or an Independent samples t-test with Bonferroni adjustment 
(for TREATMENT and GENDER) was performed (with adjustments to the degrees 
of freedom using the Welch-Satterthwaite method if Levene’s test was significant). 
Significance was set at p<0.05, with bonferroni adjustments set at p<0.017 when data 
was split for age, gender and treatment. All data is presented as mean±SEM.  
4.3 Results 
[3H]MK-801 displayed strong binding to the NMDAR in the prefrontal cortex 
and hippocampus. In comparison, [3H]CGP39653 and [3H]Ifenprodil showed 
moderate binding to NR2A and NR2B subunits respectively in the prefrontal cortex 
and hippocampus. For all radioligands, non-specific binding represented less than 
5% of total binding (see Figure 4.1).  
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Figure 4.1. A: Representative autoradiograms of total and non-specific NMDAR 
([3H]MK801), NR2A ([3H]CGP39653) and NR2B ([3H]Ifenprodil) binding in the 
prefrontal cortex (Bregma +2.34) and hippocampus (Bregma -1.94) of adult mice. B: 
Mouse brain atlas pictures showing bregma levels and locations for prefrontal cortex 
(+2.34) and hippocampus (-1.94). Abbreviations: HIP = hippocampus, PFC = 
prefrontal cortex. 
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4.3.1 NMDAR Binding 
A three way ANOVA revealed a significant main effect of AGE in the 
prefrontal cortex (F2,54=19.4, p<0.001) and hippocampus (F2,52=45.4, p<0.001) on 
[3H]MK-801 binding. There was no significant main effect of TREATMENT or 
GENDER in the prefrontal cortex or hippocampus or any interactions observed. 
 
Figure 4.2. [3H]MK-801 binding to NMDARs in the prefrontal cortex and 
hippocampus of mice at postnatal days 14, 35 and 70, following perinatal treatment 
with saline or the NR2B antagonist Ro 63-1908. Data represents males and females 
combined, n=10-12/group. Data presented as mean optical density  SEM. *: 
0.000<p<0.05. Abbreviations: PFC = prefrontal cortex; PN = postnatal day. 
 
Using the control data of both genders combined, [3H]MK-801 binding was 
significantly different between time points in the prefrontal cortex (F2,30=6.7, 
p=0.004) and hippocampus (F2,29=28.8, p<0.001) (see Figure 4.2). Post-hoc tests 
revealed an increase in binding from PN14 to PN35 in the prefrontal cortex (+23%, 
p=0.021) and hippocampus (+39%, p=0.005) but no change from PN35 to PN70 in 
the prefrontal cortex (p=0.846) and hippocampus (p=0.432). Overall there was an 
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increase from PN14 to PN70 in the prefrontal cortex (+28%, p=0.006) and 
hippocampus (+53%, p<0.001) (see Figure 4.2). 
4.3.2 NR2A Binding 
A three way ANOVA revealed a significant main effect of AGE (prefrontal 
cortex: F2,54=28.6, p<0.001; hippocampus: F2,54=13.1, p<0.001) and GENDER 
(prefrontal cortex: F1,54=43.8, p<0.001; hippocampus: F1,54=44.3, p<0.001) and an 
AGE x GENDER interaction (prefrontal cortex: F1,54=25.0, p<0.001; hippocampus: 
F1,54=13.7, p<0.001) on [3H]CGP39653 binding. There was also a trend for an AGE 
x TREATMENT interaction in the prefrontal cortex (F1,54=3.055, p=0.055). There 
was no significant main effect of TREATMENT in the prefrontal cortex or 
hippocampus or any other interactions observed. 
 
Figure 4.3. [3H]CGP39653 binding to the NR2A subunit in the prefrontal cortex and 
hippocampus of male and female mice at postnatal days 14, 35 and 70, following 
perinatal treatment with saline or the NR2B antagonist Ro 63-1908. n=5-6/group. 
Data presented as mean optical density  SEM. *: p<0.001. Abbreviations: PFC = 
prefrontal cortex; PN = postnatal day. Columns at each age group correspond to the 
descending order of the groups in the graph key.  
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In the saline animals there was an increase in [3H]CGP39653 binding in the 
female compared to the male mice at PN35 in the prefrontal cortex (+166%, t9=-4.9, 
p=0.001) and hippocampus (+144%, t9=-5.7, p<0.001) but not at PN14 (prefrontal 
cortex: p=0.078; hippocampus: p=0.096) or PN70 (prefrontal cortex: p=0.130; 
hippocampus: p=0.486) (see Figure 4.3). In the Ro 63-1908 treated animals there 
was an increase in [3H]CGP39653 binding in the female compared to the male mice 
at PN14 (prefrontal cortex: +56%, t11=-2.8, p=0.017; hippocampus: +146%, t11=-4.3, 
p=0.001) and PN35 (prefrontal cortex: 138%, t9=-6.1, p<0.001; hippocampus: 
+145%, t9=-5.0, p=0.001) but not PN70 (prefrontal cortex: p=0.762; hippocampus: 
p=0.387) (see Figure 4.3). 
Using the control data, [3H]CGP39653 binding density was significantly 
different between time points in the prefrontal cortex (male: F2,14=3.9, p=0.044; 
female: F2,13=15.1, p<0.001) and hippocampus (female: F2,13=6.5, p=0.011; male 
(trend): F2,14=3.5, p=0.060). Post-hoc tests revealed a trend for an increase in binding 
from PN14 to PN70 in the prefrontal cortex (+80%, p=0.059) and hippocampus 
(+90%, p=0.059) of the male mice. In the female mice, there was a significant 
increase in binding from PN14 to PN35 in the prefrontal cortex (+84%, p=0.001) and 
hippocampus (+63%, p=0.031) and then a decrease from PN35 to PN70 in the 
prefrontal cortex (-51%, p=0.001) and hippocampus (-46%, p=0.014). Overall there 
was no difference between PN14 to PN70 in the prefrontal cortex (p=0.864) and 
hippocampus (p=0.841) in the female mice.  
4.3.3 NR2A Protein 
There was a single band at 165 kDa as expected. A three way ANOVA 
revealed a significant main effect of AGE in the hippocampus (F2,47=8.1, p=0.001). 
Despite this, when using the control data, NR2A protein expression was not 
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significantly different between time points in the hippocampus (F2,26=2.3, p=0.120) 
(see Figure 4). There were no significant main effects of GENDER or 
TREATMENT or significant interactions in the hippocampus and no significant 
effects in the prefrontal cortex. 
 
Figure 4.4. A: Representative Western blot bands of NR2A and actin protein. B: 
Graphs showing no difference in NR2A protein in the prefrontal cortex and 
hippocampus of mice at postnatal days 14, 35 and 70, following perinatal treatment 
with saline or the NR2B antagonist Ro 63-1908. Data represents males and females 
combined, n=10-12/group. Data presented as mean optical density  SEM. 
Abbreviations: PFC = prefrontal cortex; PN = postnatal day. 
 
4.3.4 NR2B Binding  
A three way ANOVA revealed a significant main effect of AGE (prefrontal 
cortex: F2,49=115.6, p<0.001; hippocampus: F2,49=69.2, p<0.001) and TREATMENT 
(prefrontal cortex: F1,49=30.4, p<0.001; hippocampus: F1,49=55.2, p<0.001) and an 
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AGE x TREATMENT interaction (prefrontal cortex: F1,49=37.1, p<0.001; 
hippocampus: F1,49=37.6, p<0.001) on [3H]Ifenprodil binding. There was no 
significant main effect of GENDER in the prefrontal cortex or hippocampus or any 
other interactions observed. 
 
Figure 4.5.  [3H]Ifenprodil binding to the NR2B subunit in the prefrontal cortex and 
hippocampus of mice at postnatal days 14, 35 and 70, following perinatal treatment 
with saline or the NR2B antagonist Ro 63-1908. Data represents males and females 
combined, n=10-12/group). Data presented as mean density  SEM. *: 
0.000<p<0.05, ^: p<0.001 compared to saline at PN14. Abbreviations: PFC = 
prefrontal cortex; PN = postnatal day. 
 
An Independent samples t-test revealed a decrease in [3H]Ifenprodil binding 
in the Ro 63-1908 treated mice compared to the controls at PN14 in the prefrontal 
cortex (-72%, t21=12.2, p<0.001) and hippocampus (-71%, t21=14.4, p<0.001) but not 
at PN35 (prefrontal cortex: p=0.883; hippocampus: p=0.560) or PN70 (prefrontal 
cortex: p=0.640; hippocampus: p=0.371). 
Using the control data with genders combined, [3H]Ifenprodil binding 
expression was significantly different between time points in the prefrontal cortex 
(F2,27=10.8, p<0.001) and hippocampus (F2,28=4.0, p=0.029). Post-hoc tests revealed 
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an increase in binding from PN14 to PN35 in the prefrontal cortex (+20%, p=0.033) 
but not the hippocampus (p=0.413) and no change from PN35 to PN70 in the 
prefrontal cortex (p=0.197) or hippocampus (p=0.299). Overall there was an increase 
from PN14 to PN70 in the prefrontal cortex (+34%, p<0.001) and hippocampus 
(+16%, p=0.022).  
4.3.5 NR2B Protein 
There was a single band at 165 kDa as expected. A three way ANOVA 
revealed a significant main effect of TREATMENT in the hippocampus (F1,47=4.5, 
p=0.040), with an overall 8% increase in NR2B protein expression following Ro 63-
1908 treatment. A significant AGE x TREATMENT interaction was observed in the 
prefrontal cortex (F1,48=4.0, p=0.024). There was no significant main effect of 
GENDER in the prefrontal cortex or hippocampus or any other interactions 
observed. 
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Figure 4.6. A: Representative Western blot bands of NR2B and actin protein. B: 
Graphs showing a trend for an increase in NR2B protein in mice following perinatal 
NR2B antagonist (Ro 63-1908) compared to those treated with saline at postnatal 
day 35 in the prefrontal cortex. Data represents males and females combined, n=10-
12/group). Data presented as mean relative density  SEM. #: p=0.020 (bonferroni 
corrected). 8% increase (p=0.040) in Ro 63-1908 treated mice, independent of age, 
compared to saline in the hippocampus. Abbreviations: PFC = prefrontal cortex; PN 
= postnatal day. 
 
An Independent samples t-test showed a trend (using Bonferroni correction) 
for an increase in the Ro-631908 treated group compared to the control at PN35 in 
the prefrontal cortex (+23%, t18=-2.5, p=0.020) but not at PN14 (p=0.309) or PN70 
(p=0.684). Despite the main effect of treatment in the hippocampus there was no 
difference between the Ro 63-1908 treated group and control at any individual age 
(PN14: p=0.087; PN35: p=0.283; PN70: p=0.610) (see Figure 4.6). 
Using the control data, there was a trend for a difference in NR2B protein 
expression between time points in the prefrontal cortex (F2,27=2.8, p=0.077), with a 
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post hoc test revealing a trend for a decrease between PN14 and PN35 (-15%, 
p=0.070) and no other differences. 
4.4 Discussion 
The main findings from this study are: 1. Perinatal NR2B antagonism 
produced a reduction in NR2B binding at PN14 in the prefrontal cortex and 
hippocampus, but did not affect NMDAR or NR2A binding. 2. Perinatal NR2B 
antagonism produced small but significant increases in NR2B (but not NR2A) 
protein in the hippocampus and prefrontal cortex. 3. The adolescent brain showed 
evidence of gender specific NMDAR stoichiometry; NR2A binding was 
substantially increased in the prefrontal cortex and hippocampus of female mice, 
compared to males, at PN35.  
4.4.1 Perinatal NR2B antagonism produces alterations specific to the NR2B 
subunit 
Perinatal NR2B antagonism resulted in a substantial 70% decrease in 
[3H]Ifenprodil binding at PN14 in both the prefrontal cortex and hippocampus. This 
reduction was observed eight hours after the final injection of the NR2B antagonist, 
Ro 63-1908, and was not apparent in the long-term. Ro 63-1908 and [3H]ifenprodil 
are NR2B antagonists that both bind to the polyamine site on the NR2B subunit 
(Coughenour and Barr 2001, Zhou et al., 1999). Considering we did not observe a 
concomitant reduction in NR2B protein following Ro 63-1908 treatment, this finding 
strongly suggests that Ro 63-1908 displaced the [3H]Ifenprodil binding in the brain, 
providing evidence of its ability to cross the blood brain barrier in this model. It has 
previously been shown that Ro 63-1908 is present in the cerebrospinal fluid 
following intravenous administration to adult animals (Gill et al., 2002). However, 
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there are no published studies showing evidence of direct binding of this compound 
to NR2B binding sites in the brain. The present study has therefore provided 
evidence that 8 hours following a subcutaneous administration, that Ro 63-1908 does 
displace [3H]Ifenprodil from NR2B binding sites in the juvenile rat brain. Ro 63-
1908 has previously been characterised to have an apparent half-life of only 0.30-
0.39 hours following a 10 mg/kg intravenous bolus administration (Gill et al., 2002), 
however the half-life after subcutaneous administration has not been characterised. 
Based on our findings, it appears that the half-life following this administration, at 
least in juvenile mice, may in fact be much longer. 
While NR2B protein levels were unchanged at PN14 following Ro 63-1908 
treatment, there was a small, but significant, increase in NR2B protein levels in the 
hippocampus, independent of age and gender, as well as an increase in NR2B protein 
levels specifically at PN35 in the prefrontal cortex. These changes were not 
accompanied by changes in NR2B binding. As we have seen from the previous 
chapters examining NR2B binding and protein levels in the human prefrontal cortex 
and hippocampus, this disparity between binding and protein levels is not 
uncommon. This increase in NR2B protein levels observed following Ro 63-1908 
treatment might represent a compensational increase in endogenous NR2B protein 
stores due to the perinatal blockade of NR2B. An investigation of the NR2B levels of 
subcellular compartments would be an important avenue to pursue to further 
characterise the cellular alterations in this model, especially considering cell 
compartment specific alterations in NR2B have been found in schizophrenia 
(Kristiansen et al., 2010b).  
This is the first study to examine the effects of perinatal NR2B antagonism 
on the NMDAR and subunit levels. Our group has previously examined the effects of 
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the non-specific NMDAR antagonist PCP, on the developmental expression of 
NMDAR, including the NR2A and NR2B subunits. Perinatal PCP treatment showed 
an increase in NR2B protein and NMDAR binding at adolescence and similar to the 
results from the present study, these findings from du Bois and colleagues were 
observed in the prefrontal cortex but not the hippocampus (du Bois et al., 2009, du 
Bois et al., 2012). It is possible that the prefrontal cortex is not as efficient at 
returning a normal protein balance in the cell or it may be that the perinatal 
antagonism caused an imbalance in the developmental pattern of NR2B protein at 
adolescence that was specific to the prefrontal cortex. Du Bois and colleagues (2012) 
also showed that the NR2A subunit was increased in the hippocampus at 
adolescence, which contrarily did not occur in the present study. This suggests that 
non-specific antagonism of the NMDAR can affect both the NR2A and NR2B 
subunits in different parts of the brain whereas specific NR2B antagonism appears to 
only alter the NR2B subunit protein. 
At the adult time point of PN70, the mouse model used in this study showed 
no changes in NR2A or NR2B subunit binding or protein, which is similar to some 
studies in adult human schizophrenia tissue in the prefrontal cortex and hippocampus 
(Beneyto et al., 2007, Beneyto and Meador-Woodruff, 2008, Kristiansen et al., 
2006). In Chapter 2 of this thesis, it was reported that NR2B protein was reduced in 
the hippocampus of schizophrenia subjects, specifically in the left hemisphere. 
Unfortunately hemisphere specific effects were not examined as part of our animal 
study. Functional lateralisation is reported to occur in rodents in both the 
hippocampus and cortical areas (Cowell et al., 1999, Kim et al., 2012, Shipton et al., 
2014). Furthermore, in the hippocampal CA1 region, the larger synapses found on 
the right correspond with a higher density of NR1 subunit, but not the NR2B subunit 
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(Shinohara et al., 2008) and this suggests hemisphere specific differences in some 
subunits that should be followed up in future studies. In Chapter 3 of this thesis, it 
was reported that NR2B protein was reduced in female schizophrenia subjects 
compared to males, but no gender effects were observed in this study in regards to 
NR2B. This animal model produced selective subtle changes, primarily at 
adolescence. It is likely that a secondary insult, perhaps at the adolescent period, is 
required to develop this model into one that more closely models the pathological 
alterations observed in schizophrenia. 
4.4.2 Developmental profile of the NMDAR and NR2A and NR2B subunits in the 
mouse brain 
In this study, NMDAR binding showed an overall increase from PN14 to 
PN70 in both the prefrontal cortex and the hippocampus of the mouse brain, which 
confirms previous findings in rats (du Bois et al., 2009). 
This was the first study to investigate [3H]Ifenprodil binding during 
development of the rodent brain. There was an increase from PN14 to PN70 in both 
the prefrontal cortex and the hippocampus. This pattern was unlike that of the NR2B 
protein in which there was a small decrease observed between PN14 and PN35 in the 
prefrontal cortex, and no other differences in protein levels between the time points. 
In support of our protein findings, previous studies have shown that NR2B protein 
levels decrease or remain constant from peak expression at around PN21 (Sheng et 
al., 1994, Zhong et al., 1995, Portera-Cailliau et al., 1996, Wenzel et al., 1997). A 
similar pattern of tapering expression of NR2B protein during the postnatal period 
has been found in the human brain (Jantzie et al., 2013). An increase in binding 
throughout development, as observed in the present study, suggests that the 
availability or affinity of the binding sites in the membrane may change over time 
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but the amount of total protein remains fairly constant from early adolescence to 
adulthood.                      
In contrast to NR2B, NR2A binding showed a gender specific developmental 
profile. There was no change in NR2A binding during development for the male 
mice but there was an increase from PN14 to PN35 and then a decrease from PN35 
to PN70 in the female mice, showing a peak in expression at adolescence. No gender 
difference was observed in NR2A protein and there was no difference in NR2A 
protein between the developmental time points. This disparity between binding and 
protein, similar to that found with NR2B suggests that the binding sites in the 
membrane may display different developmental patterns to the total protein amount. 
The NR2A ligand, [3H]CGP39653, binds to the glutamate binding site on the NR2 
subunit with a higher affinity for NR2A but can also bind to NR2B (Christie et al., 
2000). Therefore it is possible that the discrepancy between binding and protein may 
be related to the lack of specificity of the ligand. However, considering the NR2B 
binding in this study did not show these gender specific developmental changes, this 
is unlikely. While ours is the first to examine the developmental profile in mice, one 
previous study in rats has shown an increase in NR2A protein from the early post-
natal period to PN21 and then a slight decline or plateau to adult (Wenzel et al., 
1997).  
4.4.3 Gender specific NMDAR stoichiometry at adolescence 
The gender specific developmental profile in NR2A binding results in 
substantially higher NR2A binding in the prefrontal cortex and hippocampus of 
female mice, compared to males, at PN35. This effect was specific to NR2A binding, 
with no gender effects observed for total NMDAR binding or NR2B binding/protein.  
To our knowledge a gender specific expression of NR2A binding has not been 
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previously reported. While it is possible that the gender differences observed in 
NR2A binding are associated with the oestrous cycle and hormone levels in the 
female mice, it has been reported that NR2A mRNA levels do not fluctuate with the 
oestrous cycle in adult rodents (Adams et al., 2001). Oestrogen does not appear to 
affect the protein levels of NMDAR, NR2A or NR2B either (Snyder et al., 2011). 
The disparity between male and female NR2A binding may underlie gender specific 
susceptibilities apparent in schizophrenia patients at this time point, although further 
research into the association between NR2A levels, particularly in the female, and 
schizophrenia symptom profiles is needed. Furthermore, gender differences in NR2A 
and other receptor or subunit levels elucidated in future human post mortem tissue 
studies and animal models of schizophrenia may assist in the development of gender 
specific treatments for the disorder. 
4.4.4 Conclusion 
In conclusion, perinatal NR2B antagonism had minimal effects on the 
NMDAR complex, other than a subtle increase in NR2B protein the hippocampus 
(irrespective of gender and age) and in the prefrontal cortex specifically at 
adolescence. Despite this there may indeed be altered functional capacity or activity 
of these receptors and/or the downstream signalling capacity, which was not 
measured in this study. While the significance of this subtle change in NR2B protein 
at adolescence remains to be determined, it provides the first evidence of the effects 
of perinatal NR2B antagonism on brain neurochemistry. Furthermore we provide the 
first evidence of gender specific alterations in the development of the glutamatergic 
system in mice, specifically at adolescence, although our findings are limited as we 
did not measure oestrogen levels in females or determine stage in oestrous cycle. 
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Further research is needed to confirm these gender differences in the human brain 
and whether they occur in schizophrenia pathology. 
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5 THE EFFECT OF PERINATAL NR2B ANTAGONISM ON NRG1 AND 
ERBB4 PROTEIN: A MOUSE MODEL 
5.1 Introduction  
NRG1 is a principal candidate gene implicated in schizophrenia. Although 
present in over 30 isoforms, the NRG1 protein contains a common EGF domain with 
which it signals primarily through ErbB4. Alterations in NRG1 and ErbB4 have been 
noted in the schizophrenia brain, particularly in the areas of the prefrontal cortex and 
hippocampus (Hashimoto et al., 2004, Law et al., 2006, Law et al., 2007, Chong et 
al., 2008, Barakat et al., 2010, Marballi et al., 2012).  
NRG1 plays a vital role in brain development, including synapse formation 
and plasticity, glial cell development and myelination and neuronal survival (Mei 
and Xiong, 2008). The pattern of expression of NRG1 mRNA and protein in the 
rodent central nervous system during gestational development varies between the 
different isoforms. Type I mRNA is predominant during early embryogenesis 
whereas type II and III mRNA are not detected until midgestation but display a 
broader expression pattern in the brain (Meyer et al., 1997). Similarly NRG1 type I 
protein is expressed early in embryonic development (Pinkas-Kramarski et al., 
1994). It has also been shown that the amount and composition of NRG1 mRNA 
subtypes in the cerebral cortex differs between embryonic, perinatal and adult rat 
brain, with levels of NRG1 mRNA increasing from juvenile to adult ages in both the 
rat and human cerebral cortex (Liu et al., 2001).  At adulthood, the regional 
distribution of NRG1 transcripts and protein is widespread throughout the rodent 
brain, mirroring that seen in the adult human brain (Law et al., 2004). The mRNA 
expression does not necessarily translate to protein expression (Greenbaum et al., 
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2003) and to date, the developmental expression of NRG1 protein has not been 
reported in the literature. 
Both the NR2 subunits of the NMDAR and the ErbB4 protein are linked to 
the PSD-95 family of proteins (Figure 1.1) and therefore it is possible that a 
functional association is present between these proteins. NRG1 signalling has been 
found to alter the expression and function of the NMDAR, as well as influence 
NR2B subunit phosphorylation in a brain region specific manner (Hahn et al., 2006, 
Bjarnadottir et al., 2007). More recently it has been shown in animal models that a 
blockade of the NMDAR can affect the NRG1 signalling pathway. Chronic MK-801 
treatment in adult rats results in an upregulation of NRG1 and ErbB4 proteins in the 
prefrontal cortex (Feng et al., 2010), while perinatal PCP treatment produces age-
specific alterations in NRG1 and ErbB4 protein, that are more prominent in the 
prefrontal cortex than the hippocampus (du Bois et al., 2012). These models suggest 
NRG1 and ErbB4 alterations could play a role in the development of schizophrenia 
pathology either primarily, through NRG1 mutations, or as a consequence of 
NMDAR hypofunction. 
The aims of this study were to 1. Examine NRG1 and ErbB4 protein 
expression at the juvenile, adolescent and adult time points following perinatal 
NR2B antagonist treatment, 2. Study the normal developmental profile of NRG1 and 
ErbB4, 3. Examine the developmental and treatment effects in both male and female 
mice and 4. Assess the relationship between the NRG1/ErbB4 and NMDAR 
subunits. 
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5.2 Materials and Methods 
The animal and drug treatment procedure, Western blot protocol and statistics 
were the same as detailed in Chapter 4. The antibodies used for Western blot were 
anti-NRG1 (#ab2994, 1/500; Abcam) targeting the EGF domain of the NRG1 protein 
and anti-ErbB4 (#ab32375, 1/2500; Abcam) targeting the C-terminal of the ErbB4 
protein. Pearson’s correlations were performed for each age group to determine if 
there was a relationship between the NRG1 and ErbB4 proteins, as well as with the 
NR2A and NR2B protein data (from Chapter 4).  
5.3 Results 
NRG1 was presented as a single 60 kDa band, which has been suggested to 
be the EGF domain common to all isoforms and therefore represent total NRG1 
levels (Fung et al., 2012). ErbB4 protein was also presented as a single 147 kDa band 
and quantified as previously reported (Wakuda et al., 2015). 
5.3.1 Reduction in NRG1 protein in the hippocampus at adolescence after perinatal 
NR2B antagonism  
A three way ANOVA revealed a significant main effect of AGE in the 
prefrontal cortex (F2,48=168.5, p<0.001) and hippocampus (F2,47=277.2, p<0.001) and 
a significant AGE x TREATMENT interaction in the hippocampus (F2,47=4.6, 
p=0.014). There was no significant main effect of GENDER or TREATMENT or 
any other significant interactions. 
A one way ANOVA using the control data with genders combined showed 
that NRG1 protein expression was significantly different between time points in the 
hippocampus (F2,26=188.9, p<0.001) and prefrontal cortex (F2,27=88.0, p<0.001). 
Post-hoc tests revealed a substantial increase from PN14 to PN35 in the prefrontal 
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cortex (+330%, p<0.001) and hippocampus (+326%, p<0.001) and a further increase 
from PN35 to PN70 in the prefrontal cortex (+34%, p=0.012) but not the 
hippocampus (p=0.745). Overall there was an increase from PN14 to PN70 in the 
prefrontal cortex (+479%, p<0.001) and hippocampus (+305%, p<0.001) (see Figure 
5.1). 
 
 
  
 
Figure  
 Figure 5.1. A: Representative Western blot bands of NRG1 and actin protein. B: 
Graphs showing an increase in NRG1 protein throughout development and a 
decrease in NRG1 protein in mice following perinatal NR2B antagonist (Ro 63-
1908) treatment compared to those treated with saline at postnatal day 35 in the 
hippocampus. Data represents males and females combined, n=10-12/group. Data 
presented as mean relative density  SEM. *: 0.000<p<0.05, #: p=0.012, 13% 
decrease in NRG1 protein levels of Ro 63-1908 treated mice compared to saline at 
postnatal day 35. Abbreviations: PFC = prefrontal cortex, PN = postnatal day. 
 
An Independent samples t-test revealed a decrease in the Ro-631908 treated 
group compared to the control at PN35 in the hippocampus (-13%, t18=2.8, p=0.012) 
but no difference at PN14 (p=0.859) or PN70 (p=0.316) (see Figure 5.1). 
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5.3.2 No change in ErbB4 protein after perinatal NR2B antagonism 
A three way ANOVA revealed a significant GENDER x TREATMENT 
interaction in the hippocampus (F2,47=6.5, p=0.014) but there were no significant 
differences in post hoc analyses. There were no significant main effects and no other 
significant interactions in the hippocampus and no significant effects in the 
prefrontal cortex (see Figure 5.2). 
Figure 5.2. A: Representative Western blot bands of ErbB4 and actin protein. B: 
Graphs showing no difference in ErbB4 protein in the prefrontal cortex and 
hippocampus of mice at postnatal days 14, 35 and 70 following perinatal treatment 
with saline or the NR2B antagonist Ro 63-1908. Data represents males and females 
combined, n=10-12/group. Data presented as mean relative density  SEM. 
Abbreviations: PFC = prefrontal cortex, PN = postnatal day. 
 
5.3.3 Relationship between NRG1 signalling system and the NR2A and NR2B 
subunits 
NRG1 and ErbB4 protein showed significant positive correlations in the 
hippocampus specifically at PN14 (r=0.506, p=0.023, n=20) and PN70 (r=0.476, 
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p=0.039, n=20), but not at PN35. In contrast NRG1 and ErbB4 proteins were 
positively correlated in the prefrontal cortex only at PN35 (r=0.605, p=0.005, n=20) 
(see Table 5.1). 
NR2B and NRG1 protein showed significant positive correlations at PN14 
(r=0.445, p=0.049, n=20) and PN70 (r=0.445, p=0.049, n=20) in the prefrontal 
cortex as well as at PN70 in the hippocampus (r=0.466, p=0.044, n=20). NRG1 and 
NR2A protein was significantly correlated only at PN70 in the hippocampus 
(r=0.512, p=0.025, n=20) (see Table 5.1). The NR2 subunits did not correlate with 
ErbB4 at any age. 
 
Table 5.1. Pearson’s correlations between NRG1, ErbB4, NR2A and NR2B proteins. 
  PN14 PN35 PN70 
PFC     NRG1/ErbB4 r -0.008 0.605 0.011  p 0.975 0.005* 0.965 NRG1/NR2A r 0.362 -0.132 -0.264 
 p 0.117 0.579 0.260 
NRG1/NR2B r 0.445 0.193 0.445  p 0.049* 0.415 0.049* ErbB4/NR2A r 0.431 -0.213 0.044  p 0.058^ 0.367 0.855 ErbB4/NR2B r -0.495 0.108 -0.291 
 p 0.028* 0.650 0.213 
HIP     NRG1/ErbB4 r 0.506 0.381 0.476  p 0.023* 0.098 0.039* NRG1/NR2A r -0.375 -0.363 0.512  p 0.103 0.116 0.025* NRG1/NR2B r 0.040 -0.301 0.466  p 0.868 0.197 0.044* ErbB4/NR2A r -0.182 0.054 0.449  p 0.442 0.822 0.054^ ErbB4/NR2B r 0.096 0.026 0.187 
 p 0.688 0.912 0.443 
Abbreviations: HIP = hippocampus, PFC = prefrontal cortex, PN = postnatal day. *: 
p<0.05, ^: 0.05<p<0.07. 
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5.4 Discussion 
The main findings from this study were: 1. There was a selective decrease in 
NRG1 at adolescence after perinatal NR2B antagonism. 2. NRG1 protein expression 
significantly increased from the juvenile to the adult ages in the prefrontal cortex and 
hippocampus. 3. There were age dependent positive correlations between 
NRG1/ErbB4 and NRG1/NR2B. 
5.4.1 Perinatal NR2B antagonism produces alterations in NRG1 protein at 
adolescence 
This study revealed a decrease in hippocampal NRG1 protein expression, 
specifically at adolescence, following perinatal NR2B antagonism. Alterations of 
proteins in the brain at adolescence like we see in NR2B and NRG1 in this study 
could have functional outcomes that affect behaviour, memory and cognition. 
Studies conducted on NRG1 mutant mice, for example, that have reduced expression 
of NRG1 show that this results in susceptibility to behavioural abnormalities and 
further impacts to the brain, particularly at adolescence (Long et al., 2013). Therefore 
while the alterations observed in the present study are subtle, collectively they may 
increase the susceptibility of Ro 63-1908 treated animals to secondary impacts. 
NRG1 and NR2B proteins were positively correlated in the prefrontal cortex and 
hippocampus at PN70 and in the prefrontal cortex at PN14 but there was no 
correlation at PN35. Due to the opposing changes seen in NR2B and NRG1 protein 
at adolescence in our mouse model, it is likely that the perinatal NR2B antagonism 
disrupts the positive relationship at this age and this could alter other signalling 
systems and pathways during the adolescent brain growth period, possibly rendering 
the brain vulnerable to impacts during this time. Behavioural analyses were not 
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conducted in the present study as the stress of behavioural tests themselves could 
influence brain measures (Rosenzweig and Bennett, 1996). 
One study that examined NRG1 protein following perinatal PCP treatment in 
rats found no alteration in NRG1 protein in the hippocampus at juvenile, adolescent 
or adult ages but found a decrease in the prefrontal cortex at the adolescence (du 
Bois et al., 2012). The discrepancy between our results and those of du Bois et al. 
may be due to the non-specific nature of PCP versus the specific NR2B antagonist 
used as the perinatal treatment or the differing antibodies used in the Western blot 
protocol, which could have identified different isoforms of the NRG1 protein. Du 
Bois and colleagues (2012) measured the 85 kDa band (Santa Cruz Biotechnology 
antibody sc-348) antibody of NRG1 that is thought to represent NRG1 type III, while 
we measured the 60 kDa band of NRG1 that is thought to be the EGF domain that is 
common to all isoforms of NRG1.  
Perinatal NB2B antagonist treatment had no effect on levels of ErbB4 in the 
prefrontal cortex or hippocampus at any age in our study. This is in contrast to the 
study by du Bois and colleagues, which showed alterations in ErbB4 protein 
throughout development in the prefrontal cortex (du Bois et al., 2012). Again this 
discrepancy could be due to the non-specific nature of PCP or the differing 
antibodies used for detection (the present study using Abcam antibody ab32375 to 
detect a single band at 147 kDa and du Bois et al. 2012 using Santa Cruz 
Biotechnology antibody sc-283 and quantified the 185 kDa band). 
Our study found no alteration in either NRG1 or ErbB4 protein at PN70. In 
the schizophrenia brain, studies using adult post mortem tissue have found various 
changes depending on the fraction of NRG1 and ErbB4 examined. In the prefrontal 
cortex, there has been no change in NRG1(1α) protein (Boer et al., 2009), an 
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increase in the 53 kDa cytoplasmic fragment of NRG1 protein (Chong et al., 2008), a 
decrease in the C-terminal fragment of NRG1 protein (Barakat et al., 2010), a 
decrease in the 50 kDa NRG1 protein fragment and an increase in the N-terminal 
fragment of NRG1 protein (Marballi et al., 2012) in schizophrenia. For ErbB4 
protein, an increase in the 180 kDa cytoplasmic fraction has been found in the 
prefrontal cortex (Chong et al., 2008). In the hippocampus, NRG1 protein is 
decreased in the left hemisphere (Stuart et al., 2011) and the 50 kDa fragment of 
NRG1 protein is decreased (Marballi et al., 2012) in schizophrenia subjects 
compared to controls. Considering these mixed results, it is hard to determine where 
the results of the present study lie in terms of matching the occurrence in the 
schizophrenia brain. Miraballi and colleagues suggest that an alteration in NRG1 
cleavage/cleavage enzymes rather than NRG1 protein levels may be an underlying 
factor in the schizophrenia brain (Miraballi et al., 2012). More research is required in 
both human and animal models to come to any conclusions.  
5.4.2 Increasing NRG1 protein in the mouse brain throughout development 
This is the first study in any species to our knowledge to examine NRG1 
protein levels during brain development. We found a dramatic increase from PN14 to 
PN35 in the prefrontal cortex and hippocampus and then a further increase to PN70 
in the prefrontal cortex. NRG1 mRNA has been examined throughout development 
with a decrease in the total amount from perinatal to adulthood in the monkey and 
human (Liu et al., 2011). NRG1 protein plays a vital role in brain development and 
so it is interesting that protein levels increase throughout development, however it 
also has an importance in the mature brain and can modulate synaptic transmission, 
dendrite growth, receptor expression and many other aspects of neuronal function 
(Harrison and Law, 2006). Our study used an antibody that recognises the EGF 
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domain of NRG1 protein that is present in each isoform, this suggests that total 
NRG1 protein levels increase with age however it is possible that different isoforms 
have different developmental profiles. Isoforms of NRG1 mRNA have different 
developmental profiles and are regulated by neuronal activity (Liu et al., 2011). 
Therefore it is likely that particular NRG1 isoforms and isoform ratios are more 
important during early development and not the total levels of NRG1 protein. 
In terms of ErbB4 protein, there was no change in protein levels throughout 
development or with gender and this is consistent with that shown previously in the 
monkey prefrontal cortex (Thompson et al., 2007). Considering that ErbB4 is one of 
the primary receptors for NRG1, it is surprising that it did not reflect the 
developmental profile of NRG1.  It may be that the different isoforms of ErbB4 
show distinct developmental expressions, that we were unable to detect with our use 
of a non-specific ErbB4 antibody. In addition, the full-length form of ErbB4 may 
remain unaltered over time but the ErbB4 fragments for signalling or the ErbB4 
signalling efficiency may change.  We must also consider that NRG1 does signal 
through other ErbB receptors and that ErbB4 can also interact with NRG2 and NRG3 
(Hobbs et al., 2002). While we provide novel evidence of the developmental 
expression of these proteins, clearly there is a need for more extensive investigations 
of the developmental profile of this system.  
5.4.3 Conclusion 
 In conclusion, perinatal NR2B antagonism produced a selective alteration in 
NRG1 levels at the adolescent time point and this appeared to alter the dynamics of 
the relationship with the NR2B subunit protein. In addition, we have for the first time 
found evidence of a dramatic increase of NRG1 protein levels throughout 
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development which provides a strong basis to further investigate the developmental 
expression and function of NRG1 signalling and its role of NRG1 schizophrenia.
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6 THE EFFECTS OF PERINATAL NR2B ANTAGONISM ON THE 
GABAERGIC AND CANNABINERGIC SYSTEMS: A MOUSE MODEL 
6.1 Introduction  
 The cannabinoid and GABAergic systems are key regulators of inhibition 
within the brain. The GABAAR functions to inhibit excitatory output while the CB1R 
is highly abundant on GABAergic and glutamatergic neurons where it plays a role in 
the inhibition of GABA and glutamate release as well as the modulation of other 
neurotransmitter systems.   
Both the cannabinoid and GABAergic systems have been implicated in 
schizophrenia. A deficit of GABAergic signalling has been implicated in 
schizophrenia as reductions in GABAergic interneurons and increased levels of 
GABAARs have been observed in postmortem human schizophrenia brain compared 
to controls (Benes et al., 1992; Benes et al., 1996a; Benes et al., 1996b; Dean et al., 
1999; Deng and Huang, 2006; Newell et al., 2007b, Verdurand et al., 2013). 
Increased levels of CB1R binding in the prefrontal and cingulate cortices have also 
been found in schizophrenia brain tissue (Dalton et al., 2011; Giuffrida et al., 2004; 
Newell et al., 2006; Zavitsanou et al., 2004), however a decrease in CB1Rs has been 
found in two areas of the prefrontal cortex (Eggan et al., 2008; Eggan et al., 2010b).  
As a model of schizophrenia, perinatal NMDAR antagonism has been shown 
to increase GABAARs, particularly at adolescence, in various regions of the female 
rat brain (du Bois et al., 2009). As well as this, a loss of GABAergic interneurons has 
been observed following perinatal NMDAR blockade (Nakatani-Pawlak et al., 2009), 
which is representative of the GABAergic dysfunction seen in schizophrenia 
pathology.  There are no published studies to date that have examined CB1R density 
following perinatal NMDAR antagonist treatment however an alteration in CB1R 
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mRNA has been observed (Mailleux and Vanderhaeghen, 1992). The CB1R has been 
found to co-localise with the NMDAR in the postsynaptic membrane and this 
association along with excessive cannabinoid activity can destabilise NMDARs in 
the membrane and disrupt their function (for review see Sanchez-Blazquez et al., 
2013). This restriction of NMDAR function by cannabinoid activity allows the 
reversal of NMDAR excitotoxicity but could also cause NMDAR hypofunction and 
contribute to schizophrenia pathology. Furthermore both GABAAR subunit and NR1 
and NR2B mRNA have been found altered in the hippocampus and striatum of CB1 
mutant mice (Warnault et al, 2007). Whether or not the reverse is true and CB1R 
levels are affected by NMDAR or NR2B antagonism has not been studied. 
The NR2B subunit of the NMDAR has been found on GABAergic 
interneurons and plays an important role in NMDAR mediated signalling and 
synaptic plasticity at these synapses (Szinyei et al., 2003) and NR2A and NR2B are 
thought to differentially regulate GABA release (Fantin et al, 2007). So while it is 
known that non-specific NMDAR antagonism can affect GABAergic interneuron 
and GABAAR levels it is not known if specific NR2B antagonism can affect 
GABAARs and if so are the alterations similar to that seen in schizophrenia. 
To further our understanding of the interactions between the glutamatergic, 
GABAergic and cannabinoid signalling systems, particularly with reference to 
NMDAR hypofunction, the aims of this study were to 1. Examine the effects of 
perinatal NR2B antagonism on GABAAR and CB1R density at the juvenile, 
adolescent and adult time points, 2. Investigate the normal developmental profile of 
GABAA and CB1Rs in the mouse brain and 3. Examine the developmental and 
treatment effects in both male and female mice.  
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6.2 Materials and Methods 
The animal and drug treatment procedure is the same as that from Chapter 4. 
6.2.1 Autoradiography Procedures and Quantification 
6.2.2 GABAAR Binding  
Sections for GABAAR binding were collected at levels corresponding to 
Bregma 2.34 and -1.94 mm (Paxinos and Franklin, 2001) including the structures of 
the prefrontal cortex, hippocampus and thalamus (showed a high density of 
GABAARs). [3H]Muscimol binding was performed based on the methods previously 
used by du Bois et al (2009). All sections were preincubated in 50 mM TrisCitrate 
(pH 7) for 3 x 5 minutes at 4⁰C. The sections were then incubated in the same buffer 
with the addition of 12 nM [3H]Muscimol (selective GABAAR agonist: specific 
activity 25.5 Ci/mmol; PerkinElmer) for 45 minutes at 4°C to determine total 
binding, with adjacent sections incubated in the presence of 100 µM GABA (Sigma-
Aldrich) to determine nonspecific binding. All sections were then washed in 50 mM 
TrisCitrate (pH 7) for 4 x 2 seconds at 4°C, rinsed in distilled water and air dried 
overnight.  
6.2.3 CB1R Binding 
Sections for CB1R binding were collected at levels corresponding to Bregma 
2.34, 1.32 and -1.94 mm (Paxinos and Franklin, 2001) including the structures of the 
prefrontal cortex, striatum, hippocampus and globus pallidus (showed a high density 
of CB1Rs). [3H]CP55940 binding was performed based on the methods previously 
used by Newell et al (2006). All sections were preincubated in 50 mM TrisHCl (pH 
7.4) with 5% bovine serum albumin (BSA) for 30 minutes at room temperature.  The 
sections were then incubated in the same buffer with the addition of 10 nM 
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[3H]CP55940 (specific cannabinoid receptor agonist: specific activity 174.6 
Ci/mmol, PerkinElmer, Waltham, MA, USA) for 2 hours at room temperature to 
determine total binding, with adjacent sections incubated in the presence of 10µM 
CP55940 (Sigma Aldrich, Castle Hill, NSW, Australia) to determine nonspecific 
binding. All sections were then washed, firstly in 50mM TrisHCl (pH 7.4) containing 
1% BSA for 1 hour at 4°C, then in 50mM TrisHCl (pH 7.4) for 2 hours at 4°C and 
lastly in 50 mM TrisHCl (pH 7.4) for 5 minutes at 4°C. Finally the sections were 
rinsed in distilled water and air-dried overnight.  
6.2.4 Quantification  
All slides were then placed in cassettes and exposed to tritium-sensitive 
Kodak BioMax MR Film (Sigma-Aldrich) for 6-12 weeks. The films were developed 
using the AGFA CP1000 film developer (Agfa-Gevaert N.V.) and analysed using 
Quantity One software version 4.6.7 (BioRad) connected to a GS-800 Calibrated 
Densitometer (BioRad). Quantification was performed by measuring the average 
optical density in each brain region in three adjacent sections and then averaging 
across six mice per group. 
6.2.5 Statistics 
A Pearson’s correlation was conducted to determine if there was any 
correlation between the binding levels of GABAAR, CB1R, NMDAR, NR2A 
subunits and NR2B subunits in the prefrontal cortex or hippocampus. All data is 
presented as mean±SEM.  
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6.3 Results 
6.3.1 No effect of perinatal NR2B antagonism on GABAAR Binding 
GABAAR binding density was observed in the prefrontal cortex, 
hippocampus and thalamus regions (see Figure 6.1). 
 
Figure 6.1. A: Representative autoradiograms of total and non-specific GABAAR (3H-Muscimol) binding in the prefrontal cortex (Bregma +2.34), thalamus and 
hippocampus (Bregma -1.94) of adult mice. B: Mouse brain atlas pictures showing 
bregma levels and locations of prefrontal cortex (+2.34), thalamus and hippocampus 
(-1.94). Abbreviations: HIP = hippocampus, PFC = prefrontal cortex, THAL = 
thalamus. 
 
A three way ANOVA revealed a significant main effect of AGE in the 
prefrontal cortex (F2,55=15.6, p<0.001), hippocampus (F2,54=22.1, p<0.001) and 
thalamus (F2,55=11.9, p<0.001) and of GENDER in the prefrontal cortex (F1,55=38.7, 
p<0.001), hippocampus (F1,54=29.9, p<0.001) and thalamus (F2,55=18.2, p<0.001) on 
[3H]Muscimol binding. There was an AGE x GENDER interaction in the 
hippocampus (F2,54=6.1, p=0.004) and thalamus (F2,55=4.6, p=0.014) and a trend for 
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one in the prefrontal cortex (F2,55=3.0, p=0.059). There was no significant effect of 
TREATMENT in any brain region or any other interactions observed. 
Using the control data, [3H]Muscimol binding expression was significantly 
different between time points in the prefrontal cortex (male: F2,15=8.7, p=0.003; 
female: F2,15=19.2, p<0.001), hippocampus (male: F2,15=15.2, p<0.001; female: 
F2,15=3.8, p=0.050) of both genders and in the thalamus of the male mice (F2,15=4.2, 
p=0.036)  but not the female mice (F2,15=3.1, p=0.081). Post hoc tests revealed a 
significant decrease in binding from PN14 to PN35 in the prefrontal cortex (-45%, 
p=0.003) and hippocampus (-64%, p<0.001) of male mice, but no change in the 
thalamus between these two ages (p=0.258). This was followed by an increase from 
PN35 to PN70 in all the brain regions (prefrontal cortex: +53%, p=0.042; 
hippocampus: +119%, p=0.012; thalamus: +130%, p=0.029), resulting in no overall 
difference between PN14 and PN70 (prefrontal cortex: p=0.360; hippocampus: 
p=0.114; thalamus: p=0.452). In the female mice there was a decrease from PN14 to 
PN35 in the prefrontal cortex (-26%, p=0.001), similar to the male mice, but no 
change in the hippocampus (p=0.195) or thalamus (p=0.098). There was no change 
from PN35 to PN70 in any brain region in the female mice (prefrontal cortex: 
p=0.539; hippocampus: p=0.713; thalamus: p=0.947), resulting in an overall 
decrease from PN14 to PN70 in the prefrontal cortex (-33%, p<0.001) and 
hippocampus (-27%, p=0.047) and no change in the thalamus (p=0.169). 
Independent samples t-tests with Bonferroni adjustment showed that in the 
saline animals there was a significant increase in [3H]Muscimol binding in female 
compared to male mice at PN14 in the prefrontal cortex (females: +35%, t10=-5.6, 
p<0.001) but not the hippocampus (p=0.061) and thalamus (p=0.107) and at PN35 in 
the prefrontal cortex (females: +81%, t9=-4.2, p=0.002), hippocampus (females: 
Chapter 6 
 
 
117
+181%, t9=-5.4, p<0.001) and thalamus (females: +190%, t9=-5.2, p=0.001) (see 
Figure 6.2). There was no significant difference between the male and female mice at 
PN70 in the prefrontal cortex (p=0.613), hippocampus (p=0.185) or thalamus 
(p=0.169). In the Ro 63-1908 treated animals there was an increase in [3H]Muscimol 
binding in the female compared to the male mice at PN14 in the thalamus (+40%, 
t11=-3.0, p=0.012) but not the prefrontal cortex (p=0.035) or hippocampus (p=0.039) 
and at PN35 in the prefrontal cortex (females: +54%, t9=-4.4, p=0.002) and 
hippocampus (females: +107%, t9=-3.3, p=0.009) but not the thalamus (p=0.051). 
There were no differences in gender at PN70 (prefrontal cortex: p=0.578; 
hippocampus: p=0.997; thalamus: p=0.924) (see Figure 6.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
 
 
118
 
Figure 6.2. [3H]Muscimol binding to the GABAA receptor in the prefrontal cortex, hippocampus and thalamus of male and female mice following perinatal treatment 
with saline or the NR2B antagonist Ro 63-1908 at postnatal days 14, 35 and 70. n=5-
6/group. Data presented as mean relative density  SEM. *: 0.000<p<0.0167. 
Abbreviations: PFC = prefrontal cortex, PN = postnatal day. Columns at each age 
group correspond to the descending order of the groups in the graph key. 
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6.3.2 No effect of perinatal NR2B antagonism on CB1R Binding 
CB1R binding was examined in the prefrontal cortex, striatum, hippocampus 
and globus pallidus (see Figure 6.3).  
 
Figure 6.3. A: Representative autoradiograms of total and non-specific CB1 receptor (3H-CP55940) binding in the prefrontal cortex (Bregma +2.34), striatum (Bregma 
+1.32), hippocampus and globus pallidus (Bregma -1.94) of adult mice. B: Mouse 
brain atlas pictures showing bregma levels and locations of prefrontal cortex (+2.34), 
striatum (+1.32), hippocampus and globus pallidus (-1.94). Abbreviations: GP = 
globus pallidus, HIP = hippocampus, PFC = prefrontal cortex, STR = striatum. 
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A three way ANOVA revealed a significant main effect of AGE in the 
prefrontal cortex (F2,54=198.2, P<0.001), hippocampus (F2,55=132.6, P<0.001), 
striatum (F2,54=281.3, P<0.001) and globus pallidus (F2,55=112.7, P<0.001) and a 
significant interaction of AGE x GENDER in the prefrontal cortex (F2,54=19.7, 
p<0.001), hippocampus (F2,55=8.2, p=0.001) and striatum (F2,54=43.9, p<0.001) on 
[3H]CP55940 binding. There was a significant main effect of GENDER in the 
prefrontal cortex (F1,54=6.3, p=0.015) but not in the hippocampus, striatum or globus 
pallidus. There was no significant main effect of TREATMENT in any brain region 
or any other interactions observed.  
A one way ANOVA using the control data showed that [3H]CP55940 binding 
was significantly different between time points in the prefrontal cortex (male: 
F2,15=100.4, p<0.001; female: F2,13=90.4, p<0.001), hippocampus (male: F2,15=36.1, 
p<0.001; female: F2,13=23.2, p<0.001), striatum (male: F2,15=86.6, p<0.001; female: 
F2,12=177.6, p<0.001) and globus pallidus (male: F2,15=58.4, p<0.001; female: 
F2,12=68.2, p<0.001). A post hoc test revealed a large increase in binding from PN14 
to PN35 in the male mice in all brain regions (prefrontal cortex: +174%, p<0.001; 
hippocampus: +109%, p<0.001; striatum: +157%, p<0.001; globus pallidus: +133%, 
p<0.001) and then a decrease from PN35 to PN70 in the prefrontal cortex (-32%, 
p<0.001) and striatum (-21%, p=0.001) but not the hippocampus (p=0.278) or globus 
pallidus (p=0.894). Overall there was an increase from PN14 to PN70 in all brain 
regions (prefrontal cortex: +86%, p<0.001; hippocampus: +87%, p<0.001; striatum: 
+103%, p<0.001; globus pallidus: +126%, p<0.001).  
Similarly, in the female mice there was an increase from PN14 to PN35 in all 
the brain regions (prefrontal cortex: +134%, p<0.001; hippocampus: +56%, p=0.001; 
striatum: +74%, p<0.001; globus pallidus: +63%, p<0.001), although these increases 
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were of a smaller magnitude than the male mice. In contrast to the male mice there 
was a further increase from PN35 to PN70 in the prefrontal cortex (+19%, p=0.025) 
and striatum (+29%, p<0.001) but not the hippocampus (p=0.184) or globus pallidus 
(p=0.342) resulting in an overall increase from PN14 to PN70 in all brain regions 
(prefrontal cortex: +178%, p<0.001; hippocampus: +79%, p<0.001; striatum: 
+125%, p<0.001; globus pallidus: +78%, p<0.001). 
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Figure 6.4. [3H]CP55940 binding to the CB1 receptor in the prefrontal cortex, hippocampus, striatum and globus pallidus of male and female mice following 
perinatal treatment with saline or the NR2B antaonist Ro 63-1908 at postnatal days 
14, 35 and 70. n=5-6/group. Data presented as mean relative density  SEM. *: 
0.000<p<0.0167. Abbreviations: PFC = prefrontal cortex, PN = postnatal day. 
Columns at each age group correspond to the descending order of the groups in the 
graph key. 
 
Independent samples t tests with Bonferroni adjustment showed that in the 
saline animals there was no significant difference in [3H]CP55940 binding in the 
female compared to the male mice at PN14 the prefrontal cortex (p=0.236), 
hippocampus (p=0.549), striatum (p=0.126) or globus pallidus (p=0.032). In contrast, 
at PN35 there was a significant increase in binding in the male compared to the 
female mice in the prefrontal cortex (males: +38%, t9=6.7, p<0.001), hippocampus 
(males: +25%, t9=2.9, p=0.016) and striatum (males: +34%, t9=6.5, p<0.001) but no 
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difference in the globus pallidus (p=0.208). There was also a difference between the 
genders at PN70 in the prefrontal cortex (females: +26%, t9=-3.7, p=0.005) and 
striatum (females: +22%, t9=-3.2, p=0.011) but not in the hippocampus (p=0.759) or 
globus pallidus (p=0.763) (see Figure 6.4). In the Ro 63-1908 treated animals there 
was an increase in [3H]CP55940 binding in the female compared to the male mice at 
PN14 in the striatum (females: +20%, t11=-2.8, p=0.017) but not the prefrontal cortex 
(p=0.626), hippocampus (p=0.837) or globus pallidus (p=0.270). At PN35 there was 
an increase in binding in the male compared to the female mice in the prefrontal 
cortex (+30%, t6.4=3.5, p=0.012), striatum (+43%, t9=6.8, p<0.001) and globus 
pallidus (+19%, t9=2.3, p=0.048) but not the hippocampus (p=0.031) and at PN70 
there was an increase in binding in the female compared to male mice in the 
hippocampus (females: +24%, t7=-3.5, p=0.010) and striatum (females (trend): 
+24%, t7=-2.9, p=0.024) but not the prefrontal cortex (p=0.294) or globus pallidus 
(p=0.547) (see Figure 6.4). 
6.3.3 Correlations between the GABAergic, cannabinoid and glutamatergic 
systems 
Overall there was a significant negative correlation between CB1R and 
GABAAR binding in the prefrontal cortex (r=-0.544, p<0.001) and hippocampus (r=-
0.535, p<0.001). The correlation remained significant in the male (prefrontal cortex: 
r=-0.560, p<0.001; hippocampus: r=-0.638, p<0.001) and female (prefrontal cortex: 
r=-0.680, p<0.001; hippocampus: r=-0.599, p<0.001) groups when analysed 
separately (see Table 6.1). Correlations were also run by gender due to the amount of 
gender differences found in GABAAR and CB1R binding. 
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Table 6.1. Pearson’s correlations between NMDAR, NR2A, NR2B, GABAAR and CB1R binding in male and female mice. 
    Male Female 
PFC       
GABAAR  r p r p 
  CB1R -0.560 0.000* -0.680 0.000* 
 NMDAR 0.196 0.251 -0.468 0.009* 
 NR2A 0.007 0.969 -0.104 0.557 
 NR2B -0.152 0.376 -0.373 0.042* 
CB1R       
 NMDAR 0.441 0.007* 0.672 0.000* 
  NR2A 0.278 0.106 0.360 0.046* 
  NR2B 0.563 0.000* 0.712 0.000* 
HIP       
GABAAR  r p r p 
  CB1R -0.638 0.000* -0.599 0.000* 
  NMDAR -0.216 0.227 -0.447 0.013* 
 NR2A -0.046 0.796 -0.331 0.069 
 NR2B -0.312 0.068 -0.361 0.046* 
CB1R       
 NMDAR 0.716 0.000* 0.664 0.000* 
  NR2A 0.326 0.056^ 0.257 0.164 
  NR2B 0.580 0.000* 0.647 0.000* 
Abbreviations: CB1R = cannabinoid receptor 1, GABAAR = GABAA receptor,  
HIP = hippocampus, NMDAR = N-methyl-D-aspartate receptor, NR2A/B =   
NMDAR subunits A and B, PFC = prefrontal cortex, PN = postnatal day.  
* = p<0.05, ^ = 0.05<p<0.06.    
 
 
NR2A binding showed a significant positive correlation with GABAAR 
binding in the prefrontal cortex (r=0.656, p=0.001) and the hippocampus (r=0.604, 
p=0.004) at PN35. This positive correlation was also seen in the hippocampus at 
PN70 (r=0.445, p=0.049) and in the prefrontal cortex at PN14 (r=0.700, p<0.001) 
(see Table 6.2). NR2A binding was also negatively correlated to CB1R binding at 
PN35 (prefrontal cortex: r=-0.703, p=0.000; hippocampus: r=-0.433, p=0.044). 
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Table 6.2. Pearson’s correlations between NMDAR, NR2A, NR2B, GABAAR and CB1R binding at postnatal days 14, 35 and 70.  
    PN14 PN35 PN70 
PFC         
GABAAR  r p r p r p 
  CB1R -0.320 0.119 -0.664 0.001* 0.108 0.651 
  NMDAR -0.048 0.821 0.245 0.285 0.678 0.001* 
 NR2A 0.700 0.000* 0.656 0.001* 0.387 0.092 
 NR2B 0.254 0.231 0.254 0.255 -0.053 0.825 
CB1R         
 NMDAR -0.103 0.624 -0.025 0.915 0.067 0.780 
  NR2A -0.330 0.116 -0.703 0.000* -0.283 0.226 
 NR2B -0.126 0.556 -0.125 0.579 0.284 0.226 
          
HIP         
GABAAR  r p r p r p 
  CB1R 0.074 0.725 -0.376 0.093 -0.570 0.009* 
  NMDAR 0.346 0.090 0.082 0.740 0.487 .034* 
 NR2A 0.295 0.161 0.604 0.004* 0.445 0.049* 
 NR2B 0.075 0.720 0.190 0.409 0.244 0.300 
CB1R         
 NMDAR -0.022 0.916 0.167 0.482 -0.087 0.722 
  NR2A 0.069 0.749 -0.433 0.044* -0.257 0.273 
 NR2B 0.128 0.543 0.107 0.636 -0.035 0.882 
Abbreviations: CB1R = cannabinoid receptor 1, GABAAR = GABAA receptor, HIP =  hippocampus, NMDAR = N-methyl-D-aspartate receptor, NR2A/B = NMDAR  
subunits A and B, PFC = prefrontal cortex, PN = postnatal day. 
 * = p<0.05, ^ = 0.05<p<0.06.    
 
 
6.4 Discussion 
The main findings from this study were: 1. NR2B antagonist treatment during 
the perinatal period did not alter the developmental profile of GABAAR or CB1Rs in 
either gender. 2. GABAAR binding shows significant gender differences in receptor 
development, which are positively correlated to NR2A binding results, particularly at 
adolescence. 3. CB1R binding density was also significantly different between 
genders, particularly at adolescence. 4. There was a negative correlation between 
CB1 and GABAAR binding density in the prefrontal cortex and hippocampus.  
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6.4.1 Perinatal NR2B antagonist treatment does not alter the developmental profile 
of CB1 and GABAA receptors 
This study found that perinatal NR2B antagonist treatment did not affect 
CB1R or GABAAR binding density in any brain region, age or gender. While this 
may appear that this treatment does not alter the developmental profile of CB1 or 
GABAAR density, we cannot rule out that there may be alterations in receptor 
function, localization, or regulation, that have not been measured in this study. It is 
possible that receptor binding can be unaltered, but there can be deficits in functional 
activation of those receptors. Therefore, further studies would be required to 
determine whether this is the case for the present study. 
  This is the first study to examine perinatal NR2B antagonist treatment on 
GABAARs. The present study found no effect of NR2B antagonist treatment on 
GABAARs while an increase in GABAARs at adolescence following perinatal PCP 
treatment has been reported previously (du Bois et al., 2009). The non-specific 
nature of PCP blocking all NMDARs may account for the discrepancy between 
results.  
While this is the first study to report on CB1Rs following any form of 
perinatal NMDAR insult, our finding of no change in the brain regions examined is 
consistent with studies using adult NMDAR antagonist treatment. Phencyclidine 
(PCP) treatment has been reported to cause no change in CB1R binding density in the 
adult rat brain 72 hours following treatment (Vigano et al., 2009). Similarly, there is 
no change in CB1R density five or 10 days following PCP treatment (Seillier et al., 
2010). These studies did however find changes in CB1R stimulation following PCP 
treatment and a further study found changes in CB1 mRNA following MK801 
treatment (Mailleux and Vanderhaeghen, 1994). Therefore considering these 
Chapter 6 
 
 
127
functional changes were associated with a lack of binding density change, we cannot 
rule out the possibility of CB1R functional changes in our animal model. 
6.4.2 Developmental profile of the GABAAR binding in the mouse brain 
This study showed that GABAAR binding changes significantly during mouse 
brain development, with different developmental profiles between male and female 
mice. We found male GABAAR expression decreased from PN14 to PN35 and then 
increased to PN70, and female GABAAR expression decreased from PN14 to PN70 
in both the prefrontal cortex and hippocampus. We also examined GABAAR binding 
in the thalamus, which increased from juvenile to adult levels, in contrast to that 
occurring in the prefrontal cortex and hippocampus. Similar to the present study, 
another study found a decrease in GABAARs throughout development in the 
hippocampus in female rats (du Bois et al., 2009). Although, in contrast, an increase 
in GABAAR binding was found in the prefrontal cortex and a decrease was found in 
the thalamus (du Bois et al., 2009) however this was in a different species. 
6.4.3 Gender differences in GABAAR binding 
An increase in female compared to male GABAAR expression in the saline 
animals at PN14 (prefrontal cortex) and PN35 (prefrontal cortex, hippocampus and 
thalamus) was revealed in this study, with no gender differences observed in the 
adult mouse brain. Other studies which have examined gender differences in the 
adult mouse brain have similarly found no difference in GABAAR density between 
genders in the hippocampus and thalamus (Canonaco et al., 1996; Skilbeck et al., 
2008) but have found an increase in GABAARs in cortical regions in female 
compared to male mice (Skilbeck et al., 2008) (see Table 6.3). Studies in the 
developing (PN1 to 20) rat brain have found no differences in GABAAR expression 
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between genders in the medial preoptic area, ventrolateral thalamus, cingulate cortex, 
ventromedial nucleus of the hypothalamus, CA1 and CA2 regions of the 
hippocampus and amygdala (Davis and McCarthy 2000). From the present study and 
others, it appears important for future studies to examine both genders in studies 
focused on GABAAR expression and function as well as treatments that may affect 
the GABAergic system. It will also be important to consider the possible effects of 
oestrous cycle on these measures, especially considering the finding that some 
GABAAR subunits fluctuate with the oestrous cycle (Lovick et al., 2005, Maguire et 
al., 2005). 
 
 
 
 
129
Table 6.3. Gender differences in CB1 and GABAA receptors in the rodent brain.  
Reference Species Method Brain Region Age Differences 
CB1      
Rodriguez de Fonseca 
et al., 1993 
Wistar rat Membrane 
binding 
Limbic forebrain PN2 ↑ female 61% 
  PN5 ↑ male 42% 
  PN10,15,20,30,40,70 No difference 
 Striatum PN10 ↑ male 45% 
  PN20 ↑ female 36% 
  PN15,30,40,70 No difference 
 Mesencephalon PN10,15,40,70 ↑male 25,45,31,23% 
  PN20,30 No difference 
Mateos et al., 2011 Wistar rat Autoradiography 
- [3H]CP55940 
Hippocampus  (CA1,2,3) PN81 ↑ male 11%  
   Dentate gyrus, Cingulate cortex, 
Amygdala 
 No difference 
Castelli et al., 2014 Lister 
Hooded 
rat 
Autoradiography 
– [3H]CP55940 
Prefrontal cortex 
Amygdala 
Nucleus accumbens, Striatum, Ventral 
tegmental area, Hippocampus 
 ↑ male 28-30% 
↑ male 27% 
No difference 
Riebe et al., 2010 Sprague-
Dawley rat 
Membrane 
binding 
Hypothalamus Adult (300-400g) ↑ male 54% 
 Amygdala ↑ female 31% 
 Hippocampus No difference 
Rodriguez de Fonseca 
et al., 1994 
Wistar rat Membrane 
binding 
Hypothalamus, Limbic forebrain, 
Striatum 
Adult (>8weeks) No difference 
   Mesencephalon  ↑ male 31% 
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Riech et al., 2009 Sprague-
Dawley rat 
Western blot Hippocampus Adult (7-8 weeks) ↑ male 66% 
Marco et al., 2007 Wistar rat Western blot Hippocampus PN43 ↑ male 10% 
    PN75 No difference 
   Striatum PN43,75 No difference 
Suarez et al., 2009 Wistar rat Immuno- 
histochemistry 
Hippocampus PN13 No difference 
Gonzalez et al., 2000 Sprague-
Dawley rat 
In situ 
hybridisation 
Anterior pituitary Adult ↑ male 40-610% 
GABAA      Davis and McCarthy, 
2000 
Sprague-
Dawley rat 
Autoradiography 
- [3H]Muscimol 
Medial preoptic area, Ventrolateral 
thalamus, Cingulate cortex, 
Ventromedial hypothamalus, 
Hippocampus, Amygdala 
PN1,5,10,20 No difference 
Skilbeck et al., 2008  QS mice Autoradiography 
- [3H]GABA 
Cingulate and Motor  cortex Adult ↑ female 15-20% 
   
Temporal cortex, Striatum, Lateral 
septum, Hippocampus, Amygdala  
No difference 
Canonaco et al., 1996  Wood 
mice 
Autoradiography 
- [3H]Muscimol 
Striatum, Anterior hypothalamus Adult ↑ male 36-50% 
   
Stria terminalis, Ventromedial 
hypothalamus, Ventrolateral thalamus, 
Central grey pontine, Substantia nigra  
↑ female 81%,43%,                       
36%, 62%, 51%                      
   
Medial preoptic area, Globus pallidus, 
Medial dorsal thalamus, Medial and 
dorsolateral geniculate  
No difference 
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Juptner and Heimke, 
1990  
Sprague-
Dawley rat 
Membrane 
binding 
Medial preoptic area, Hypothalamus  Adult ↑ male 305-430% 
      Amygdala, Cortex   No difference 
Abbreviations: PN = postnatal day. 
Chapter 6 
 
 
132
6.4.4 Sexual dimorphism in the developmental profile of CB1 receptors 
To our knowledge, the present study is the first to report the developmental 
profile of CB1R binding density in the mouse brain. Our findings are in general 
agreement with others who have reported increased levels from juvenile to adulthood 
in CB1R levels in the rat, monkey and human brains (Belue et al., 1995; Berrendero 
et al., 1999; Eggan et al., 2010a; Mato et al., 2003, Van Laere et al., 2008), however 
our study furthered these previous studies by reporting clear gender differences in the 
developmental profile of CB1R s in the mouse brain (peak expression of male CB1Rs 
at adolescence and female CB1Rs at adulthood). One previous developmental study 
in rats reported peak expression of CB1R density at adolescence in the striatum and 
at adolescence to adulthood in the forebrain of both male and female rats (Rodriguez 
de Fonseca et al., 1993). It is hard to directly compare our findings to those in the rat 
because of the conflicting findings in the literature, but also it is clear from our study 
and others that there are species specific differences in CB1R (and GABAARs) 
between rats and mice and even within species disparities due to strain differences 
(Haller et al., 2007; Hungund and Basavarajappa, 2000).  
The differential profiles between the male and female mice in the present 
study resulted in gender differences in CB1R expression at the adolescent (prefrontal 
cortex, striatum and hippocampus) and adult (prefrontal cortex and striatum) time 
periods in the mouse brain of the saline animals. While no other studies have 
examined gender differences in CB1R binding density in the mouse brain, a previous 
study using the same receptor binding technique in adult rats found no difference in 
gender in the dentate gyrus and only a 10% reduction in the CA1, CA2 and CA3 
regions of the hippocampus in females compared to males (Mateos et al., 2011). A 
human study using [18F]MK-9470 PET to determine in vivo CB1R distribution found 
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an increase CB1Rs with age only in females (Van Laere et al., 2008), mirroring our 
finding of an incremental increase in CB1R density in female but not male mice. 
Other studies using different techniques, such as Western blot and membrane 
binding, to examine CB1Rs in the rat have found both similar and contrasting results 
to that of the present study (summarised in Table 6.3), indicating the presence of 
brain regional and species and/or strain variations when examining neurotransmitter 
receptors. It has been reported previously that there are gender-specific behavioural 
effects of CB1R agonist treated rats at adolescence (Biscaia et al., 2003; Mateos et 
al., 2011), possibly due to differences in cannabinoid system development and 
regulation. We suggest that the gender specific findings observed in the present study 
would render the genders different susceptibilities to CB1R impacts, which should be 
considered in the design of future studies, and that caution should be applied in the 
extrapolation of data from one gender to another.  The literature, combined with the 
results from the present study, therefore points to the importance of examination of 
gender specific development of the cannabinoid system in the human brain in terms 
of both expression and function. 
One obvious reason for gender differences in CB1R and GABAAR levels, 
particularly at adolescence, is sex steroids. One study has shown that although CB1R 
density fluctuates throughout the oestrous cycle in adult female rodents in the 
hypothalamus, there were no changes in the striatum, limbic forebrain and 
mesencephalon (Rodriguez de Fonseca et al., 1994), which are similar brain regions 
to those examined in the present study. Another, more recent study has found that 
CB1R density is reduced in cycling females compared to male and ovariectomised 
rats in the prefrontal cortex but not the hippocampus (Castelli et al., 2014). To our 
knowledge, studies of this nature have not been conducted with regards to whole 
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GABAARs, however it has been found that some GABAAR subunits fluctuate with 
the oestrous cycle in adult female rodents (Lovick et al., 2005; Maguire et al., 2005) 
as previously mentioned.  This however does not explain the disparity between the 
gender differences seen at adolescence and the lack of or reversed gender differences 
seen at adulthood.  
6.4.5 Correlations 
As expected, there was a significant correlation between CB1 and GABAARs. 
While the relationship between the cannabinoid and GABAergic systems is well 
established, i.e. CB1Rs located on GABAergic interneurons act to inhibit GABA 
release, the relationship between the GABAA and CB1R, especially during 
development is not well known.  CB1R density increased throughout development to 
adulthood, while there was a reduction in GABAAR density from juvenile to adult 
levels. The GABAergic system is vitally important in early neurodevelopment 
(Deidda et al., 2014) and therefore we would expect levels to be high. The 
cannabinoid system acts to inhibit the GABAergic system, so with low levels early in 
life this allows for less inhibition of the GABAergic system to allow GABA to 
perform its developmental functions. Later in life as CB1R density increases, there is 
more inhibition of GABA, and CB1Rs on GABAergic neurons in ageing rodents 
have been found to protect against cognitive decline by decreasing pyramidal cell 
degeneration and neuroinflammation (Albayram et al., 2011). 
We found a positive correlation between NR2A and GABAAR binding (and a 
negative correlation between NR2A and CB1R binding) in the prefrontal cortex and 
hippocampus at adolescence and this correlation was not observed with NMDAR or 
NR2B binding.  This appears to be a unique finding and although the relevance of 
this correlation at adolescence is not clear, it has been found previously that the 
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NR2A subunit plays a more important role in the regulation of GABAergic function 
in parvalbumin interneurons than NR2B and the presence of NR2A in these neurons 
is much higher than NR2B (Kinney et al., 2005). Whether this then affects the levels 
of GABAARs is not known but may contribute to this association at adolescence, 
during a period of enhanced synaptic pruning and regulation. While our study did not 
examine the levels of proteins in specific neuron subtypes, it may be necessary to do 
so in future studies in order to further understand this relationship. 
6.4.6 Conclusion 
In conclusion, GABAA and CB1Rs have opposing developmental profiles. 
GABAAR density differed between genders in the early to adolescent ages, whereas 
CB1R density showed gender differences at the adolescence to adult ages. NR2B 
antagonist treatment in the perinatal period had no effect on CB1 or GABAAR levels 
throughout development and therefore this model does not demonstrate 
neurochemical alterations in the GABAergic and cannabinoid systems similar to 
schizophrenia.  
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7 OVERALL DISCUSSION, CONCLUSIONS AND RECOMMENDATIONS 
7.1 Overall Discussion  
This study investigated the role of the NR2B subunit of the NMDAR in the 
pathophysiology and development of schizophrenia. Two approaches were used; 
First, NR2B subunit protein and binding density was examined in the postmortem 
human brain, specifically in the brain regions of the hippocampus and prefrontal 
cortex, including an analysis of gender and hemispheric effects. Postmortem human 
brain is a valuable tool to understand molecular processes occurring in the 
neuropsychiatric disorders such as schizophrenia. One of the limitations of this 
however is that there is an inability to assess molecular changes that occur prior to 
the onset of the disorder, to develop an understanding of the development of the 
disorder. This is where animal models provide value. Second, an animal model was 
employed to assess the effects of perinatal NR2B antagonism on the developmental 
profile of systems implicated in schizophrenia, including NMDA, NRG1/ErbB4, 
GABAergic and canabinnoid systems. In this animal model we also examined the 
effects of gender on the developmental profile of the proteins. The main findings 
from these studies are: 1. A decrease in NR2B protein in the left hippocampal 
hemisphere of the schizophrenia brain compared to control; 2. A decrease in NR2B 
protein in the prefrontal cortex of the female schizophrenia brain compared to males; 
3. A reduction in NR2B binding following perinatal NR2B antagonism in the 
prefrontal cortex and hippocampus of the mouse brain; 4. Alterations in NR2B 
protein in the prefrontal cortex and NRG1 protein in the hippocampus at adolescence 
following perinatal NR2B antagonism; 5. Increases in NR2B binding and NRG1 
protein during development; 6. Gender specific developmental profiles of NR2A, 
GABAAR and CB1R binding. 
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7.1.1 Hemispheric alterations in the human hippocampus: 
This is the first study to report a lateralisation effect of NR2B protein in the 
hippocampus in schizophrenia subjects and this could be associated with the 
reductions in NR1 previously reported in the left hippocampus in schizophrenia 
(Vrajova et al., 2010). Selective reduction of NR2B-containing NMDARs in the 
hippocampus has been reported to produce cognitive deficits in rodents (Brigman et 
al., 2010; Clayton et al., 2002) as well as disrupting underlying molecular processes 
such as LTP (Clayton et al., 2002). Our findings therefore of reduced NR2B protein 
in the hippocampus, where it plays a critical role in cognitive function, and is 
possibly related to cognitive dysfunction in schizophrenia patients, supports the idea 
that NR2B positive allosteric modulators could potentially be therapeutic for 
cognitive dysfunctions in schizophrenia.  
7.1.2 Gender alterations in the human prefrontal cortex: 
This is the first study to report a gender difference in NR2B protein in the 
prefrontal cortex of schizophrenia subjects. The decrease of NR2B protein in the 
female schizophrenia subjects compared to the male schizophrenia subjects shows it 
is important to consider gender when analysing post mortem cohorts. Although this 
result is only preliminary, as the sample size was not large enough to detect an 
observed difference between the female control and female schizophrenia groups, 
this is one of the largest schizophrenia post mortem cohorts to date and highlights the 
need for larger cohorts to investigate variables such as gender and hemisphere.  
7.1.3 Treatment effects from the perinatal NR2B antagonist animal model: 
In our animal model a decrease in NR2B binding at the juvenile time point in 
both the prefrontal cortex and hippocampus as well as a small increase in NR2B 
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protein at adolescence in the prefrontal cortex and a small reduction in NRG1 protein 
in the hippocampus following perinatal NR2B antagonist treatment. There was also 
an overall reduction in NR2B protein in the hippocampus, independent of age or 
gender. There were no treatment effects on NMDAR binding, NR2A subunit binding 
or protein, ErbB4 protein, GABAAR binding or CB1R binding at any time point in 
any brain region.  
Our study provides the first evidence of the effects of perinatal NR2B 
antagonism on brain neurochemistry. Perinatal NR2B antagonism had minimal 
effects on the NMDAR complex and NRG1 signalling system however despite this 
there may be altered functional activity of these receptors and/or the downstream 
signalling capacity, which is an avenue of research that would further the results of 
this study. Reduced expression of NRG1, as seen in the hippocampus at adolescence 
in our study, has been found to increase susceptibility to behavioural abnormalities 
and further impacts to the brain, particularly at adolescence (Long et al., 2013). 
Therefore while these alterations are subtle, collectively they may increase the 
susceptibility of Ro 63-1908 treated animals to secondary impacts. In addition to the 
alterations in NR2B and NRG1 at adolescence in our animal model we found NRG1 
and NR2B proteins to be positively correlated in the prefrontal cortex and 
hippocampus at PN70 and in the prefrontal cortex at PN14 but there was no 
correlation at PN35. It is possible that perinatal NR2B antagonism disrupts the 
positive relationship between these proteins at this age and this could alter other 
signalling systems and pathways during the adolescent brain growth period, possibly 
rendering the brain vulnerable to impacts during this time. Furthermore while there 
was no effect of the perinatal NR2B antagonist treatment on GABAAR and CB1R 
levels, previous studies have shown functional changes in the CB1R despite a lack of 
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binding density change. Therefore we cannot rule out the possibility of functional 
changes in our animal model and again these experiments are recommended to 
further the results of our study. 
7.1.4 Gender effects from the perinatal NR2B antagonist animal model: 
 Our study is the first to provide evidence in mice of gender differences in the 
glutamatergic system, particularly of NR2A binding at adolescence, which may 
underlie gender specific susceptibilities apparent in schizophrenia patients at this 
time point. Gender differences were also observed in the GABAergic and 
cannabinoid systems, similar to what has been reported previously however 
interestingly there was a significant correlation between the NR2A, GABAAR and 
CB1R binding results. Again this highlights the need to examine gender differences, 
not only in post mortem cohorts, but also in animal models.  
7.1.5 Developmental effects from the perinatal NR2B antagonist animal model: 
This was the first study to investigate [3H]Ifenprodil binding during 
development of the mouse brain. There was an increase from PN14 to PN70 in both 
the prefrontal cortex and the hippocampus unlike that of the NR2B protein, which 
confirmed previous findings of a small decrease between PN14 and PN35 in the 
prefrontal cortex, otherwise, no difference between the time points. An increase in 
binding throughout development suggests that the availability or affinity of the 
binding sites in the membrane may change over time but the amount of total protein 
remains fairly constant. No difference in NR2A protein was observed between the 
time points in either gender or with NR2A binding in the male mice however in the 
female mice there was a peak expression of NR2A binding at adolescence. This 
highlights the importance of gender separation in future NR2A related studies.      
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The developmental profile of the NRG1 protein was also an interesting 
finding in our study and the first to be presented in any species. Previous studies of 
NRG1 mRNA have found a decrease during development however in our study we 
found an increase in NRG1 protein during development. Given the importance of 
NRG1 in early development this was unexpected. Isoforms of NRG1 mRNA have 
different developmental profiles therefore it is likely that particular NRG1 isoforms 
and isoform ratios are more important during early development and not the total 
levels of NRG1 protein that were measured in this study. Examining NRG1 isoform 
expression during development would be a valuable experiment to perform to further 
our research. 
7.2 Limitations 
There are several limitations of this thesis that must be considered. In our 
animal study we did not measure the oestrous cycle status of the female mice and 
therefore it is possible that differing levels of oestrogen may have affected the 
proteins that were examined. Previous studies have shown that oestrogen does not 
appear to affect NMDAR, NR2A, NR2B levels (Snyder et al., 2011) (which were 
measured in this study) although it could affect the function of these proteins 
(Vedder et al., 2013). CB1R and GABAAR proteins on the other hand could be 
affected by oestrous cycle status (Castelli et al., 2014, Lovick et al., 2005, Maguire et 
al., 2005). 
 This study did not examine lateralisation in the animal tissue. While 
laterality is present in the rodent brain (Cowell et al., 1999) and functional 
processing, such as long-term memory, does appear to be lateralised in mice (Shipton 
et al., 2014), we combined the left and right hemisphere brain structures for tissue 
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collection for our Western blot studies to assure we had sufficient protein for our 
studies. Considering our finding in the human tissue of a decrease in NR2B protein 
(using Western blot) in the left hippocampal hemisphere but not the right it appears 
that this may indeed be worthwhile to pursue in the future. 
The protein expression levels in this study were examined in a specific brain 
regions, however they were not examined in different subpopulations of neurons (ie. 
excitatory vs inhibitory) or in separate compartments of the cell (ie. ER vs soma vs 
synaptic terminal). Despite no change in total binding or protein, it has previously 
been shown that NR2B is altered in schizophrenia subjects specifically in the 
endoplasmic reticulum fraction of cells in the prefrontal cortex (Kristiansen et al., 
2010b). In an animal model changes were also observed in NR2A and NR2B protein 
in the endoplasmic reticulum after perinatal treatment with the NMDAR antagonist 
PCP (Anastasio and Johnson 2008). Furthermore, it has been found that the 
expression of NR2A is much higher than NR2B in a specific subtype of inhibitory 
interneurons (Kinney et al., 2005) and therefore the examination of tissue in different 
cellular populations and compartments of the cell would follow nicely from the 
experiments in this thesis.  
7.3 Future Directions 
In addition to addressing some of the limitations presented above, there are 
several avenues to be pursued in future investigations. Considering the close 
relationship between the NMDAR subunits (and NRG1 and ErbB4) and the 
MAGUK family of proteins in the postsynaptic density (PSD-95, PSD-93, SAP97 
and SAP102) and the changes that have been found in these postsynaptic density 
proteins in the schizophrenia brain (for review see Geddes et al., 2011), it will be 
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worthwhile in the future to examine the effect an NMDAR antagonist (global or 
subunit specific) model has on these proteins. Conversely it may be that a 
disassociation with a particular postsynaptic density protein is what causes  
impairment in NMDAR stoichiometry or function. Therefore examination of the 
coupling or co-localisation between the NMDAR subunits and these MAGUKs in 
schizophrenia should be investigated.  
As discussed throughout this thesis, there is evidence to suggest that despite 
no change in protein levels, disturbances to trafficking, degradation and regulation of 
the NR2B subunit may occur in schizophrenia (Kristiansen et al., 2010a). Further 
research to investigate whether any alterations in NR2B in schizophrenia are specific 
to the cell surface, the synapse or extrasynaptic region, and whether proteins that 
regulate the trafficking of NR2B are altered in schizophrenia. This may have 
implications for the effectiveness of NR2B positive allosteric modulators or similar 
drugs that are in preclinical development for the potential treatment of schizophrenia 
(Menniti et al., 2013). 
Future studies on NR2B and schizophrenia, particularly animal models, may 
also want to consider the behavioural aspects of an impact to the NR2B subunit 
during early development and whether they correspond to functional changes in 
NR2B or other NMDAR associated proteins. Although there were limited alterations 
to NMDAR subunit expression in the present study, it remains possible that there are 
functional changes to these proteins as this has been shown in regards to the CB1R 
(Vigano et al., 2009, Seillier et al., 2010).  
Finally, while this study focused on the hippocampus and prefrontal cortex 
brain regions, others have found alterations in the NR2B subunit in schizophrenia in 
the superior temporal cortex and various parts of the thalamus (Grimwood et al., 
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1999, Ibrahim et al., 2000, Clinton and Meador-Woodruff, 2004, Clinton et al., 
2006). Therefore there are other parts of the cortex and brain that could be examined 
in relation to the animal model in this thesis, as well as numerous other parts of the 
brain that have not been studied in relation to the NMDAR subunit expression in 
schizophrenia. 
7.4 Conclusion 
In conclusion, this thesis has provided novel insights into the changes that 
occur in the NR2B subunit in schizophrenia, revealing for the first time that 
expression of NR2B is altered in the DLPFC and hippocampus of schizophrenia 
subjects, in a gender and hemisphere specific manner. These alterations may be 
related to cognitive symptoms experienced by patients, however further studies are 
required to determine this. There are numerous studies showing the functional 
importance of the NR2B subunit in both the prefrontal cortex and hippocampus, 
particularly in terms of cognitive performance; future investigations should therefore 
focus on the functional changes to NR2B including any alterations to NR2B 
trafficking or regulation. Importantly, this will align with research into the 
development of novel glutamatergic agents, including NR2B positive allosteric 
modulators, for the treatment of cognitive dysfunction in schizophrenia patients.  
This thesis also showed that a pharmacological impact to the NR2B subunit 
during perinatal development causes some alterations to schizophrenia relevant 
systems, including NR2B and NRG1, at adolescence, which could potentially make 
this animal model more vulnerable to further impacts at adolescence. It should be 
noted however, that this model did not cause widespread changes in systems (at least 
in terms of protein expression) relevant to the pathophysiology of schizophrenia. 
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Finally, this thesis has identified that the developmental profiles of schizophrenia 
relevant systems, differs between the two genders (at least in a mouse model), 
highlighting the importance of considering this in the design of future studies.
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APPENDIX 
Tables showing average demographic values split by hemisphere and gender 
in the human tissue hippocampus and prefrontal cortex. 
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